#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Mapping thalamocortical functional connectivity in chronic and early stages of psychotic disorders
1-1	0-7	Mapping	_	
1-2	8-23	thalamocortical	_	
1-3	24-34	functional	_	
1-4	35-47	connectivity	_	
1-5	48-50	in	_	
1-6	51-58	chronic	_	
1-7	59-62	and	_	
1-8	63-68	early	_	
1-9	69-75	stages	_	
1-10	76-78	of	_	
1-11	79-88	psychotic	_	
1-12	89-98	disorders	_	

#Text=Objective
2-1	99-108	Objective	_	

#Text=There is considerable evidence that the thalamus is abnormal in psychotic disorders. Resting-state fMRI (RS-fMRI) has revealed an intriguing pattern of thalamic dysconnectivity in psychosis characterized by reduced prefrontal cortex (PFC) connectivity and increased somatomotor-thalamic connectivity. However, critical knowledge gaps remain with respect to the onset, anatomical specificity, and clinical correlates of thalamic dysconnectivity in psychosis.
3-1	109-114	There	_	
3-2	115-117	is	_	
3-3	118-130	considerable	_	
3-4	131-139	evidence	_	
3-5	140-144	that	_	
3-6	145-148	the	_	
3-7	149-157	thalamus	_	
3-8	158-160	is	_	
3-9	161-169	abnormal	_	
3-10	170-172	in	_	
3-11	173-182	psychotic	_	
3-12	183-192	disorders	_	
3-13	192-193	.	_	
3-14	194-207	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[1]	
3-15	208-212	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[1]	
3-16	213-214	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[1]	
3-17	214-221	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[1]	
3-18	221-222	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[1]	
3-19	223-226	has	_	
3-20	227-235	revealed	_	
3-21	236-238	an	_	
3-22	239-249	intriguing	_	
3-23	250-257	pattern	_	
3-24	258-260	of	_	
3-25	261-269	thalamic	_	
3-26	270-285	dysconnectivity	_	
3-27	286-288	in	_	
3-28	289-298	psychosis	_	
3-29	299-312	characterized	_	
3-30	313-315	by	_	
3-31	316-323	reduced	_	
3-32	324-334	prefrontal	_	
3-33	335-341	cortex	_	
3-34	342-343	(	_	
3-35	343-346	PFC	_	
3-36	346-347	)	_	
3-37	348-360	connectivity	_	
3-38	361-364	and	_	
3-39	365-374	increased	_	
3-40	375-395	somatomotor-thalamic	_	
3-41	396-408	connectivity	_	
3-42	408-409	.	_	
3-43	410-417	However	_	
3-44	417-418	,	_	
3-45	419-427	critical	_	
3-46	428-437	knowledge	_	
3-47	438-442	gaps	_	
3-48	443-449	remain	_	
3-49	450-454	with	_	
3-50	455-462	respect	_	
3-51	463-465	to	_	
3-52	466-469	the	_	
3-53	470-475	onset	_	
3-54	475-476	,	_	
3-55	477-487	anatomical	_	
3-56	488-499	specificity	_	
3-57	499-500	,	_	
3-58	501-504	and	_	
3-59	505-513	clinical	_	
3-60	514-524	correlates	_	
3-61	525-527	of	_	
3-62	528-536	thalamic	_	
3-63	537-552	dysconnectivity	_	
3-64	553-555	in	_	
3-65	556-565	psychosis	_	
3-66	565-566	.	_	

#Text=Method
4-1	567-573	Method	_	

#Text=RS-fMRI was collected on 105 healthy subjects and 148 individuals with psychosis, including 53 early stage psychosis patients. Using all 253 subjects, the thalamus was parceled into functional regions-of-interest (ROIs) on the basis of connectivity with six a-priori defined cortical ROIs covering most of the cortical mantle. Functional connectivity between each cortical ROI and its corresponding thalamic ROI was quantified and compared across groups. Significant differences in the ROI-to-ROI analysis were followed up with voxel-wise seed-based analyses to further localize thalamic dysconnectivity.
5-1	574-581	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol	
5-2	582-585	was	_	
5-3	586-595	collected	_	
5-4	596-598	on	_	
5-5	599-602	105	_	
5-6	603-610	healthy	http://www.ukp.informatik.tu-darmstadt.de/inception/1.0#node1f7tpjks8x1[2]	
5-7	611-619	subjects	http://www.ukp.informatik.tu-darmstadt.de/inception/1.0#node1f7tpjks8x1[2]	
5-8	620-623	and	_	
5-9	624-627	148	_	
5-10	628-639	individuals	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
5-11	640-644	with	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
5-12	645-654	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
5-13	654-655	,	_	
5-14	656-665	including	_	
5-15	666-668	53	_	
5-16	669-674	early	_	
5-17	675-680	stage	_	
5-18	681-690	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[4]	
5-19	691-699	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[4]	
5-20	699-700	.	_	
5-21	701-706	Using	_	
5-22	707-710	all	_	
5-23	711-714	253	_	
5-24	715-723	subjects	_	
5-25	723-724	,	_	
5-26	725-728	the	_	
5-27	729-737	thalamus	_	
5-28	738-741	was	_	
5-29	742-750	parceled	_	
5-30	751-755	into	_	
5-31	756-766	functional	_	
5-32	767-786	regions-of-interest	_	
5-33	787-788	(	_	
5-34	788-792	ROIs	_	
5-35	792-793	)	_	
5-36	794-796	on	_	
5-37	797-800	the	_	
5-38	801-806	basis	_	
5-39	807-809	of	_	
5-40	810-822	connectivity	_	
5-41	823-827	with	_	
5-42	828-831	six	_	
5-43	832-840	a-priori	_	
5-44	841-848	defined	_	
5-45	849-857	cortical	_	
5-46	858-862	ROIs	_	
5-47	863-871	covering	_	
5-48	872-876	most	_	
5-49	877-879	of	_	
5-50	880-883	the	_	
5-51	884-892	cortical	_	
5-52	893-899	mantle	_	
5-53	899-900	.	_	
5-54	901-911	Functional	_	
5-55	912-924	connectivity	_	
5-56	925-932	between	_	
5-57	933-937	each	_	
5-58	938-946	cortical	_	
5-59	947-950	ROI	_	
5-60	951-954	and	_	
5-61	955-958	its	_	
5-62	959-972	corresponding	_	
5-63	973-981	thalamic	_	
5-64	982-985	ROI	_	
5-65	986-989	was	_	
5-66	990-1000	quantified	_	
5-67	1001-1004	and	_	
5-68	1005-1013	compared	_	
5-69	1014-1020	across	_	
5-70	1021-1027	groups	_	
5-71	1027-1028	.	_	
5-72	1029-1040	Significant	_	
5-73	1041-1052	differences	_	
5-74	1053-1055	in	_	
5-75	1056-1059	the	_	
5-76	1060-1070	ROI-to-ROI	_	
5-77	1071-1079	analysis	_	
5-78	1080-1084	were	_	
5-79	1085-1093	followed	_	
5-80	1094-1096	up	_	
5-81	1097-1101	with	_	
5-82	1102-1112	voxel-wise	_	
5-83	1113-1123	seed-based	_	
5-84	1124-1132	analyses	_	
5-85	1133-1135	to	_	
5-86	1136-1143	further	_	
5-87	1144-1152	localize	_	
5-88	1153-1161	thalamic	_	
5-89	1162-1177	dysconnectivity	_	
5-90	1177-1178	.	_	

#Text=Results
6-1	1179-1186	Results	_	

#Text=ROI analysis revealed reduced PFC-thalamic connectivity and increased somatomotor-thalamic connectivity in both chronic and early stages psychosis patients. PFC hypo-connectivity and motor cortex hyper-connectivity correlated in patients suggesting they result from a common pathophysiological mechanism. Seed-based analyses revealed thalamic hypo-connectivity in psychosis localized to dorsolateral PFC, medial PFC, and cerebellar areas of the well-described ‘executive control’ network. Across all subjects, thalamic connectivity with areas of the fronto-parietal network correlated with cognitive functioning, including verbal learning and memory.
7-1	1187-1190	ROI	_	
7-2	1191-1199	analysis	_	
7-3	1200-1208	revealed	_	
7-4	1209-1216	reduced	_	
7-5	1217-1229	PFC-thalamic	_	
7-6	1230-1242	connectivity	_	
7-7	1243-1246	and	_	
7-8	1247-1256	increased	_	
7-9	1257-1277	somatomotor-thalamic	_	
7-10	1278-1290	connectivity	_	
7-11	1291-1293	in	_	
7-12	1294-1298	both	_	
7-13	1299-1306	chronic	_	
7-14	1307-1310	and	_	
7-15	1311-1316	early	_	
7-16	1317-1323	stages	_	
7-17	1324-1333	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[5]	
7-18	1334-1342	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[5]	
7-19	1342-1343	.	_	
7-20	1344-1347	PFC	_	
7-21	1348-1365	hypo-connectivity	_	
7-22	1366-1369	and	_	
7-23	1370-1375	motor	_	
7-24	1376-1382	cortex	_	
7-25	1383-1401	hyper-connectivity	_	
7-26	1402-1412	correlated	_	
7-27	1413-1415	in	_	
7-28	1416-1424	patients	_	
7-29	1425-1435	suggesting	_	
7-30	1436-1440	they	_	
7-31	1441-1447	result	_	
7-32	1448-1452	from	_	
7-33	1453-1454	a	_	
7-34	1455-1461	common	_	
7-35	1462-1480	pathophysiological	_	
7-36	1481-1490	mechanism	_	
7-37	1490-1491	.	_	
7-38	1492-1502	Seed-based	_	
7-39	1503-1511	analyses	_	
7-40	1512-1520	revealed	_	
7-41	1521-1529	thalamic	_	
7-42	1530-1547	hypo-connectivity	_	
7-43	1548-1550	in	_	
7-44	1551-1560	psychosis	_	
7-45	1561-1570	localized	_	
7-46	1571-1573	to	_	
7-47	1574-1586	dorsolateral	_	
7-48	1587-1590	PFC	_	
7-49	1590-1591	,	_	
7-50	1592-1598	medial	_	
7-51	1599-1602	PFC	_	
7-52	1602-1603	,	_	
7-53	1604-1607	and	_	
7-54	1608-1618	cerebellar	_	
7-55	1619-1624	areas	_	
7-56	1625-1627	of	_	
7-57	1628-1631	the	_	
7-58	1632-1646	well-described	_	
7-59	1647-1648	‘	_	
7-60	1648-1657	executive	_	
7-61	1658-1665	control	_	
7-62	1665-1666	’	_	
7-63	1667-1674	network	_	
7-64	1674-1675	.	_	
7-65	1676-1682	Across	_	
7-66	1683-1686	all	_	
7-67	1687-1695	subjects	_	
7-68	1695-1696	,	_	
7-69	1697-1705	thalamic	_	
7-70	1706-1718	connectivity	_	
7-71	1719-1723	with	_	
7-72	1724-1729	areas	_	
7-73	1730-1732	of	_	
7-74	1733-1736	the	_	
7-75	1737-1752	fronto-parietal	_	
7-76	1753-1760	network	_	
7-77	1761-1771	correlated	_	
7-78	1772-1776	with	_	
7-79	1777-1786	cognitive	_	
7-80	1787-1798	functioning	_	
7-81	1798-1799	,	_	
7-82	1800-1809	including	_	
7-83	1810-1816	verbal	_	
7-84	1817-1825	learning	_	
7-85	1826-1829	and	_	
7-86	1830-1836	memory	_	
7-87	1836-1837	.	_	

#Text=Conclusions
8-1	1838-1849	Conclusions	_	

#Text=Thalamocortical dysconnectivity is present in both chronic and early stages of psychosis, includes reduced thalamic connectivity with the executive control network, and is related to cognitive impairment.
9-1	1850-1865	Thalamocortical	_	
9-2	1866-1881	dysconnectivity	_	
9-3	1882-1884	is	_	
9-4	1885-1892	present	_	
9-5	1893-1895	in	_	
9-6	1896-1900	both	_	
9-7	1901-1908	chronic	_	
9-8	1909-1912	and	_	
9-9	1913-1918	early	_	
9-10	1919-1925	stages	_	
9-11	1926-1928	of	_	
9-12	1929-1938	psychosis	_	
9-13	1938-1939	,	_	
9-14	1940-1948	includes	_	
9-15	1949-1956	reduced	_	
9-16	1957-1965	thalamic	_	
9-17	1966-1978	connectivity	_	
9-18	1979-1983	with	_	
9-19	1984-1987	the	_	
9-20	1988-1997	executive	_	
9-21	1998-2005	control	_	
9-22	2006-2013	network	_	
9-23	2013-2014	,	_	
9-24	2015-2018	and	_	
9-25	2019-2021	is	_	
9-26	2022-2029	related	_	
9-27	2030-2032	to	_	
9-28	2033-2042	cognitive	_	
9-29	2043-2053	impairment	_	
9-30	2053-2054	.	_	

#Text=INTRODUCTION
10-1	2055-2067	INTRODUCTION	_	

#Text=There is considerable evidence that the thalamus and associated cortical connections are abnormal in psychotic disorders. However, it has been difficult to localize thalamic pathology and identify dysfunction in specific thalamocortical circuits due to the complex architecture of the thalamus and limitations of traditional neuroimaging methods. Furthermore, post mortem investigations have produced conflicting findings or, in the case of bipolar disorder, are few in number.
11-1	2068-2073	There	_	
11-2	2074-2076	is	_	
11-3	2077-2089	considerable	_	
11-4	2090-2098	evidence	_	
11-5	2099-2103	that	_	
11-6	2104-2107	the	_	
11-7	2108-2116	thalamus	_	
11-8	2117-2120	and	_	
11-9	2121-2131	associated	_	
11-10	2132-2140	cortical	_	
11-11	2141-2152	connections	_	
11-12	2153-2156	are	_	
11-13	2157-2165	abnormal	_	
11-14	2166-2168	in	_	
11-15	2169-2178	psychotic	_	
11-16	2179-2188	disorders	_	
11-17	2188-2189	.	_	
11-18	2190-2197	However	_	
11-19	2197-2198	,	_	
11-20	2199-2201	it	_	
11-21	2202-2205	has	_	
11-22	2206-2210	been	_	
11-23	2211-2220	difficult	_	
11-24	2221-2223	to	_	
11-25	2224-2232	localize	_	
11-26	2233-2241	thalamic	_	
11-27	2242-2251	pathology	_	
11-28	2252-2255	and	_	
11-29	2256-2264	identify	_	
11-30	2265-2276	dysfunction	_	
11-31	2277-2279	in	_	
11-32	2280-2288	specific	_	
11-33	2289-2304	thalamocortical	_	
11-34	2305-2313	circuits	_	
11-35	2314-2317	due	_	
11-36	2318-2320	to	_	
11-37	2321-2324	the	_	
11-38	2325-2332	complex	_	
11-39	2333-2345	architecture	_	
11-40	2346-2348	of	_	
11-41	2349-2352	the	_	
11-42	2353-2361	thalamus	_	
11-43	2362-2365	and	_	
11-44	2366-2377	limitations	_	
11-45	2378-2380	of	_	
11-46	2381-2392	traditional	_	
11-47	2393-2405	neuroimaging	_	
11-48	2406-2413	methods	_	
11-49	2413-2414	.	_	
11-50	2415-2426	Furthermore	_	
11-51	2426-2427	,	_	
11-52	2428-2432	post	_	
11-53	2433-2439	mortem	_	
11-54	2440-2454	investigations	_	
11-55	2455-2459	have	_	
11-56	2460-2468	produced	_	
11-57	2469-2480	conflicting	_	
11-58	2481-2489	findings	_	
11-59	2490-2492	or	_	
11-60	2492-2493	,	_	
11-61	2494-2496	in	_	
11-62	2497-2500	the	_	
11-63	2501-2505	case	_	
11-64	2506-2508	of	_	
11-65	2509-2516	bipolar	_	
11-66	2517-2525	disorder	_	
11-67	2525-2526	,	_	
11-68	2527-2530	are	_	
11-69	2531-2534	few	_	
11-70	2535-2537	in	_	
11-71	2538-2544	number	_	
11-72	2544-2545	.	_	

#Text=Resting-state fMRI (RS-fMRI) is a useful method for mapping functional brain networks and identifying circuit abnormalities in neurological and psychiatric disorders. Recently, we used RS-fMRI to investigate thalamocortical functional connectivity in a sample of 62 individuals with schizophrenia and 77 healthy subjects. Consistent with an earlier small investigation of 10 patients, we found that prefrontal cortex (PFC) connectivity with the thalamus was reduced in schizophrenia. Surprisingly, patients also demonstrated increased thalamic connectivity with motor and somatosensory cortex. The combination of reduced prefrontal and increased sensorimotor connectivity was subsequently replicated by several groups and extended to bipolar disorder.
12-1	2546-2559	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[6]	
12-2	2560-2564	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[6]	
12-3	2565-2566	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[6]	
12-4	2566-2573	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[6]	
12-5	2573-2574	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[6]	
12-6	2575-2577	is	_	
12-7	2578-2579	a	_	
12-8	2580-2586	useful	_	
12-9	2587-2593	method	_	
12-10	2594-2597	for	_	
12-11	2598-2605	mapping	_	
12-12	2606-2616	functional	_	
12-13	2617-2622	brain	_	
12-14	2623-2631	networks	_	
12-15	2632-2635	and	_	
12-16	2636-2647	identifying	_	
12-17	2648-2655	circuit	_	
12-18	2656-2669	abnormalities	_	
12-19	2670-2672	in	_	
12-20	2673-2685	neurological	_	
12-21	2686-2689	and	_	
12-22	2690-2701	psychiatric	_	
12-23	2702-2711	disorders	_	
12-24	2711-2712	.	_	
12-25	2713-2721	Recently	_	
12-26	2721-2722	,	_	
12-27	2723-2725	we	_	
12-28	2726-2730	used	_	
12-29	2731-2738	RS-fMRI	_	
12-30	2739-2741	to	_	
12-31	2742-2753	investigate	_	
12-32	2754-2769	thalamocortical	_	
12-33	2770-2780	functional	_	
12-34	2781-2793	connectivity	_	
12-35	2794-2796	in	_	
12-36	2797-2798	a	_	
12-37	2799-2805	sample	_	
12-38	2806-2808	of	_	
12-39	2809-2811	62	_	
12-40	2812-2823	individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
12-41	2824-2828	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
12-42	2829-2842	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
12-43	2843-2846	and	_	
12-44	2847-2849	77	_	
12-45	2850-2857	healthy	_	
12-46	2858-2866	subjects	_	
12-47	2866-2867	.	_	
12-48	2868-2878	Consistent	_	
12-49	2879-2883	with	_	
12-50	2884-2886	an	_	
12-51	2887-2894	earlier	_	
12-52	2895-2900	small	_	
12-53	2901-2914	investigation	_	
12-54	2915-2917	of	_	
12-55	2918-2920	10	_	
12-56	2921-2929	patients	_	
12-57	2929-2930	,	_	
12-58	2931-2933	we	_	
12-59	2934-2939	found	_	
12-60	2940-2944	that	_	
12-61	2945-2955	prefrontal	_	
12-62	2956-2962	cortex	_	
12-63	2963-2964	(	_	
12-64	2964-2967	PFC	_	
12-65	2967-2968	)	_	
12-66	2969-2981	connectivity	_	
12-67	2982-2986	with	_	
12-68	2987-2990	the	_	
12-69	2991-2999	thalamus	_	
12-70	3000-3003	was	_	
12-71	3004-3011	reduced	_	
12-72	3012-3014	in	_	
12-73	3015-3028	schizophrenia	_	
12-74	3028-3029	.	_	
12-75	3030-3042	Surprisingly	_	
12-76	3042-3043	,	_	
12-77	3044-3052	patients	_	
12-78	3053-3057	also	_	
12-79	3058-3070	demonstrated	_	
12-80	3071-3080	increased	_	
12-81	3081-3089	thalamic	_	
12-82	3090-3102	connectivity	_	
12-83	3103-3107	with	_	
12-84	3108-3113	motor	_	
12-85	3114-3117	and	_	
12-86	3118-3131	somatosensory	_	
12-87	3132-3138	cortex	_	
12-88	3138-3139	.	_	
12-89	3140-3143	The	_	
12-90	3144-3155	combination	_	
12-91	3156-3158	of	_	
12-92	3159-3166	reduced	_	
12-93	3167-3177	prefrontal	_	
12-94	3178-3181	and	_	
12-95	3182-3191	increased	_	
12-96	3192-3204	sensorimotor	_	
12-97	3205-3217	connectivity	_	
12-98	3218-3221	was	_	
12-99	3222-3234	subsequently	_	
12-100	3235-3245	replicated	_	
12-101	3246-3248	by	_	
12-102	3249-3256	several	_	
12-103	3257-3263	groups	_	
12-104	3264-3267	and	_	
12-105	3268-3276	extended	_	
12-106	3277-3279	to	_	
12-107	3280-3287	bipolar	_	
12-108	3288-3296	disorder	_	
12-109	3296-3297	.	_	

#Text=Despite the consistency of the findings across studies, key questions remain about the onset, anatomical specificity, and clinical correlates of thalamic dysconnectivity. It is unclear if the abnormalities are present early in the illness or emerge as the illness progresses. Based on what is known about the development of thalamocortical functional connectivity, we hypothesized that the combination of reduced PFC connectivity and increased somatomotor connectivity results from a disturbance in brain development during the transition from adolescence to adulthood that prevents PFC-thalamic circuitry from fully developing and derails the normal refinement of somatomotor-thalamic connectivity. Evidence of similar connectivity disturbances in the early stage of psychosis would support this hypothesis. Alternatively, if the abnormalities are not present in early stage patients it would suggest that thalamocortical dysconnectivity may be progressive and a possible target for treatment intervention.
13-1	3298-3305	Despite	_	
13-2	3306-3309	the	_	
13-3	3310-3321	consistency	_	
13-4	3322-3324	of	_	
13-5	3325-3328	the	_	
13-6	3329-3337	findings	_	
13-7	3338-3344	across	_	
13-8	3345-3352	studies	_	
13-9	3352-3353	,	_	
13-10	3354-3357	key	_	
13-11	3358-3367	questions	_	
13-12	3368-3374	remain	_	
13-13	3375-3380	about	_	
13-14	3381-3384	the	_	
13-15	3385-3390	onset	_	
13-16	3390-3391	,	_	
13-17	3392-3402	anatomical	_	
13-18	3403-3414	specificity	_	
13-19	3414-3415	,	_	
13-20	3416-3419	and	_	
13-21	3420-3428	clinical	_	
13-22	3429-3439	correlates	_	
13-23	3440-3442	of	_	
13-24	3443-3451	thalamic	_	
13-25	3452-3467	dysconnectivity	_	
13-26	3467-3468	.	_	
13-27	3469-3471	It	_	
13-28	3472-3474	is	_	
13-29	3475-3482	unclear	_	
13-30	3483-3485	if	_	
13-31	3486-3489	the	_	
13-32	3490-3503	abnormalities	_	
13-33	3504-3507	are	_	
13-34	3508-3515	present	_	
13-35	3516-3521	early	_	
13-36	3522-3524	in	_	
13-37	3525-3528	the	_	
13-38	3529-3536	illness	_	
13-39	3537-3539	or	_	
13-40	3540-3546	emerge	_	
13-41	3547-3549	as	_	
13-42	3550-3553	the	_	
13-43	3554-3561	illness	_	
13-44	3562-3572	progresses	_	
13-45	3572-3573	.	_	
13-46	3574-3579	Based	_	
13-47	3580-3582	on	_	
13-48	3583-3587	what	_	
13-49	3588-3590	is	_	
13-50	3591-3596	known	_	
13-51	3597-3602	about	_	
13-52	3603-3606	the	_	
13-53	3607-3618	development	_	
13-54	3619-3621	of	_	
13-55	3622-3637	thalamocortical	_	
13-56	3638-3648	functional	_	
13-57	3649-3661	connectivity	_	
13-58	3661-3662	,	_	
13-59	3663-3665	we	_	
13-60	3666-3678	hypothesized	_	
13-61	3679-3683	that	_	
13-62	3684-3687	the	_	
13-63	3688-3699	combination	_	
13-64	3700-3702	of	_	
13-65	3703-3710	reduced	_	
13-66	3711-3714	PFC	_	
13-67	3715-3727	connectivity	_	
13-68	3728-3731	and	_	
13-69	3732-3741	increased	_	
13-70	3742-3753	somatomotor	_	
13-71	3754-3766	connectivity	_	
13-72	3767-3774	results	_	
13-73	3775-3779	from	_	
13-74	3780-3781	a	_	
13-75	3782-3793	disturbance	_	
13-76	3794-3796	in	_	
13-77	3797-3802	brain	_	
13-78	3803-3814	development	_	
13-79	3815-3821	during	_	
13-80	3822-3825	the	_	
13-81	3826-3836	transition	_	
13-82	3837-3841	from	_	
13-83	3842-3853	adolescence	_	
13-84	3854-3856	to	_	
13-85	3857-3866	adulthood	_	
13-86	3867-3871	that	_	
13-87	3872-3880	prevents	_	
13-88	3881-3893	PFC-thalamic	_	
13-89	3894-3903	circuitry	_	
13-90	3904-3908	from	_	
13-91	3909-3914	fully	_	
13-92	3915-3925	developing	_	
13-93	3926-3929	and	_	
13-94	3930-3937	derails	_	
13-95	3938-3941	the	_	
13-96	3942-3948	normal	_	
13-97	3949-3959	refinement	_	
13-98	3960-3962	of	_	
13-99	3963-3983	somatomotor-thalamic	_	
13-100	3984-3996	connectivity	_	
13-101	3996-3997	.	_	
13-102	3998-4006	Evidence	_	
13-103	4007-4009	of	_	
13-104	4010-4017	similar	_	
13-105	4018-4030	connectivity	_	
13-106	4031-4043	disturbances	_	
13-107	4044-4046	in	_	
13-108	4047-4050	the	_	
13-109	4051-4056	early	_	
13-110	4057-4062	stage	_	
13-111	4063-4065	of	_	
13-112	4066-4075	psychosis	_	
13-113	4076-4081	would	_	
13-114	4082-4089	support	_	
13-115	4090-4094	this	_	
13-116	4095-4105	hypothesis	_	
13-117	4105-4106	.	_	
13-118	4107-4120	Alternatively	_	
13-119	4120-4121	,	_	
13-120	4122-4124	if	_	
13-121	4125-4128	the	_	
13-122	4129-4142	abnormalities	_	
13-123	4143-4146	are	_	
13-124	4147-4150	not	_	
13-125	4151-4158	present	_	
13-126	4159-4161	in	_	
13-127	4162-4167	early	_	
13-128	4168-4173	stage	_	
13-129	4174-4182	patients	_	
13-130	4183-4185	it	_	
13-131	4186-4191	would	_	
13-132	4192-4199	suggest	_	
13-133	4200-4204	that	_	
13-134	4205-4220	thalamocortical	_	
13-135	4221-4236	dysconnectivity	_	
13-136	4237-4240	may	_	
13-137	4241-4243	be	_	
13-138	4244-4255	progressive	_	
13-139	4256-4259	and	_	
13-140	4260-4261	a	_	
13-141	4262-4270	possible	_	
13-142	4271-4277	target	_	
13-143	4278-4281	for	_	
13-144	4282-4291	treatment	_	
13-145	4292-4304	intervention	_	
13-146	4304-4305	.	_	

#Text=The anatomical details of thalamocortical functional dysconnectivity in psychotic disorders are not well known. Our prior study used a method initially developed to map anatomical connectivity in which the cortex is divided into large regions-of-interest (ROIs) corresponding to the main targets of specific thalamic nuclei (e.g. prefrontal cortex (PFC), occipital lobe) which are then used as seeds to delineate connectivity within the thalamus. While this method is excellent for localizing connectivity abnormalities within the thalamus, the use of large cortical ROIs limits anatomical specificity in the cortex and the rest of the brain. Alternatively, other groups have used the whole thalamus as a seed to identify thalamic connectivity abnormalities throughout the brain. However, by averaging BOLD signals across the entire thalamus, this approach treats the thalamus as a homogenous structure with a unitary connectivity profile, thereby obscuring network specific disturbances.
14-1	4306-4309	The	_	
14-2	4310-4320	anatomical	_	
14-3	4321-4328	details	_	
14-4	4329-4331	of	_	
14-5	4332-4347	thalamocortical	_	
14-6	4348-4358	functional	_	
14-7	4359-4374	dysconnectivity	_	
14-8	4375-4377	in	_	
14-9	4378-4387	psychotic	_	
14-10	4388-4397	disorders	_	
14-11	4398-4401	are	_	
14-12	4402-4405	not	_	
14-13	4406-4410	well	_	
14-14	4411-4416	known	_	
14-15	4416-4417	.	_	
14-16	4418-4421	Our	_	
14-17	4422-4427	prior	_	
14-18	4428-4433	study	_	
14-19	4434-4438	used	_	
14-20	4439-4440	a	_	
14-21	4441-4447	method	_	
14-22	4448-4457	initially	_	
14-23	4458-4467	developed	_	
14-24	4468-4470	to	_	
14-25	4471-4474	map	_	
14-26	4475-4485	anatomical	_	
14-27	4486-4498	connectivity	_	
14-28	4499-4501	in	_	
14-29	4502-4507	which	_	
14-30	4508-4511	the	_	
14-31	4512-4518	cortex	_	
14-32	4519-4521	is	_	
14-33	4522-4529	divided	_	
14-34	4530-4534	into	_	
14-35	4535-4540	large	_	
14-36	4541-4560	regions-of-interest	_	
14-37	4561-4562	(	_	
14-38	4562-4566	ROIs	_	
14-39	4566-4567	)	_	
14-40	4568-4581	corresponding	_	
14-41	4582-4584	to	_	
14-42	4585-4588	the	_	
14-43	4589-4593	main	_	
14-44	4594-4601	targets	_	
14-45	4602-4604	of	_	
14-46	4605-4613	specific	_	
14-47	4614-4622	thalamic	_	
14-48	4623-4629	nuclei	_	
14-49	4630-4631	(	_	
14-50	4631-4634	e.g	_	
14-51	4634-4635	.	_	
14-52	4636-4646	prefrontal	_	
14-53	4647-4653	cortex	_	
14-54	4654-4655	(	_	
14-55	4655-4658	PFC	_	
14-56	4658-4659	)	_	
14-57	4659-4660	,	_	
14-58	4661-4670	occipital	_	
14-59	4671-4675	lobe	_	
14-60	4675-4676	)	_	
14-61	4677-4682	which	_	
14-62	4683-4686	are	_	
14-63	4687-4691	then	_	
14-64	4692-4696	used	_	
14-65	4697-4699	as	_	
14-66	4700-4705	seeds	_	
14-67	4706-4708	to	_	
14-68	4709-4718	delineate	_	
14-69	4719-4731	connectivity	_	
14-70	4732-4738	within	_	
14-71	4739-4742	the	_	
14-72	4743-4751	thalamus	_	
14-73	4751-4752	.	_	
14-74	4753-4758	While	_	
14-75	4759-4763	this	_	
14-76	4764-4770	method	_	
14-77	4771-4773	is	_	
14-78	4774-4783	excellent	_	
14-79	4784-4787	for	_	
14-80	4788-4798	localizing	_	
14-81	4799-4811	connectivity	_	
14-82	4812-4825	abnormalities	_	
14-83	4826-4832	within	_	
14-84	4833-4836	the	_	
14-85	4837-4845	thalamus	_	
14-86	4845-4846	,	_	
14-87	4847-4850	the	_	
14-88	4851-4854	use	_	
14-89	4855-4857	of	_	
14-90	4858-4863	large	_	
14-91	4864-4872	cortical	_	
14-92	4873-4877	ROIs	_	
14-93	4878-4884	limits	_	
14-94	4885-4895	anatomical	_	
14-95	4896-4907	specificity	_	
14-96	4908-4910	in	_	
14-97	4911-4914	the	_	
14-98	4915-4921	cortex	_	
14-99	4922-4925	and	_	
14-100	4926-4929	the	_	
14-101	4930-4934	rest	_	
14-102	4935-4937	of	_	
14-103	4938-4941	the	_	
14-104	4942-4947	brain	_	
14-105	4947-4948	.	_	
14-106	4949-4962	Alternatively	_	
14-107	4962-4963	,	_	
14-108	4964-4969	other	_	
14-109	4970-4976	groups	_	
14-110	4977-4981	have	_	
14-111	4982-4986	used	_	
14-112	4987-4990	the	_	
14-113	4991-4996	whole	_	
14-114	4997-5005	thalamus	_	
14-115	5006-5008	as	_	
14-116	5009-5010	a	_	
14-117	5011-5015	seed	_	
14-118	5016-5018	to	_	
14-119	5019-5027	identify	_	
14-120	5028-5036	thalamic	_	
14-121	5037-5049	connectivity	_	
14-122	5050-5063	abnormalities	_	
14-123	5064-5074	throughout	_	
14-124	5075-5078	the	_	
14-125	5079-5084	brain	_	
14-126	5084-5085	.	_	
14-127	5086-5093	However	_	
14-128	5093-5094	,	_	
14-129	5095-5097	by	_	
14-130	5098-5107	averaging	_	
14-131	5108-5112	BOLD	_	
14-132	5113-5120	signals	_	
14-133	5121-5127	across	_	
14-134	5128-5131	the	_	
14-135	5132-5138	entire	_	
14-136	5139-5147	thalamus	_	
14-137	5147-5148	,	_	
14-138	5149-5153	this	_	
14-139	5154-5162	approach	_	
14-140	5163-5169	treats	_	
14-141	5170-5173	the	_	
14-142	5174-5182	thalamus	_	
14-143	5183-5185	as	_	
14-144	5186-5187	a	_	
14-145	5188-5198	homogenous	_	
14-146	5199-5208	structure	_	
14-147	5209-5213	with	_	
14-148	5214-5215	a	_	
14-149	5216-5223	unitary	_	
14-150	5224-5236	connectivity	_	
14-151	5237-5244	profile	_	
14-152	5244-5245	,	_	
14-153	5246-5253	thereby	_	
14-154	5254-5263	obscuring	_	
14-155	5264-5271	network	_	
14-156	5272-5280	specific	_	
14-157	5281-5293	disturbances	_	
14-158	5293-5294	.	_	

#Text=With these knowledge gaps in mind, the current investigation was undertaken to determine if similar patterns of thalamocortical dysconnectivity are observed in the early and chronic stages of psychotic disorders. Specifically, using a novel approach to better localize thalamocortical network abnormalities, we hypothesized that both chronic and early stage patients with psychosis would exhibit reduced PFC-thalamic connectivity and increased somatomotor-thalamic connectivity. Additionally, we performed exploratory analyses comparing thalamocortical dysconnectivity between schizophrenia and psychotic bipolar disorder, and examined the cognitive correlates of thalamocortical connectivity.
15-1	5295-5299	With	_	
15-2	5300-5305	these	_	
15-3	5306-5315	knowledge	_	
15-4	5316-5320	gaps	_	
15-5	5321-5323	in	_	
15-6	5324-5328	mind	_	
15-7	5328-5329	,	_	
15-8	5330-5333	the	_	
15-9	5334-5341	current	_	
15-10	5342-5355	investigation	_	
15-11	5356-5359	was	_	
15-12	5360-5370	undertaken	_	
15-13	5371-5373	to	_	
15-14	5374-5383	determine	_	
15-15	5384-5386	if	_	
15-16	5387-5394	similar	_	
15-17	5395-5403	patterns	_	
15-18	5404-5406	of	_	
15-19	5407-5422	thalamocortical	_	
15-20	5423-5438	dysconnectivity	_	
15-21	5439-5442	are	_	
15-22	5443-5451	observed	_	
15-23	5452-5454	in	_	
15-24	5455-5458	the	_	
15-25	5459-5464	early	_	
15-26	5465-5468	and	_	
15-27	5469-5476	chronic	_	
15-28	5477-5483	stages	_	
15-29	5484-5486	of	_	
15-30	5487-5496	psychotic	_	
15-31	5497-5506	disorders	_	
15-32	5506-5507	.	_	
15-33	5508-5520	Specifically	_	
15-34	5520-5521	,	_	
15-35	5522-5527	using	_	
15-36	5528-5529	a	_	
15-37	5530-5535	novel	_	
15-38	5536-5544	approach	_	
15-39	5545-5547	to	_	
15-40	5548-5554	better	_	
15-41	5555-5563	localize	_	
15-42	5564-5579	thalamocortical	_	
15-43	5580-5587	network	_	
15-44	5588-5601	abnormalities	_	
15-45	5601-5602	,	_	
15-46	5603-5605	we	_	
15-47	5606-5618	hypothesized	_	
15-48	5619-5623	that	_	
15-49	5624-5628	both	_	
15-50	5629-5636	chronic	_	
15-51	5637-5640	and	_	
15-52	5641-5646	early	_	
15-53	5647-5652	stage	_	
15-54	5653-5661	patients	_	
15-55	5662-5666	with	_	
15-56	5667-5676	psychosis	_	
15-57	5677-5682	would	_	
15-58	5683-5690	exhibit	_	
15-59	5691-5698	reduced	_	
15-60	5699-5711	PFC-thalamic	_	
15-61	5712-5724	connectivity	_	
15-62	5725-5728	and	_	
15-63	5729-5738	increased	_	
15-64	5739-5759	somatomotor-thalamic	_	
15-65	5760-5772	connectivity	_	
15-66	5772-5773	.	_	
15-67	5774-5786	Additionally	_	
15-68	5786-5787	,	_	
15-69	5788-5790	we	_	
15-70	5791-5800	performed	_	
15-71	5801-5812	exploratory	_	
15-72	5813-5821	analyses	_	
15-73	5822-5831	comparing	_	
15-74	5832-5847	thalamocortical	_	
15-75	5848-5863	dysconnectivity	_	
15-76	5864-5871	between	_	
15-77	5872-5885	schizophrenia	_	
15-78	5886-5889	and	_	
15-79	5890-5899	psychotic	_	
15-80	5900-5907	bipolar	_	
15-81	5908-5916	disorder	_	
15-82	5916-5917	,	_	
15-83	5918-5921	and	_	
15-84	5922-5930	examined	_	
15-85	5931-5934	the	_	
15-86	5935-5944	cognitive	_	
15-87	5945-5955	correlates	_	
15-88	5956-5958	of	_	
15-89	5959-5974	thalamocortical	_	
15-90	5975-5987	connectivity	_	
15-91	5987-5988	.	_	

#Text=METHODS AND MATERIALS
16-1	5989-5996	METHODS	_	
16-2	5997-6000	AND	_	
16-3	6001-6010	MATERIALS	_	

#Text=Study Participants
17-1	6011-6016	Study	_	
17-2	6017-6029	Participants	_	

#Text=105 healthy subjects and 148 individuals with a psychotic disorder were included in this investigation (see Table 1). The psychosis group included individuals with schizophrenia/schizoaffective disorder (i.e. non-affective psychosis) and bipolar I disorder with psychotic features (i.e. affective psychosis). 53 patients were within two years of illness onset and considered early stage. Most early stage psychosis patients were studied at the time of their first hospitalization for a psychotic disorder, or very shortly thereafter, and had been ill for less than 4 months on average. At the time of study participation, 25 early stage patients were diagnosed with schizophreniform disorder. Follow-up diagnostic data was available on 22 of these patients; 20 converted to a non-affective psychotic disorder, 1 remained diagnosed with schizophreniform disorder, and 1 was subsequently re-classified as affective psychosis. All subjects underwent a structured clinical interview and completed a brief cognitive assessment that included the Wechsler Test of Adult Reading to estimate pre-morbid IQ and the Screen for Cognitive Impairment in Psychiatry which includes tests of verbal learning, working memory, verbal fluency, and processing speed. In addition, patients were also assessed with the Positive and Negative Syndrome Scale (PANSS: 22) to quantify severity of clinical symptoms. Study procedures and exclusion criteria are described in detail in the Supplemental Material. This study was approved by the Vanderbilt University Institutional Review Board.
18-1	6030-6033	105	_	
18-2	6034-6041	healthy	_	
18-3	6042-6050	subjects	_	
18-4	6051-6054	and	_	
18-5	6055-6058	148	_	
18-6	6059-6070	individuals	_	
18-7	6071-6075	with	_	
18-8	6076-6077	a	_	
18-9	6078-6087	psychotic	_	
18-10	6088-6096	disorder	_	
18-11	6097-6101	were	_	
18-12	6102-6110	included	_	
18-13	6111-6113	in	_	
18-14	6114-6118	this	_	
18-15	6119-6132	investigation	_	
18-16	6133-6134	(	_	
18-17	6134-6137	see	_	
18-18	6138-6143	Table	_	
18-19	6144-6145	1	_	
18-20	6145-6146	)	_	
18-21	6146-6147	.	_	
18-22	6148-6151	The	_	
18-23	6152-6161	psychosis	_	
18-24	6162-6167	group	_	
18-25	6168-6176	included	_	
18-26	6177-6188	individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
18-27	6189-6193	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
18-28	6194-6207	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
18-29	6207-6208	/	_	
18-30	6208-6223	schizoaffective	_	
18-31	6224-6232	disorder	_	
18-32	6233-6234	(	_	
18-33	6234-6237	i.e	_	
18-34	6237-6238	.	_	
18-35	6239-6252	non-affective	_	
18-36	6253-6262	psychosis	_	
18-37	6262-6263	)	_	
18-38	6264-6267	and	_	
18-39	6268-6275	bipolar	_	
18-40	6276-6277	I	_	
18-41	6278-6286	disorder	_	
18-42	6287-6291	with	_	
18-43	6292-6301	psychotic	_	
18-44	6302-6310	features	_	
18-45	6311-6312	(	_	
18-46	6312-6315	i.e	_	
18-47	6315-6316	.	_	
18-48	6317-6326	affective	_	
18-49	6327-6336	psychosis	_	
18-50	6336-6337	)	_	
18-51	6337-6338	.	_	
18-52	6339-6341	53	_	
18-53	6342-6350	patients	_	
18-54	6351-6355	were	_	
18-55	6356-6362	within	_	
18-56	6363-6366	two	_	
18-57	6367-6372	years	_	
18-58	6373-6375	of	_	
18-59	6376-6383	illness	_	
18-60	6384-6389	onset	_	
18-61	6390-6393	and	_	
18-62	6394-6404	considered	_	
18-63	6405-6410	early	_	
18-64	6411-6416	stage	_	
18-65	6416-6417	.	_	
18-66	6418-6422	Most	_	
18-67	6423-6428	early	_	
18-68	6429-6434	stage	_	
18-69	6435-6444	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[9]	
18-70	6445-6453	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[9]	
18-71	6454-6458	were	_	
18-72	6459-6466	studied	_	
18-73	6467-6469	at	_	
18-74	6470-6473	the	_	
18-75	6474-6478	time	_	
18-76	6479-6481	of	_	
18-77	6482-6487	their	_	
18-78	6488-6493	first	_	
18-79	6494-6509	hospitalization	_	
18-80	6510-6513	for	_	
18-81	6514-6515	a	_	
18-82	6516-6525	psychotic	_	
18-83	6526-6534	disorder	_	
18-84	6534-6535	,	_	
18-85	6536-6538	or	_	
18-86	6539-6543	very	_	
18-87	6544-6551	shortly	_	
18-88	6552-6562	thereafter	_	
18-89	6562-6563	,	_	
18-90	6564-6567	and	_	
18-91	6568-6571	had	_	
18-92	6572-6576	been	_	
18-93	6577-6580	ill	_	
18-94	6581-6584	for	_	
18-95	6585-6589	less	_	
18-96	6590-6594	than	_	
18-97	6595-6596	4	_	
18-98	6597-6603	months	_	
18-99	6604-6606	on	_	
18-100	6607-6614	average	_	
18-101	6614-6615	.	_	
18-102	6616-6618	At	_	
18-103	6619-6622	the	_	
18-104	6623-6627	time	_	
18-105	6628-6630	of	_	
18-106	6631-6636	study	_	
18-107	6637-6650	participation	_	
18-108	6650-6651	,	_	
18-109	6652-6654	25	_	
18-110	6655-6660	early	_	
18-111	6661-6666	stage	_	
18-112	6667-6675	patients	_	
18-113	6676-6680	were	_	
18-114	6681-6690	diagnosed	_	
18-115	6691-6695	with	_	
18-116	6696-6712	schizophreniform	_	
18-117	6713-6721	disorder	_	
18-118	6721-6722	.	_	
18-119	6723-6732	Follow-up	_	
18-120	6733-6743	diagnostic	_	
18-121	6744-6748	data	_	
18-122	6749-6752	was	_	
18-123	6753-6762	available	_	
18-124	6763-6765	on	_	
18-125	6766-6768	22	_	
18-126	6769-6771	of	_	
18-127	6772-6777	these	_	
18-128	6778-6786	patients	_	
18-129	6786-6787	;	_	
18-130	6788-6790	20	_	
18-131	6791-6800	converted	_	
18-132	6801-6803	to	_	
18-133	6804-6805	a	_	
18-134	6806-6819	non-affective	_	
18-135	6820-6829	psychotic	_	
18-136	6830-6838	disorder	_	
18-137	6838-6839	,	_	
18-138	6840-6841	1	_	
18-139	6842-6850	remained	_	
18-140	6851-6860	diagnosed	_	
18-141	6861-6865	with	_	
18-142	6866-6882	schizophreniform	_	
18-143	6883-6891	disorder	_	
18-144	6891-6892	,	_	
18-145	6893-6896	and	_	
18-146	6897-6898	1	_	
18-147	6899-6902	was	_	
18-148	6903-6915	subsequently	_	
18-149	6916-6929	re-classified	_	
18-150	6930-6932	as	_	
18-151	6933-6942	affective	_	
18-152	6943-6952	psychosis	_	
18-153	6952-6953	.	_	
18-154	6954-6957	All	_	
18-155	6958-6966	subjects	_	
18-156	6967-6976	underwent	_	
18-157	6977-6978	a	_	
18-158	6979-6989	structured	_	
18-159	6990-6998	clinical	_	
18-160	6999-7008	interview	_	
18-161	7009-7012	and	_	
18-162	7013-7022	completed	_	
18-163	7023-7024	a	_	
18-164	7025-7030	brief	_	
18-165	7031-7040	cognitive	_	
18-166	7041-7051	assessment	_	
18-167	7052-7056	that	_	
18-168	7057-7065	included	_	
18-169	7066-7069	the	_	
18-170	7070-7078	Wechsler	_	
18-171	7079-7083	Test	_	
18-172	7084-7086	of	_	
18-173	7087-7092	Adult	_	
18-174	7093-7100	Reading	_	
18-175	7101-7103	to	_	
18-176	7104-7112	estimate	_	
18-177	7113-7123	pre-morbid	_	
18-178	7124-7126	IQ	_	
18-179	7127-7130	and	_	
18-180	7131-7134	the	_	
18-181	7135-7141	Screen	_	
18-182	7142-7145	for	_	
18-183	7146-7155	Cognitive	_	
18-184	7156-7166	Impairment	_	
18-185	7167-7169	in	_	
18-186	7170-7180	Psychiatry	_	
18-187	7181-7186	which	_	
18-188	7187-7195	includes	_	
18-189	7196-7201	tests	_	
18-190	7202-7204	of	_	
18-191	7205-7211	verbal	_	
18-192	7212-7220	learning	_	
18-193	7220-7221	,	_	
18-194	7222-7229	working	_	
18-195	7230-7236	memory	_	
18-196	7236-7237	,	_	
18-197	7238-7244	verbal	_	
18-198	7245-7252	fluency	_	
18-199	7252-7253	,	_	
18-200	7254-7257	and	_	
18-201	7258-7268	processing	_	
18-202	7269-7274	speed	_	
18-203	7274-7275	.	_	
18-204	7276-7278	In	_	
18-205	7279-7287	addition	_	
18-206	7287-7288	,	_	
18-207	7289-7297	patients	_	
18-208	7298-7302	were	_	
18-209	7303-7307	also	_	
18-210	7308-7316	assessed	_	
18-211	7317-7321	with	_	
18-212	7322-7325	the	_	
18-213	7326-7334	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
18-214	7335-7338	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
18-215	7339-7347	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
18-216	7348-7356	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
18-217	7357-7362	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
18-218	7363-7364	(	_	
18-219	7364-7369	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
18-220	7369-7370	:	_	
18-221	7371-7373	22	_	
18-222	7373-7374	)	_	
18-223	7375-7377	to	_	
18-224	7378-7386	quantify	_	
18-225	7387-7395	severity	_	
18-226	7396-7398	of	_	
18-227	7399-7407	clinical	_	
18-228	7408-7416	symptoms	_	
18-229	7416-7417	.	_	
18-230	7418-7423	Study	_	
18-231	7424-7434	procedures	_	
18-232	7435-7438	and	_	
18-233	7439-7448	exclusion	_	
18-234	7449-7457	criteria	_	
18-235	7458-7461	are	_	
18-236	7462-7471	described	_	
18-237	7472-7474	in	_	
18-238	7475-7481	detail	_	
18-239	7482-7484	in	_	
18-240	7485-7488	the	_	
18-241	7489-7501	Supplemental	_	
18-242	7502-7510	Material	_	
18-243	7510-7511	.	_	
18-244	7512-7516	This	_	
18-245	7517-7522	study	_	
18-246	7523-7526	was	_	
18-247	7527-7535	approved	_	
18-248	7536-7538	by	_	
18-249	7539-7542	the	_	
18-250	7543-7553	Vanderbilt	_	
18-251	7554-7564	University	_	
18-252	7565-7578	Institutional	_	
18-253	7579-7585	Review	_	
18-254	7586-7591	Board	_	
18-255	7591-7592	.	_	

#Text=Neuroimaging Data Acquisition and Functional Connectivity Analysis
19-1	7593-7605	Neuroimaging	_	
19-2	7606-7610	Data	_	
19-3	7611-7622	Acquisition	_	
19-4	7623-7626	and	_	
19-5	7627-7637	Functional	_	
19-6	7638-7650	Connectivity	_	
19-7	7651-7659	Analysis	_	

#Text=Imaging data acquisition and pre-processing are described in detail in the Supplemental Material. Briefly, a 7-minute echo-planar imaging resting-state scan and a high-resolution T1-weighted structural scan were collected on each subject. Functional images were slice-time corrected, motion corrected, co-registered to native space structural data, and normalized to MNI space. As described earlier, prior investigations of thalamocortical functional dysconnectivity in psychosis have either: 1) parceled the cortex into large, anatomically defined ROIs corresponding to the primary cortical targets of specific thalamic sub-regions (e.g. PFC) and used these as seeds to identify functional connectivity within the thalamus; or 2) used the whole thalamus as a seed to map thalamic connectivity with the rest of the brain. The primary advantage of the first method is that it can map multiple thalamic networks and segment the thalamus according to its functional connectivity. However, the use of large cortical ROIs limits spatial specificity within the cortex. Using the whole thalamus as a seed overcomes this limitation, but, by averaging BOLD signals from the entire thalamus, precludes an analysis of specific thalamocortical networks.
20-1	7660-7667	Imaging	_	
20-2	7668-7672	data	_	
20-3	7673-7684	acquisition	_	
20-4	7685-7688	and	_	
20-5	7689-7703	pre-processing	_	
20-6	7704-7707	are	_	
20-7	7708-7717	described	_	
20-8	7718-7720	in	_	
20-9	7721-7727	detail	_	
20-10	7728-7730	in	_	
20-11	7731-7734	the	_	
20-12	7735-7747	Supplemental	_	
20-13	7748-7756	Material	_	
20-14	7756-7757	.	_	
20-15	7758-7765	Briefly	_	
20-16	7765-7766	,	_	
20-17	7767-7768	a	_	
20-18	7769-7770	7	_	
20-19	7770-7771	-	_	
20-20	7771-7777	minute	_	
20-21	7778-7789	echo-planar	_	
20-22	7790-7797	imaging	_	
20-23	7798-7811	resting-state	_	
20-24	7812-7816	scan	_	
20-25	7817-7820	and	_	
20-26	7821-7822	a	_	
20-27	7823-7838	high-resolution	_	
20-28	7839-7841	T1	_	
20-29	7841-7842	-	_	
20-30	7842-7850	weighted	_	
20-31	7851-7861	structural	_	
20-32	7862-7866	scan	_	
20-33	7867-7871	were	_	
20-34	7872-7881	collected	_	
20-35	7882-7884	on	_	
20-36	7885-7889	each	_	
20-37	7890-7897	subject	_	
20-38	7897-7898	.	_	
20-39	7899-7909	Functional	_	
20-40	7910-7916	images	_	
20-41	7917-7921	were	_	
20-42	7922-7932	slice-time	_	
20-43	7933-7942	corrected	_	
20-44	7942-7943	,	_	
20-45	7944-7950	motion	_	
20-46	7951-7960	corrected	_	
20-47	7960-7961	,	_	
20-48	7962-7975	co-registered	_	
20-49	7976-7978	to	_	
20-50	7979-7985	native	_	
20-51	7986-7991	space	_	
20-52	7992-8002	structural	_	
20-53	8003-8007	data	_	
20-54	8007-8008	,	_	
20-55	8009-8012	and	_	
20-56	8013-8023	normalized	_	
20-57	8024-8026	to	_	
20-58	8027-8030	MNI	_	
20-59	8031-8036	space	_	
20-60	8036-8037	.	_	
20-61	8038-8040	As	_	
20-62	8041-8050	described	_	
20-63	8051-8058	earlier	_	
20-64	8058-8059	,	_	
20-65	8060-8065	prior	_	
20-66	8066-8080	investigations	_	
20-67	8081-8083	of	_	
20-68	8084-8099	thalamocortical	_	
20-69	8100-8110	functional	_	
20-70	8111-8126	dysconnectivity	_	
20-71	8127-8129	in	_	
20-72	8130-8139	psychosis	_	
20-73	8140-8144	have	_	
20-74	8145-8151	either	_	
20-75	8151-8152	:	_	
20-76	8153-8154	1	_	
20-77	8154-8155	)	_	
20-78	8156-8164	parceled	_	
20-79	8165-8168	the	_	
20-80	8169-8175	cortex	_	
20-81	8176-8180	into	_	
20-82	8181-8186	large	_	
20-83	8186-8187	,	_	
20-84	8188-8200	anatomically	_	
20-85	8201-8208	defined	_	
20-86	8209-8213	ROIs	_	
20-87	8214-8227	corresponding	_	
20-88	8228-8230	to	_	
20-89	8231-8234	the	_	
20-90	8235-8242	primary	_	
20-91	8243-8251	cortical	_	
20-92	8252-8259	targets	_	
20-93	8260-8262	of	_	
20-94	8263-8271	specific	_	
20-95	8272-8280	thalamic	_	
20-96	8281-8292	sub-regions	_	
20-97	8293-8294	(	_	
20-98	8294-8297	e.g	_	
20-99	8297-8298	.	_	
20-100	8299-8302	PFC	_	
20-101	8302-8303	)	_	
20-102	8304-8307	and	_	
20-103	8308-8312	used	_	
20-104	8313-8318	these	_	
20-105	8319-8321	as	_	
20-106	8322-8327	seeds	_	
20-107	8328-8330	to	_	
20-108	8331-8339	identify	_	
20-109	8340-8350	functional	_	
20-110	8351-8363	connectivity	_	
20-111	8364-8370	within	_	
20-112	8371-8374	the	_	
20-113	8375-8383	thalamus	_	
20-114	8383-8384	;	_	
20-115	8385-8387	or	_	
20-116	8388-8389	2	_	
20-117	8389-8390	)	_	
20-118	8391-8395	used	_	
20-119	8396-8399	the	_	
20-120	8400-8405	whole	_	
20-121	8406-8414	thalamus	_	
20-122	8415-8417	as	_	
20-123	8418-8419	a	_	
20-124	8420-8424	seed	_	
20-125	8425-8427	to	_	
20-126	8428-8431	map	_	
20-127	8432-8440	thalamic	_	
20-128	8441-8453	connectivity	_	
20-129	8454-8458	with	_	
20-130	8459-8462	the	_	
20-131	8463-8467	rest	_	
20-132	8468-8470	of	_	
20-133	8471-8474	the	_	
20-134	8475-8480	brain	_	
20-135	8480-8481	.	_	
20-136	8482-8485	The	_	
20-137	8486-8493	primary	_	
20-138	8494-8503	advantage	_	
20-139	8504-8506	of	_	
20-140	8507-8510	the	_	
20-141	8511-8516	first	_	
20-142	8517-8523	method	_	
20-143	8524-8526	is	_	
20-144	8527-8531	that	_	
20-145	8532-8534	it	_	
20-146	8535-8538	can	_	
20-147	8539-8542	map	_	
20-148	8543-8551	multiple	_	
20-149	8552-8560	thalamic	_	
20-150	8561-8569	networks	_	
20-151	8570-8573	and	_	
20-152	8574-8581	segment	_	
20-153	8582-8585	the	_	
20-154	8586-8594	thalamus	_	
20-155	8595-8604	according	_	
20-156	8605-8607	to	_	
20-157	8608-8611	its	_	
20-158	8612-8622	functional	_	
20-159	8623-8635	connectivity	_	
20-160	8635-8636	.	_	
20-161	8637-8644	However	_	
20-162	8644-8645	,	_	
20-163	8646-8649	the	_	
20-164	8650-8653	use	_	
20-165	8654-8656	of	_	
20-166	8657-8662	large	_	
20-167	8663-8671	cortical	_	
20-168	8672-8676	ROIs	_	
20-169	8677-8683	limits	_	
20-170	8684-8691	spatial	_	
20-171	8692-8703	specificity	_	
20-172	8704-8710	within	_	
20-173	8711-8714	the	_	
20-174	8715-8721	cortex	_	
20-175	8721-8722	.	_	
20-176	8723-8728	Using	_	
20-177	8729-8732	the	_	
20-178	8733-8738	whole	_	
20-179	8739-8747	thalamus	_	
20-180	8748-8750	as	_	
20-181	8751-8752	a	_	
20-182	8753-8757	seed	_	
20-183	8758-8767	overcomes	_	
20-184	8768-8772	this	_	
20-185	8773-8783	limitation	_	
20-186	8783-8784	,	_	
20-187	8785-8788	but	_	
20-188	8788-8789	,	_	
20-189	8790-8792	by	_	
20-190	8793-8802	averaging	_	
20-191	8803-8807	BOLD	_	
20-192	8808-8815	signals	_	
20-193	8816-8820	from	_	
20-194	8821-8824	the	_	
20-195	8825-8831	entire	_	
20-196	8832-8840	thalamus	_	
20-197	8840-8841	,	_	
20-198	8842-8851	precludes	_	
20-199	8852-8854	an	_	
20-200	8855-8863	analysis	_	
20-201	8864-8866	of	_	
20-202	8867-8875	specific	_	
20-203	8876-8891	thalamocortical	_	
20-204	8892-8900	networks	_	
20-205	8900-8901	.	_	

#Text=To overcome these limitations, we combined elements of both methods. First, we performed a ‘cortical ROI-to-thalamus ROI’ analysis in which connectivity between anatomically defined cortical ROIs and functionally defined thalamic ROIs was calculated and compared across groups (see Figure 1A). This primary analysis was followed up with seed-based analyses examining connectivity of functionally defined thalamic sub-regions with the rest of the brain. The analysis steps were as follows. First, as described previously, the cortex was divided into six, a-priori defined non-overlapping ROIs shown in Figure 1A. Functional connectivity maps, restricted to the Harvard-Oxford thalamus probabilistic atlas (thresholded at 10%), were then created for each cortical ROI. Using the entire dataset of 253 individuals, the thalamus was parceled into functional ROIs using the ‘winner take all’ strategy; each voxel in the thalamus was assigned to the cortical ROI it was most strongly connected to. Average connectivity of the voxels within each thalamic ROI with its respective cortical ROI was then calculated resulting in 6 thalamocortical ‘network’ values for each subject; one for each cortical anatomical ROI and its corresponding thalamic functional ROI which served as the dependent variables in the statistical analysis. Thalamocortical network values were analyzed using multivariate repeated measures ANOVA with network entered as the within the subjects variable, group a between subjects variable, and age and sex entered as covariates.
21-1	8902-8904	To	_	
21-2	8905-8913	overcome	_	
21-3	8914-8919	these	_	
21-4	8920-8931	limitations	_	
21-5	8931-8932	,	_	
21-6	8933-8935	we	_	
21-7	8936-8944	combined	_	
21-8	8945-8953	elements	_	
21-9	8954-8956	of	_	
21-10	8957-8961	both	_	
21-11	8962-8969	methods	_	
21-12	8969-8970	.	_	
21-13	8971-8976	First	_	
21-14	8976-8977	,	_	
21-15	8978-8980	we	_	
21-16	8981-8990	performed	_	
21-17	8991-8992	a	_	
21-18	8993-8994	‘	_	
21-19	8994-9002	cortical	_	
21-20	9003-9018	ROI-to-thalamus	_	
21-21	9019-9022	ROI	_	
21-22	9022-9023	’	_	
21-23	9024-9032	analysis	_	
21-24	9033-9035	in	_	
21-25	9036-9041	which	_	
21-26	9042-9054	connectivity	_	
21-27	9055-9062	between	_	
21-28	9063-9075	anatomically	_	
21-29	9076-9083	defined	_	
21-30	9084-9092	cortical	_	
21-31	9093-9097	ROIs	_	
21-32	9098-9101	and	_	
21-33	9102-9114	functionally	_	
21-34	9115-9122	defined	_	
21-35	9123-9131	thalamic	_	
21-36	9132-9136	ROIs	_	
21-37	9137-9140	was	_	
21-38	9141-9151	calculated	_	
21-39	9152-9155	and	_	
21-40	9156-9164	compared	_	
21-41	9165-9171	across	_	
21-42	9172-9178	groups	_	
21-43	9179-9180	(	_	
21-44	9180-9183	see	_	
21-45	9184-9190	Figure	_	
21-46	9191-9193	1A	_	
21-47	9193-9194	)	_	
21-48	9194-9195	.	_	
21-49	9196-9200	This	_	
21-50	9201-9208	primary	_	
21-51	9209-9217	analysis	_	
21-52	9218-9221	was	_	
21-53	9222-9230	followed	_	
21-54	9231-9233	up	_	
21-55	9234-9238	with	_	
21-56	9239-9249	seed-based	_	
21-57	9250-9258	analyses	_	
21-58	9259-9268	examining	_	
21-59	9269-9281	connectivity	_	
21-60	9282-9284	of	_	
21-61	9285-9297	functionally	_	
21-62	9298-9305	defined	_	
21-63	9306-9314	thalamic	_	
21-64	9315-9326	sub-regions	_	
21-65	9327-9331	with	_	
21-66	9332-9335	the	_	
21-67	9336-9340	rest	_	
21-68	9341-9343	of	_	
21-69	9344-9347	the	_	
21-70	9348-9353	brain	_	
21-71	9353-9354	.	_	
21-72	9355-9358	The	_	
21-73	9359-9367	analysis	_	
21-74	9368-9373	steps	_	
21-75	9374-9378	were	_	
21-76	9379-9381	as	_	
21-77	9382-9389	follows	_	
21-78	9389-9390	.	_	
21-79	9391-9396	First	_	
21-80	9396-9397	,	_	
21-81	9398-9400	as	_	
21-82	9401-9410	described	_	
21-83	9411-9421	previously	_	
21-84	9421-9422	,	_	
21-85	9423-9426	the	_	
21-86	9427-9433	cortex	_	
21-87	9434-9437	was	_	
21-88	9438-9445	divided	_	
21-89	9446-9450	into	_	
21-90	9451-9454	six	_	
21-91	9454-9455	,	_	
21-92	9456-9464	a-priori	_	
21-93	9465-9472	defined	_	
21-94	9473-9488	non-overlapping	_	
21-95	9489-9493	ROIs	_	
21-96	9494-9499	shown	_	
21-97	9500-9502	in	_	
21-98	9503-9509	Figure	_	
21-99	9510-9512	1A	_	
21-100	9512-9513	.	_	
21-101	9514-9524	Functional	_	
21-102	9525-9537	connectivity	_	
21-103	9538-9542	maps	_	
21-104	9542-9543	,	_	
21-105	9544-9554	restricted	_	
21-106	9555-9557	to	_	
21-107	9558-9561	the	_	
21-108	9562-9576	Harvard-Oxford	_	
21-109	9577-9585	thalamus	_	
21-110	9586-9599	probabilistic	_	
21-111	9600-9605	atlas	_	
21-112	9606-9607	(	_	
21-113	9607-9618	thresholded	_	
21-114	9619-9621	at	_	
21-115	9622-9625	10%	_	
21-116	9625-9626	)	_	
21-117	9626-9627	,	_	
21-118	9628-9632	were	_	
21-119	9633-9637	then	_	
21-120	9638-9645	created	_	
21-121	9646-9649	for	_	
21-122	9650-9654	each	_	
21-123	9655-9663	cortical	_	
21-124	9664-9667	ROI	_	
21-125	9667-9668	.	_	
21-126	9669-9674	Using	_	
21-127	9675-9678	the	_	
21-128	9679-9685	entire	_	
21-129	9686-9693	dataset	_	
21-130	9694-9696	of	_	
21-131	9697-9700	253	_	
21-132	9701-9712	individuals	_	
21-133	9712-9713	,	_	
21-134	9714-9717	the	_	
21-135	9718-9726	thalamus	_	
21-136	9727-9730	was	_	
21-137	9731-9739	parceled	_	
21-138	9740-9744	into	_	
21-139	9745-9755	functional	_	
21-140	9756-9760	ROIs	_	
21-141	9761-9766	using	_	
21-142	9767-9770	the	_	
21-143	9771-9772	‘	_	
21-144	9772-9778	winner	_	
21-145	9779-9783	take	_	
21-146	9784-9787	all	_	
21-147	9787-9788	’	_	
21-148	9789-9797	strategy	_	
21-149	9797-9798	;	_	
21-150	9799-9803	each	_	
21-151	9804-9809	voxel	_	
21-152	9810-9812	in	_	
21-153	9813-9816	the	_	
21-154	9817-9825	thalamus	_	
21-155	9826-9829	was	_	
21-156	9830-9838	assigned	_	
21-157	9839-9841	to	_	
21-158	9842-9845	the	_	
21-159	9846-9854	cortical	_	
21-160	9855-9858	ROI	_	
21-161	9859-9861	it	_	
21-162	9862-9865	was	_	
21-163	9866-9870	most	_	
21-164	9871-9879	strongly	_	
21-165	9880-9889	connected	_	
21-166	9890-9892	to	_	
21-167	9892-9893	.	_	
21-168	9894-9901	Average	_	
21-169	9902-9914	connectivity	_	
21-170	9915-9917	of	_	
21-171	9918-9921	the	_	
21-172	9922-9928	voxels	_	
21-173	9929-9935	within	_	
21-174	9936-9940	each	_	
21-175	9941-9949	thalamic	_	
21-176	9950-9953	ROI	_	
21-177	9954-9958	with	_	
21-178	9959-9962	its	_	
21-179	9963-9973	respective	_	
21-180	9974-9982	cortical	_	
21-181	9983-9986	ROI	_	
21-182	9987-9990	was	_	
21-183	9991-9995	then	_	
21-184	9996-10006	calculated	_	
21-185	10007-10016	resulting	_	
21-186	10017-10019	in	_	
21-187	10020-10021	6	_	
21-188	10022-10037	thalamocortical	_	
21-189	10038-10039	‘	_	
21-190	10039-10046	network	_	
21-191	10046-10047	’	_	
21-192	10048-10054	values	_	
21-193	10055-10058	for	_	
21-194	10059-10063	each	_	
21-195	10064-10071	subject	_	
21-196	10071-10072	;	_	
21-197	10073-10076	one	_	
21-198	10077-10080	for	_	
21-199	10081-10085	each	_	
21-200	10086-10094	cortical	_	
21-201	10095-10105	anatomical	_	
21-202	10106-10109	ROI	_	
21-203	10110-10113	and	_	
21-204	10114-10117	its	_	
21-205	10118-10131	corresponding	_	
21-206	10132-10140	thalamic	_	
21-207	10141-10151	functional	_	
21-208	10152-10155	ROI	_	
21-209	10156-10161	which	_	
21-210	10162-10168	served	_	
21-211	10169-10171	as	_	
21-212	10172-10175	the	_	
21-213	10176-10185	dependent	_	
21-214	10186-10195	variables	_	
21-215	10196-10198	in	_	
21-216	10199-10202	the	_	
21-217	10203-10214	statistical	_	
21-218	10215-10223	analysis	_	
21-219	10223-10224	.	_	
21-220	10225-10240	Thalamocortical	_	
21-221	10241-10248	network	_	
21-222	10249-10255	values	_	
21-223	10256-10260	were	_	
21-224	10261-10269	analyzed	_	
21-225	10270-10275	using	_	
21-226	10276-10288	multivariate	_	
21-227	10289-10297	repeated	_	
21-228	10298-10306	measures	_	
21-229	10307-10312	ANOVA	_	
21-230	10313-10317	with	_	
21-231	10318-10325	network	_	
21-232	10326-10333	entered	_	
21-233	10334-10336	as	_	
21-234	10337-10340	the	_	
21-235	10341-10347	within	_	
21-236	10348-10351	the	_	
21-237	10352-10360	subjects	_	
21-238	10361-10369	variable	_	
21-239	10369-10370	,	_	
21-240	10371-10376	group	_	
21-241	10377-10378	a	_	
21-242	10379-10386	between	_	
21-243	10387-10395	subjects	_	
21-244	10396-10404	variable	_	
21-245	10404-10405	,	_	
21-246	10406-10409	and	_	
21-247	10410-10413	age	_	
21-248	10414-10417	and	_	
21-249	10418-10421	sex	_	
21-250	10422-10429	entered	_	
21-251	10430-10432	as	_	
21-252	10433-10443	covariates	_	
21-253	10443-10444	.	_	

#Text=The ‘cortical ROI-to-thalamic ROI’ analysis described above was followed up with seed-based connectivity analyses using the thalamic functional ROIs as seeds to examine connectivity of specific thalamic sub-regions with the rest of the brain. Briefly, the mean BOLD times series derived from the thalamic ROIs was extracted from each subjects’ unsmoothed functional data and entered into a general linear model to create functional connectivity maps of specific thalamic ROIs. The functional connectivity maps, in beta units, were then smoothed (6 mm) and entered into a one-way ANOVA with group entered as the between subjects variable, and age and sex as covariates. A priori contrasts comparing healthy subjects to psychosis patients and each patient group (i.e. chronic, early stage) to healthy subjects were performed. Results were thresholded at the cluster-level pFWE-corrected=.05 for voxel-wise p=.005, masked to include only voxels that demonstrated significant positive functional connectivity in healthy subjects and/or psychosis patients at the cluster-level pFWE-corrected=.05 for voxel-wise p=.005.
22-1	10445-10448	The	_	
22-2	10449-10450	‘	_	
22-3	10450-10458	cortical	_	
22-4	10459-10474	ROI-to-thalamic	_	
22-5	10475-10478	ROI	_	
22-6	10478-10479	’	_	
22-7	10480-10488	analysis	_	
22-8	10489-10498	described	_	
22-9	10499-10504	above	_	
22-10	10505-10508	was	_	
22-11	10509-10517	followed	_	
22-12	10518-10520	up	_	
22-13	10521-10525	with	_	
22-14	10526-10536	seed-based	_	
22-15	10537-10549	connectivity	_	
22-16	10550-10558	analyses	_	
22-17	10559-10564	using	_	
22-18	10565-10568	the	_	
22-19	10569-10577	thalamic	_	
22-20	10578-10588	functional	_	
22-21	10589-10593	ROIs	_	
22-22	10594-10596	as	_	
22-23	10597-10602	seeds	_	
22-24	10603-10605	to	_	
22-25	10606-10613	examine	_	
22-26	10614-10626	connectivity	_	
22-27	10627-10629	of	_	
22-28	10630-10638	specific	_	
22-29	10639-10647	thalamic	_	
22-30	10648-10659	sub-regions	_	
22-31	10660-10664	with	_	
22-32	10665-10668	the	_	
22-33	10669-10673	rest	_	
22-34	10674-10676	of	_	
22-35	10677-10680	the	_	
22-36	10681-10686	brain	_	
22-37	10686-10687	.	_	
22-38	10688-10695	Briefly	_	
22-39	10695-10696	,	_	
22-40	10697-10700	the	_	
22-41	10701-10705	mean	_	
22-42	10706-10710	BOLD	_	
22-43	10711-10716	times	_	
22-44	10717-10723	series	_	
22-45	10724-10731	derived	_	
22-46	10732-10736	from	_	
22-47	10737-10740	the	_	
22-48	10741-10749	thalamic	_	
22-49	10750-10754	ROIs	_	
22-50	10755-10758	was	_	
22-51	10759-10768	extracted	_	
22-52	10769-10773	from	_	
22-53	10774-10778	each	_	
22-54	10779-10787	subjects	_	
22-55	10787-10788	’	_	
22-56	10789-10799	unsmoothed	_	
22-57	10800-10810	functional	_	
22-58	10811-10815	data	_	
22-59	10816-10819	and	_	
22-60	10820-10827	entered	_	
22-61	10828-10832	into	_	
22-62	10833-10834	a	_	
22-63	10835-10842	general	_	
22-64	10843-10849	linear	_	
22-65	10850-10855	model	_	
22-66	10856-10858	to	_	
22-67	10859-10865	create	_	
22-68	10866-10876	functional	_	
22-69	10877-10889	connectivity	_	
22-70	10890-10894	maps	_	
22-71	10895-10897	of	_	
22-72	10898-10906	specific	_	
22-73	10907-10915	thalamic	_	
22-74	10916-10920	ROIs	_	
22-75	10920-10921	.	_	
22-76	10922-10925	The	_	
22-77	10926-10936	functional	_	
22-78	10937-10949	connectivity	_	
22-79	10950-10954	maps	_	
22-80	10954-10955	,	_	
22-81	10956-10958	in	_	
22-82	10959-10963	beta	_	
22-83	10964-10969	units	_	
22-84	10969-10970	,	_	
22-85	10971-10975	were	_	
22-86	10976-10980	then	_	
22-87	10981-10989	smoothed	_	
22-88	10990-10991	(	_	
22-89	10991-10992	6	_	
22-90	10993-10995	mm	_	
22-91	10995-10996	)	_	
22-92	10997-11000	and	_	
22-93	11001-11008	entered	_	
22-94	11009-11013	into	_	
22-95	11014-11015	a	_	
22-96	11016-11023	one-way	_	
22-97	11024-11029	ANOVA	_	
22-98	11030-11034	with	_	
22-99	11035-11040	group	_	
22-100	11041-11048	entered	_	
22-101	11049-11051	as	_	
22-102	11052-11055	the	_	
22-103	11056-11063	between	_	
22-104	11064-11072	subjects	_	
22-105	11073-11081	variable	_	
22-106	11081-11082	,	_	
22-107	11083-11086	and	_	
22-108	11087-11090	age	_	
22-109	11091-11094	and	_	
22-110	11095-11098	sex	_	
22-111	11099-11101	as	_	
22-112	11102-11112	covariates	_	
22-113	11112-11113	.	_	
22-114	11114-11115	A	_	
22-115	11116-11122	priori	_	
22-116	11123-11132	contrasts	_	
22-117	11133-11142	comparing	_	
22-118	11143-11150	healthy	_	
22-119	11151-11159	subjects	_	
22-120	11160-11162	to	_	
22-121	11163-11172	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[11]	
22-122	11173-11181	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[11]	
22-123	11182-11185	and	_	
22-124	11186-11190	each	_	
22-125	11191-11198	patient	_	
22-126	11199-11204	group	_	
22-127	11205-11206	(	_	
22-128	11206-11209	i.e	_	
22-129	11209-11210	.	_	
22-130	11211-11218	chronic	_	
22-131	11218-11219	,	_	
22-132	11220-11225	early	_	
22-133	11226-11231	stage	_	
22-134	11231-11232	)	_	
22-135	11233-11235	to	_	
22-136	11236-11243	healthy	_	
22-137	11244-11252	subjects	_	
22-138	11253-11257	were	_	
22-139	11258-11267	performed	_	
22-140	11267-11268	.	_	
22-141	11269-11276	Results	_	
22-142	11277-11281	were	_	
22-143	11282-11293	thresholded	_	
22-144	11294-11296	at	_	
22-145	11297-11300	the	_	
22-146	11301-11314	cluster-level	_	
22-147	11315-11329	pFWE-corrected	_	
22-148	11329-11330	=	_	
22-149	11330-11333	.05	_	
22-150	11334-11337	for	_	
22-151	11338-11348	voxel-wise	_	
22-152	11349-11350	p	_	
22-153	11350-11351	=	_	
22-154	11351-11355	.005	_	
22-155	11355-11356	,	_	
22-156	11357-11363	masked	_	
22-157	11364-11366	to	_	
22-158	11367-11374	include	_	
22-159	11375-11379	only	_	
22-160	11380-11386	voxels	_	
22-161	11387-11391	that	_	
22-162	11392-11404	demonstrated	_	
22-163	11405-11416	significant	_	
22-164	11417-11425	positive	_	
22-165	11426-11436	functional	_	
22-166	11437-11449	connectivity	_	
22-167	11450-11452	in	_	
22-168	11453-11460	healthy	_	
22-169	11461-11469	subjects	_	
22-170	11470-11473	and	_	
22-171	11473-11474	/	_	
22-172	11474-11476	or	_	
22-173	11477-11486	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[12]	
22-174	11487-11495	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[12]	
22-175	11496-11498	at	_	
22-176	11499-11502	the	_	
22-177	11503-11516	cluster-level	_	
22-178	11517-11531	pFWE-corrected	_	
22-179	11531-11532	=	_	
22-180	11532-11535	.05	_	
22-181	11536-11539	for	_	
22-182	11540-11550	voxel-wise	_	
22-183	11551-11552	p	_	
22-184	11552-11553	=	_	
22-185	11553-11557	.005	_	
22-186	11557-11558	.	_	

#Text=Functional connectivity maps for the thalamic ROIs were created using the CONN-fMRI Functional Connectivity toolbox. Briefly, the mean BOLD time series was extracted from an ROI and entered as a predictor in a multiple regression general linear model (GLM). Regressors corresponding to the 6 motion correction parameters and their first temporal derivatives, along with grey matter, white matter, and CSF were included to remove variance related to head motion, the global grey matter signal, white matter, and CSF, respectively. Functional data were band-pass filtered (.01-.10 Hz). We took several steps to limit the effects of head motion. First, resting-state scans underwent “motion scrubbing” as described by Power et al.. Volumes with frame-wise displacement greater than 0.5 and BOLD intensity changes between frames greater than 0.5% were identified and excluded from the functional connectivity analysis by including the tagged scans as nuisance regressors in the connectivity GLM. Second, nuisance regressors for white matter and CSF were derived from each subject’s white matter and CSF segmentations using the anatomical component-based noise reduction method (aCompCor), as implemented in the Conn-fMRI toolbox. The aCompCor method has been shown to be effective at reducing the effects of head movement on functional connectivity estimates. Finally, motion correction parameters were regressed out before temporal band pass filtering was applied as performing these steps in reverse order (i.e. band-pass filtering before nuisance regression) over-estimates connectivity and exacerbates the effects of head motion due to re-introduction of nuisance related variation.
23-1	11559-11569	Functional	_	
23-2	11570-11582	connectivity	_	
23-3	11583-11587	maps	_	
23-4	11588-11591	for	_	
23-5	11592-11595	the	_	
23-6	11596-11604	thalamic	_	
23-7	11605-11609	ROIs	_	
23-8	11610-11614	were	_	
23-9	11615-11622	created	_	
23-10	11623-11628	using	_	
23-11	11629-11632	the	_	
23-12	11633-11642	CONN-fMRI	_	
23-13	11643-11653	Functional	_	
23-14	11654-11666	Connectivity	_	
23-15	11667-11674	toolbox	_	
23-16	11674-11675	.	_	
23-17	11676-11683	Briefly	_	
23-18	11683-11684	,	_	
23-19	11685-11688	the	_	
23-20	11689-11693	mean	_	
23-21	11694-11698	BOLD	_	
23-22	11699-11703	time	_	
23-23	11704-11710	series	_	
23-24	11711-11714	was	_	
23-25	11715-11724	extracted	_	
23-26	11725-11729	from	_	
23-27	11730-11732	an	_	
23-28	11733-11736	ROI	_	
23-29	11737-11740	and	_	
23-30	11741-11748	entered	_	
23-31	11749-11751	as	_	
23-32	11752-11753	a	_	
23-33	11754-11763	predictor	_	
23-34	11764-11766	in	_	
23-35	11767-11768	a	_	
23-36	11769-11777	multiple	_	
23-37	11778-11788	regression	_	
23-38	11789-11796	general	_	
23-39	11797-11803	linear	_	
23-40	11804-11809	model	_	
23-41	11810-11811	(	_	
23-42	11811-11814	GLM	_	
23-43	11814-11815	)	_	
23-44	11815-11816	.	_	
23-45	11817-11827	Regressors	_	
23-46	11828-11841	corresponding	_	
23-47	11842-11844	to	_	
23-48	11845-11848	the	_	
23-49	11849-11850	6	_	
23-50	11851-11857	motion	_	
23-51	11858-11868	correction	_	
23-52	11869-11879	parameters	_	
23-53	11880-11883	and	_	
23-54	11884-11889	their	_	
23-55	11890-11895	first	_	
23-56	11896-11904	temporal	_	
23-57	11905-11916	derivatives	_	
23-58	11916-11917	,	_	
23-59	11918-11923	along	_	
23-60	11924-11928	with	_	
23-61	11929-11933	grey	_	
23-62	11934-11940	matter	_	
23-63	11940-11941	,	_	
23-64	11942-11947	white	_	
23-65	11948-11954	matter	_	
23-66	11954-11955	,	_	
23-67	11956-11959	and	_	
23-68	11960-11963	CSF	_	
23-69	11964-11968	were	_	
23-70	11969-11977	included	_	
23-71	11978-11980	to	_	
23-72	11981-11987	remove	_	
23-73	11988-11996	variance	_	
23-74	11997-12004	related	_	
23-75	12005-12007	to	_	
23-76	12008-12012	head	_	
23-77	12013-12019	motion	_	
23-78	12019-12020	,	_	
23-79	12021-12024	the	_	
23-80	12025-12031	global	_	
23-81	12032-12036	grey	_	
23-82	12037-12043	matter	_	
23-83	12044-12050	signal	_	
23-84	12050-12051	,	_	
23-85	12052-12057	white	_	
23-86	12058-12064	matter	_	
23-87	12064-12065	,	_	
23-88	12066-12069	and	_	
23-89	12070-12073	CSF	_	
23-90	12073-12074	,	_	
23-91	12075-12087	respectively	_	
23-92	12087-12088	.	_	
23-93	12089-12099	Functional	_	
23-94	12100-12104	data	_	
23-95	12105-12109	were	_	
23-96	12110-12119	band-pass	_	
23-97	12120-12128	filtered	_	
23-98	12129-12130	(	_	
23-99	12130-12133	.01	_	
23-100	12133-12134	-	_	
23-101	12134-12137	.10	_	
23-102	12138-12140	Hz	_	
23-103	12140-12141	)	_	
23-104	12141-12142	.	_	
23-105	12143-12145	We	_	
23-106	12146-12150	took	_	
23-107	12151-12158	several	_	
23-108	12159-12164	steps	_	
23-109	12165-12167	to	_	
23-110	12168-12173	limit	_	
23-111	12174-12177	the	_	
23-112	12178-12185	effects	_	
23-113	12186-12188	of	_	
23-114	12189-12193	head	_	
23-115	12194-12200	motion	_	
23-116	12200-12201	.	_	
23-117	12202-12207	First	_	
23-118	12207-12208	,	_	
23-119	12209-12222	resting-state	_	
23-120	12223-12228	scans	_	
23-121	12229-12238	underwent	_	
23-122	12239-12240	“	_	
23-123	12240-12246	motion	_	
23-124	12247-12256	scrubbing	_	
23-125	12256-12257	”	_	
23-126	12258-12260	as	_	
23-127	12261-12270	described	_	
23-128	12271-12273	by	_	
23-129	12274-12279	Power	_	
23-130	12280-12282	et	_	
23-131	12283-12285	al	_	
23-132	12285-12286	.	_	
23-133	12286-12287	.	_	
23-134	12288-12295	Volumes	_	
23-135	12296-12300	with	_	
23-136	12301-12311	frame-wise	_	
23-137	12312-12324	displacement	_	
23-138	12325-12332	greater	_	
23-139	12333-12337	than	_	
23-140	12338-12341	0.5	_	
23-141	12342-12345	and	_	
23-142	12346-12350	BOLD	_	
23-143	12351-12360	intensity	_	
23-144	12361-12368	changes	_	
23-145	12369-12376	between	_	
23-146	12377-12383	frames	_	
23-147	12384-12391	greater	_	
23-148	12392-12396	than	_	
23-149	12397-12401	0.5%	_	
23-150	12402-12406	were	_	
23-151	12407-12417	identified	_	
23-152	12418-12421	and	_	
23-153	12422-12430	excluded	_	
23-154	12431-12435	from	_	
23-155	12436-12439	the	_	
23-156	12440-12450	functional	_	
23-157	12451-12463	connectivity	_	
23-158	12464-12472	analysis	_	
23-159	12473-12475	by	_	
23-160	12476-12485	including	_	
23-161	12486-12489	the	_	
23-162	12490-12496	tagged	_	
23-163	12497-12502	scans	_	
23-164	12503-12505	as	_	
23-165	12506-12514	nuisance	_	
23-166	12515-12525	regressors	_	
23-167	12526-12528	in	_	
23-168	12529-12532	the	_	
23-169	12533-12545	connectivity	_	
23-170	12546-12549	GLM	_	
23-171	12549-12550	.	_	
23-172	12551-12557	Second	_	
23-173	12557-12558	,	_	
23-174	12559-12567	nuisance	_	
23-175	12568-12578	regressors	_	
23-176	12579-12582	for	_	
23-177	12583-12588	white	_	
23-178	12589-12595	matter	_	
23-179	12596-12599	and	_	
23-180	12600-12603	CSF	_	
23-181	12604-12608	were	_	
23-182	12609-12616	derived	_	
23-183	12617-12621	from	_	
23-184	12622-12626	each	_	
23-185	12627-12634	subject	_	
23-186	12634-12635	’	_	
23-187	12635-12636	s	_	
23-188	12637-12642	white	_	
23-189	12643-12649	matter	_	
23-190	12650-12653	and	_	
23-191	12654-12657	CSF	_	
23-192	12658-12671	segmentations	_	
23-193	12672-12677	using	_	
23-194	12678-12681	the	_	
23-195	12682-12692	anatomical	_	
23-196	12693-12708	component-based	_	
23-197	12709-12714	noise	_	
23-198	12715-12724	reduction	_	
23-199	12725-12731	method	_	
23-200	12732-12733	(	_	
23-201	12733-12741	aCompCor	_	
23-202	12741-12742	)	_	
23-203	12742-12743	,	_	
23-204	12744-12746	as	_	
23-205	12747-12758	implemented	_	
23-206	12759-12761	in	_	
23-207	12762-12765	the	_	
23-208	12766-12775	Conn-fMRI	_	
23-209	12776-12783	toolbox	_	
23-210	12783-12784	.	_	
23-211	12785-12788	The	_	
23-212	12789-12797	aCompCor	_	
23-213	12798-12804	method	_	
23-214	12805-12808	has	_	
23-215	12809-12813	been	_	
23-216	12814-12819	shown	_	
23-217	12820-12822	to	_	
23-218	12823-12825	be	_	
23-219	12826-12835	effective	_	
23-220	12836-12838	at	_	
23-221	12839-12847	reducing	_	
23-222	12848-12851	the	_	
23-223	12852-12859	effects	_	
23-224	12860-12862	of	_	
23-225	12863-12867	head	_	
23-226	12868-12876	movement	_	
23-227	12877-12879	on	_	
23-228	12880-12890	functional	_	
23-229	12891-12903	connectivity	_	
23-230	12904-12913	estimates	_	
23-231	12913-12914	.	_	
23-232	12915-12922	Finally	_	
23-233	12922-12923	,	_	
23-234	12924-12930	motion	_	
23-235	12931-12941	correction	_	
23-236	12942-12952	parameters	_	
23-237	12953-12957	were	_	
23-238	12958-12967	regressed	_	
23-239	12968-12971	out	_	
23-240	12972-12978	before	_	
23-241	12979-12987	temporal	_	
23-242	12988-12992	band	_	
23-243	12993-12997	pass	_	
23-244	12998-13007	filtering	_	
23-245	13008-13011	was	_	
23-246	13012-13019	applied	_	
23-247	13020-13022	as	_	
23-248	13023-13033	performing	_	
23-249	13034-13039	these	_	
23-250	13040-13045	steps	_	
23-251	13046-13048	in	_	
23-252	13049-13056	reverse	_	
23-253	13057-13062	order	_	
23-254	13063-13064	(	_	
23-255	13064-13067	i.e	_	
23-256	13067-13068	.	_	
23-257	13069-13078	band-pass	_	
23-258	13079-13088	filtering	_	
23-259	13089-13095	before	_	
23-260	13096-13104	nuisance	_	
23-261	13105-13115	regression	_	
23-262	13115-13116	)	_	
23-263	13117-13131	over-estimates	_	
23-264	13132-13144	connectivity	_	
23-265	13145-13148	and	_	
23-266	13149-13160	exacerbates	_	
23-267	13161-13164	the	_	
23-268	13165-13172	effects	_	
23-269	13173-13175	of	_	
23-270	13176-13180	head	_	
23-271	13181-13187	motion	_	
23-272	13188-13191	due	_	
23-273	13192-13194	to	_	
23-274	13195-13210	re-introduction	_	
23-275	13211-13213	of	_	
23-276	13214-13222	nuisance	_	
23-277	13223-13230	related	_	
23-278	13231-13240	variation	_	
23-279	13240-13241	.	_	

#Text=RESULTS
24-1	13242-13249	RESULTS	_	

#Text=Demographic, cognitive, and clinical data are presented in Table 1. The overall patient cohort was well matched to healthy subjects on sex (healthy subjects; 58.1% male; psychosis: 60.1% male; x2=0.11, p=.745) and age (healthy subjects: 32.5; patients: 32.3; (251)=0.07, p=.941). Importantly, the distribution of ages was virtually identical in healthy subjects and patients (see Supplementary Figure S1). As expected, early stage patients were younger than healthy subjects (p<.001), which, in turn, were younger than chronic patients (p<.001). Average daily dose of antipsychotic, in chlorpromazine equivalents based on Gardner et al.,, was higher in chronic patients (478.0±247.8 mg vs. 308.4±174.3 mg; t(128)=4.08, p<.001).
25-1	13250-13261	Demographic	_	
25-2	13261-13262	,	_	
25-3	13263-13272	cognitive	_	
25-4	13272-13273	,	_	
25-5	13274-13277	and	_	
25-6	13278-13286	clinical	_	
25-7	13287-13291	data	_	
25-8	13292-13295	are	_	
25-9	13296-13305	presented	_	
25-10	13306-13308	in	_	
25-11	13309-13314	Table	_	
25-12	13315-13316	1	_	
25-13	13316-13317	.	_	
25-14	13318-13321	The	_	
25-15	13322-13329	overall	_	
25-16	13330-13337	patient	_	
25-17	13338-13344	cohort	_	
25-18	13345-13348	was	_	
25-19	13349-13353	well	_	
25-20	13354-13361	matched	_	
25-21	13362-13364	to	_	
25-22	13365-13372	healthy	_	
25-23	13373-13381	subjects	_	
25-24	13382-13384	on	_	
25-25	13385-13388	sex	_	
25-26	13389-13390	(	_	
25-27	13390-13397	healthy	_	
25-28	13398-13406	subjects	_	
25-29	13406-13407	;	_	
25-30	13408-13413	58.1%	_	
25-31	13414-13418	male	_	
25-32	13418-13419	;	_	
25-33	13420-13429	psychosis	_	
25-34	13429-13430	:	_	
25-35	13431-13436	60.1%	_	
25-36	13437-13441	male	_	
25-37	13441-13442	;	_	
25-38	13443-13445	x2	_	
25-39	13445-13446	=	_	
25-40	13446-13450	0.11	_	
25-41	13450-13451	,	_	
25-42	13452-13453	p	_	
25-43	13453-13454	=	_	
25-44	13454-13458	.745	_	
25-45	13458-13459	)	_	
25-46	13460-13463	and	_	
25-47	13464-13467	age	_	
25-48	13468-13469	(	_	
25-49	13469-13476	healthy	_	
25-50	13477-13485	subjects	_	
25-51	13485-13486	:	_	
25-52	13487-13491	32.5	_	
25-53	13491-13492	;	_	
25-54	13493-13501	patients	_	
25-55	13501-13502	:	_	
25-56	13503-13507	32.3	_	
25-57	13507-13508	;	_	
25-58	13509-13510	(	_	
25-59	13510-13513	251	_	
25-60	13513-13514	)	_	
25-61	13514-13515	=	_	
25-62	13515-13519	0.07	_	
25-63	13519-13520	,	_	
25-64	13521-13522	p	_	
25-65	13522-13523	=	_	
25-66	13523-13527	.941	_	
25-67	13527-13528	)	_	
25-68	13528-13529	.	_	
25-69	13530-13541	Importantly	_	
25-70	13541-13542	,	_	
25-71	13543-13546	the	_	
25-72	13547-13559	distribution	_	
25-73	13560-13562	of	_	
25-74	13563-13567	ages	_	
25-75	13568-13571	was	_	
25-76	13572-13581	virtually	_	
25-77	13582-13591	identical	_	
25-78	13592-13594	in	_	
25-79	13595-13602	healthy	_	
25-80	13603-13611	subjects	_	
25-81	13612-13615	and	_	
25-82	13616-13624	patients	_	
25-83	13625-13626	(	_	
25-84	13626-13629	see	_	
25-85	13630-13643	Supplementary	_	
25-86	13644-13650	Figure	_	
25-87	13651-13653	S1	_	
25-88	13653-13654	)	_	
25-89	13654-13655	.	_	
25-90	13656-13658	As	_	
25-91	13659-13667	expected	_	
25-92	13667-13668	,	_	
25-93	13669-13674	early	_	
25-94	13675-13680	stage	_	
25-95	13681-13689	patients	_	
25-96	13690-13694	were	_	
25-97	13695-13702	younger	_	
25-98	13703-13707	than	_	
25-99	13708-13715	healthy	_	
25-100	13716-13724	subjects	_	
25-101	13725-13726	(	_	
25-102	13726-13727	p	_	
25-103	13727-13728	<	_	
25-104	13728-13732	.001	_	
25-105	13732-13733	)	_	
25-106	13733-13734	,	_	
25-107	13735-13740	which	_	
25-108	13740-13741	,	_	
25-109	13742-13744	in	_	
25-110	13745-13749	turn	_	
25-111	13749-13750	,	_	
25-112	13751-13755	were	_	
25-113	13756-13763	younger	_	
25-114	13764-13768	than	_	
25-115	13769-13776	chronic	_	
25-116	13777-13785	patients	_	
25-117	13786-13787	(	_	
25-118	13787-13788	p	_	
25-119	13788-13789	<	_	
25-120	13789-13793	.001	_	
25-121	13793-13794	)	_	
25-122	13794-13795	.	_	
25-123	13796-13803	Average	_	
25-124	13804-13809	daily	_	
25-125	13810-13814	dose	_	
25-126	13815-13817	of	_	
25-127	13818-13831	antipsychotic	_	
25-128	13831-13832	,	_	
25-129	13833-13835	in	_	
25-130	13836-13850	chlorpromazine	_	
25-131	13851-13862	equivalents	_	
25-132	13863-13868	based	_	
25-133	13869-13871	on	_	
25-134	13872-13879	Gardner	_	
25-135	13880-13882	et	_	
25-136	13883-13885	al	_	
25-137	13885-13886	.	_	
25-138	13886-13887	,	_	
25-139	13887-13888	,	_	
25-140	13889-13892	was	_	
25-141	13893-13899	higher	_	
25-142	13900-13902	in	_	
25-143	13903-13910	chronic	_	
25-144	13911-13919	patients	_	
25-145	13920-13921	(	_	
25-146	13921-13926	478.0	_	
25-147	13926-13927	±	_	
25-148	13927-13932	247.8	_	
25-149	13933-13935	mg	_	
25-150	13936-13938	vs	_	
25-151	13938-13939	.	_	
25-152	13940-13945	308.4	_	
25-153	13945-13946	±	_	
25-154	13946-13951	174.3	_	
25-155	13952-13954	mg	_	
25-156	13954-13955	;	_	
25-157	13956-13957	t	_	
25-158	13957-13958	(	_	
25-159	13958-13961	128	_	
25-160	13961-13962	)	_	
25-161	13962-13963	=	_	
25-162	13963-13967	4.08	_	
25-163	13967-13968	,	_	
25-164	13969-13970	p	_	
25-165	13970-13971	<	_	
25-166	13971-13975	.001	_	
25-167	13975-13976	)	_	
25-168	13976-13977	.	_	

#Text=Thalamocortical Functional Connectivity: Cortical ROI-to-Thalamic ROI Analysis
26-1	13978-13993	Thalamocortical	_	
26-2	13994-14004	Functional	_	
26-3	14005-14017	Connectivity	_	
26-4	14017-14018	:	_	
26-5	14019-14027	Cortical	_	
26-6	14028-14043	ROI-to-Thalamic	_	
26-7	14044-14047	ROI	_	
26-8	14048-14056	Analysis	_	

#Text=As shown in Figure 1A and Supplemental Figure S2, functional sub-divisions of the thalamus were very consistent with prior studies that have parceled the thalamus based on its functional and structural connectivity (e.g.).
27-1	14057-14059	As	_	
27-2	14060-14065	shown	_	
27-3	14066-14068	in	_	
27-4	14069-14075	Figure	_	
27-5	14076-14078	1A	_	
27-6	14079-14082	and	_	
27-7	14083-14095	Supplemental	_	
27-8	14096-14102	Figure	_	
27-9	14103-14105	S2	_	
27-10	14105-14106	,	_	
27-11	14107-14117	functional	_	
27-12	14118-14131	sub-divisions	_	
27-13	14132-14134	of	_	
27-14	14135-14138	the	_	
27-15	14139-14147	thalamus	_	
27-16	14148-14152	were	_	
27-17	14153-14157	very	_	
27-18	14158-14168	consistent	_	
27-19	14169-14173	with	_	
27-20	14174-14179	prior	_	
27-21	14180-14187	studies	_	
27-22	14188-14192	that	_	
27-23	14193-14197	have	_	
27-24	14198-14206	parceled	_	
27-25	14207-14210	the	_	
27-26	14211-14219	thalamus	_	
27-27	14220-14225	based	_	
27-28	14226-14228	on	_	
27-29	14229-14232	its	_	
27-30	14233-14243	functional	_	
27-31	14244-14247	and	_	
27-32	14248-14258	structural	_	
27-33	14259-14271	connectivity	_	
27-34	14272-14273	(	_	
27-35	14273-14276	e.g	_	
27-36	14276-14277	.	_	
27-37	14277-14278	)	_	
27-38	14278-14279	.	_	

#Text=Results of the cortical ROI-to-thalamic ROI analysis is presented in Figure 1B. Multivariate repeated measures ANOVA revealed a significant network × group interaction (F(10,490)=3.20, p=.001), but no main effects of network (F(5,244)=1.56, p=.165) and group (F(2,248)=1.22, p=.298). Follow-up univariate ANOVAs indicated that the interaction was due to significant group differences in PFC-thalamic (F(2,248)=5.97, p=.003), motor-thalamic (F(2,248)=8.96, p=.0002), and somatosensory-thalamic (F(2,248)=5.37, p=.005) networks. Compared to healthy subjects, PFC-thalamic network connectivity was reduced in both chronic (p=.002) and early stage (p=.020) psychosis, whereas motor-thalamic and somatosensory-thalamic network connectivity was increased in chronic (p=.00006 and p=.006, respectively) and early stage psychosis (p=.027 and p=.014, respectively). In terms of effect sizes (ES), the reduction in PFC-thalamic hypo-connectivity was comparable in chronic (ES=−0.45) and early stage (ES=−0.43) patient groups. Motor-thalamic hyper-connectivity was somewhat larger chronic compared to early stage patients (ES=0.59 and ES=0.41, respectively); although somatosensory-thalamic hyper-connectivity was virtually identical in chronic and early stage groups (ES=0.40 and 0.43, respectively).
28-1	14280-14287	Results	_	
28-2	14288-14290	of	_	
28-3	14291-14294	the	_	
28-4	14295-14303	cortical	_	
28-5	14304-14319	ROI-to-thalamic	_	
28-6	14320-14323	ROI	_	
28-7	14324-14332	analysis	_	
28-8	14333-14335	is	_	
28-9	14336-14345	presented	_	
28-10	14346-14348	in	_	
28-11	14349-14355	Figure	_	
28-12	14356-14358	1B	_	
28-13	14358-14359	.	_	
28-14	14360-14372	Multivariate	_	
28-15	14373-14381	repeated	_	
28-16	14382-14390	measures	_	
28-17	14391-14396	ANOVA	_	
28-18	14397-14405	revealed	_	
28-19	14406-14407	a	_	
28-20	14408-14419	significant	_	
28-21	14420-14427	network	_	
28-22	14428-14429	×	_	
28-23	14430-14435	group	_	
28-24	14436-14447	interaction	_	
28-25	14448-14449	(	_	
28-26	14449-14450	F	_	
28-27	14450-14451	(	_	
28-28	14451-14457	10,490	_	
28-29	14457-14458	)	_	
28-30	14458-14459	=	_	
28-31	14459-14463	3.20	_	
28-32	14463-14464	,	_	
28-33	14465-14466	p	_	
28-34	14466-14467	=	_	
28-35	14467-14471	.001	_	
28-36	14471-14472	)	_	
28-37	14472-14473	,	_	
28-38	14474-14477	but	_	
28-39	14478-14480	no	_	
28-40	14481-14485	main	_	
28-41	14486-14493	effects	_	
28-42	14494-14496	of	_	
28-43	14497-14504	network	_	
28-44	14505-14506	(	_	
28-45	14506-14507	F	_	
28-46	14507-14508	(	_	
28-47	14508-14513	5,244	_	
28-48	14513-14514	)	_	
28-49	14514-14515	=	_	
28-50	14515-14519	1.56	_	
28-51	14519-14520	,	_	
28-52	14521-14522	p	_	
28-53	14522-14523	=	_	
28-54	14523-14527	.165	_	
28-55	14527-14528	)	_	
28-56	14529-14532	and	_	
28-57	14533-14538	group	_	
28-58	14539-14540	(	_	
28-59	14540-14541	F	_	
28-60	14541-14542	(	_	
28-61	14542-14547	2,248	_	
28-62	14547-14548	)	_	
28-63	14548-14549	=	_	
28-64	14549-14553	1.22	_	
28-65	14553-14554	,	_	
28-66	14555-14556	p	_	
28-67	14556-14557	=	_	
28-68	14557-14561	.298	_	
28-69	14561-14562	)	_	
28-70	14562-14563	.	_	
28-71	14564-14573	Follow-up	_	
28-72	14574-14584	univariate	_	
28-73	14585-14591	ANOVAs	_	
28-74	14592-14601	indicated	_	
28-75	14602-14606	that	_	
28-76	14607-14610	the	_	
28-77	14611-14622	interaction	_	
28-78	14623-14626	was	_	
28-79	14627-14630	due	_	
28-80	14631-14633	to	_	
28-81	14634-14645	significant	_	
28-82	14646-14651	group	_	
28-83	14652-14663	differences	_	
28-84	14664-14666	in	_	
28-85	14667-14679	PFC-thalamic	_	
28-86	14680-14681	(	_	
28-87	14681-14682	F	_	
28-88	14682-14683	(	_	
28-89	14683-14688	2,248	_	
28-90	14688-14689	)	_	
28-91	14689-14690	=	_	
28-92	14690-14694	5.97	_	
28-93	14694-14695	,	_	
28-94	14696-14697	p	_	
28-95	14697-14698	=	_	
28-96	14698-14702	.003	_	
28-97	14702-14703	)	_	
28-98	14703-14704	,	_	
28-99	14705-14719	motor-thalamic	_	
28-100	14720-14721	(	_	
28-101	14721-14722	F	_	
28-102	14722-14723	(	_	
28-103	14723-14728	2,248	_	
28-104	14728-14729	)	_	
28-105	14729-14730	=	_	
28-106	14730-14734	8.96	_	
28-107	14734-14735	,	_	
28-108	14736-14737	p	_	
28-109	14737-14738	=	_	
28-110	14738-14743	.0002	_	
28-111	14743-14744	)	_	
28-112	14744-14745	,	_	
28-113	14746-14749	and	_	
28-114	14750-14772	somatosensory-thalamic	_	
28-115	14773-14774	(	_	
28-116	14774-14775	F	_	
28-117	14775-14776	(	_	
28-118	14776-14781	2,248	_	
28-119	14781-14782	)	_	
28-120	14782-14783	=	_	
28-121	14783-14787	5.37	_	
28-122	14787-14788	,	_	
28-123	14789-14790	p	_	
28-124	14790-14791	=	_	
28-125	14791-14795	.005	_	
28-126	14795-14796	)	_	
28-127	14797-14805	networks	_	
28-128	14805-14806	.	_	
28-129	14807-14815	Compared	_	
28-130	14816-14818	to	_	
28-131	14819-14826	healthy	_	
28-132	14827-14835	subjects	_	
28-133	14835-14836	,	_	
28-134	14837-14849	PFC-thalamic	_	
28-135	14850-14857	network	_	
28-136	14858-14870	connectivity	_	
28-137	14871-14874	was	_	
28-138	14875-14882	reduced	_	
28-139	14883-14885	in	_	
28-140	14886-14890	both	_	
28-141	14891-14898	chronic	_	
28-142	14899-14900	(	_	
28-143	14900-14901	p	_	
28-144	14901-14902	=	_	
28-145	14902-14906	.002	_	
28-146	14906-14907	)	_	
28-147	14908-14911	and	_	
28-148	14912-14917	early	_	
28-149	14918-14923	stage	_	
28-150	14924-14925	(	_	
28-151	14925-14926	p	_	
28-152	14926-14927	=	_	
28-153	14927-14931	.020	_	
28-154	14931-14932	)	_	
28-155	14933-14942	psychosis	_	
28-156	14942-14943	,	_	
28-157	14944-14951	whereas	_	
28-158	14952-14966	motor-thalamic	_	
28-159	14967-14970	and	_	
28-160	14971-14993	somatosensory-thalamic	_	
28-161	14994-15001	network	_	
28-162	15002-15014	connectivity	_	
28-163	15015-15018	was	_	
28-164	15019-15028	increased	_	
28-165	15029-15031	in	_	
28-166	15032-15039	chronic	_	
28-167	15040-15041	(	_	
28-168	15041-15042	p	_	
28-169	15042-15043	=	_	
28-170	15043-15049	.00006	_	
28-171	15050-15053	and	_	
28-172	15054-15055	p	_	
28-173	15055-15056	=	_	
28-174	15056-15060	.006	_	
28-175	15060-15061	,	_	
28-176	15062-15074	respectively	_	
28-177	15074-15075	)	_	
28-178	15076-15079	and	_	
28-179	15080-15085	early	_	
28-180	15086-15091	stage	_	
28-181	15092-15101	psychosis	_	
28-182	15102-15103	(	_	
28-183	15103-15104	p	_	
28-184	15104-15105	=	_	
28-185	15105-15109	.027	_	
28-186	15110-15113	and	_	
28-187	15114-15115	p	_	
28-188	15115-15116	=	_	
28-189	15116-15120	.014	_	
28-190	15120-15121	,	_	
28-191	15122-15134	respectively	_	
28-192	15134-15135	)	_	
28-193	15135-15136	.	_	
28-194	15137-15139	In	_	
28-195	15140-15145	terms	_	
28-196	15146-15148	of	_	
28-197	15149-15155	effect	_	
28-198	15156-15161	sizes	_	
28-199	15162-15163	(	_	
28-200	15163-15165	ES	_	
28-201	15165-15166	)	_	
28-202	15166-15167	,	_	
28-203	15168-15171	the	_	
28-204	15172-15181	reduction	_	
28-205	15182-15184	in	_	
28-206	15185-15197	PFC-thalamic	_	
28-207	15198-15215	hypo-connectivity	_	
28-208	15216-15219	was	_	
28-209	15220-15230	comparable	_	
28-210	15231-15233	in	_	
28-211	15234-15241	chronic	_	
28-212	15242-15243	(	_	
28-213	15243-15245	ES	_	
28-214	15245-15246	=	_	
28-215	15246-15247	−	_	
28-216	15247-15251	0.45	_	
28-217	15251-15252	)	_	
28-218	15253-15256	and	_	
28-219	15257-15262	early	_	
28-220	15263-15268	stage	_	
28-221	15269-15270	(	_	
28-222	15270-15272	ES	_	
28-223	15272-15273	=	_	
28-224	15273-15274	−	_	
28-225	15274-15278	0.43	_	
28-226	15278-15279	)	_	
28-227	15280-15287	patient	_	
28-228	15288-15294	groups	_	
28-229	15294-15295	.	_	
28-230	15296-15310	Motor-thalamic	_	
28-231	15311-15329	hyper-connectivity	_	
28-232	15330-15333	was	_	
28-233	15334-15342	somewhat	_	
28-234	15343-15349	larger	_	
28-235	15350-15357	chronic	_	
28-236	15358-15366	compared	_	
28-237	15367-15369	to	_	
28-238	15370-15375	early	_	
28-239	15376-15381	stage	_	
28-240	15382-15390	patients	_	
28-241	15391-15392	(	_	
28-242	15392-15394	ES	_	
28-243	15394-15395	=	_	
28-244	15395-15399	0.59	_	
28-245	15400-15403	and	_	
28-246	15404-15406	ES	_	
28-247	15406-15407	=	_	
28-248	15407-15411	0.41	_	
28-249	15411-15412	,	_	
28-250	15413-15425	respectively	_	
28-251	15425-15426	)	_	
28-252	15426-15427	;	_	
28-253	15428-15436	although	_	
28-254	15437-15459	somatosensory-thalamic	_	
28-255	15460-15478	hyper-connectivity	_	
28-256	15479-15482	was	_	
28-257	15483-15492	virtually	_	
28-258	15493-15502	identical	_	
28-259	15503-15505	in	_	
28-260	15506-15513	chronic	_	
28-261	15514-15517	and	_	
28-262	15518-15523	early	_	
28-263	15524-15529	stage	_	
28-264	15530-15536	groups	_	
28-265	15537-15538	(	_	
28-266	15538-15540	ES	_	
28-267	15540-15541	=	_	
28-268	15541-15545	0.40	_	
28-269	15546-15549	and	_	
28-270	15550-15554	0.43	_	
28-271	15554-15555	,	_	
28-272	15556-15568	respectively	_	
28-273	15568-15569	)	_	
28-274	15569-15570	.	_	

#Text=To confirm the results were not affected by head motion, scanner assignment, age, and sex, we performed a series of analysis controlling for these effects as best as possible (see Supplemental Material). In brief, adding scanner or percentage of functional volumes excluded due to head motion as covariates did not affect the results (see Supplemental Figure S3). We also obtained very similar results when we compared sub-groups of patients and healthy subjects matched on age and sex, and age, sex, and head motion.
29-1	15571-15573	To	_	
29-2	15574-15581	confirm	_	
29-3	15582-15585	the	_	
29-4	15586-15593	results	_	
29-5	15594-15598	were	_	
29-6	15599-15602	not	_	
29-7	15603-15611	affected	_	
29-8	15612-15614	by	_	
29-9	15615-15619	head	_	
29-10	15620-15626	motion	_	
29-11	15626-15627	,	_	
29-12	15628-15635	scanner	_	
29-13	15636-15646	assignment	_	
29-14	15646-15647	,	_	
29-15	15648-15651	age	_	
29-16	15651-15652	,	_	
29-17	15653-15656	and	_	
29-18	15657-15660	sex	_	
29-19	15660-15661	,	_	
29-20	15662-15664	we	_	
29-21	15665-15674	performed	_	
29-22	15675-15676	a	_	
29-23	15677-15683	series	_	
29-24	15684-15686	of	_	
29-25	15687-15695	analysis	_	
29-26	15696-15707	controlling	_	
29-27	15708-15711	for	_	
29-28	15712-15717	these	_	
29-29	15718-15725	effects	_	
29-30	15726-15728	as	_	
29-31	15729-15733	best	_	
29-32	15734-15736	as	_	
29-33	15737-15745	possible	_	
29-34	15746-15747	(	_	
29-35	15747-15750	see	_	
29-36	15751-15763	Supplemental	_	
29-37	15764-15772	Material	_	
29-38	15772-15773	)	_	
29-39	15773-15774	.	_	
29-40	15775-15777	In	_	
29-41	15778-15783	brief	_	
29-42	15783-15784	,	_	
29-43	15785-15791	adding	_	
29-44	15792-15799	scanner	_	
29-45	15800-15802	or	_	
29-46	15803-15813	percentage	_	
29-47	15814-15816	of	_	
29-48	15817-15827	functional	_	
29-49	15828-15835	volumes	_	
29-50	15836-15844	excluded	_	
29-51	15845-15848	due	_	
29-52	15849-15851	to	_	
29-53	15852-15856	head	_	
29-54	15857-15863	motion	_	
29-55	15864-15866	as	_	
29-56	15867-15877	covariates	_	
29-57	15878-15881	did	_	
29-58	15882-15885	not	_	
29-59	15886-15892	affect	_	
29-60	15893-15896	the	_	
29-61	15897-15904	results	_	
29-62	15905-15906	(	_	
29-63	15906-15909	see	_	
29-64	15910-15922	Supplemental	_	
29-65	15923-15929	Figure	_	
29-66	15930-15932	S3	_	
29-67	15932-15933	)	_	
29-68	15933-15934	.	_	
29-69	15935-15937	We	_	
29-70	15938-15942	also	_	
29-71	15943-15951	obtained	_	
29-72	15952-15956	very	_	
29-73	15957-15964	similar	_	
29-74	15965-15972	results	_	
29-75	15973-15977	when	_	
29-76	15978-15980	we	_	
29-77	15981-15989	compared	_	
29-78	15990-16000	sub-groups	_	
29-79	16001-16003	of	_	
29-80	16004-16012	patients	_	
29-81	16013-16016	and	_	
29-82	16017-16024	healthy	_	
29-83	16025-16033	subjects	_	
29-84	16034-16041	matched	_	
29-85	16042-16044	on	_	
29-86	16045-16048	age	_	
29-87	16049-16052	and	_	
29-88	16053-16056	sex	_	
29-89	16056-16057	,	_	
29-90	16058-16061	and	_	
29-91	16062-16065	age	_	
29-92	16065-16066	,	_	
29-93	16067-16070	sex	_	
29-94	16070-16071	,	_	
29-95	16072-16075	and	_	
29-96	16076-16080	head	_	
29-97	16081-16087	motion	_	
29-98	16087-16088	.	_	

#Text=In light of a previous report linking PFC-hypo-connectivity and somatomotor-thalamic hyper-connectivity in psychosis, we examined correlations between PFC-thalamic, motor-thalamic, and somatosensory-thalamic networks. Replicating the results of Anticevic et al., we found a significant inverse correlation between PFC-thalamic network under-connectivity and motor-thalamic network hyper-connectivity in patients with psychosis (r=-.40, p<.001). However, in contrast to Anticevic et al. (2013), this relationship was not present in healthy subjects (r=-.11, p=.264). As shown in Figure 1C, the correlation was significantly greater in the psychosis group compared to healthy subjects (Fisher Z=2.42, p=.016). Somatosensory-thalamic connectivity was unrelated to PFC-thalamic connectivity in both psychosis (r=-.02, p=.816) and healthy subjects (r=.01, p=.906)
30-1	16089-16091	In	_	
30-2	16092-16097	light	_	
30-3	16098-16100	of	_	
30-4	16101-16102	a	_	
30-5	16103-16111	previous	_	
30-6	16112-16118	report	_	
30-7	16119-16126	linking	_	
30-8	16127-16148	PFC-hypo-connectivity	_	
30-9	16149-16152	and	_	
30-10	16153-16173	somatomotor-thalamic	_	
30-11	16174-16192	hyper-connectivity	_	
30-12	16193-16195	in	_	
30-13	16196-16205	psychosis	_	
30-14	16205-16206	,	_	
30-15	16207-16209	we	_	
30-16	16210-16218	examined	_	
30-17	16219-16231	correlations	_	
30-18	16232-16239	between	_	
30-19	16240-16252	PFC-thalamic	_	
30-20	16252-16253	,	_	
30-21	16254-16268	motor-thalamic	_	
30-22	16268-16269	,	_	
30-23	16270-16273	and	_	
30-24	16274-16296	somatosensory-thalamic	_	
30-25	16297-16305	networks	_	
30-26	16305-16306	.	_	
30-27	16307-16318	Replicating	_	
30-28	16319-16322	the	_	
30-29	16323-16330	results	_	
30-30	16331-16333	of	_	
30-31	16334-16343	Anticevic	_	
30-32	16344-16346	et	_	
30-33	16347-16349	al	_	
30-34	16349-16350	.	_	
30-35	16350-16351	,	_	
30-36	16352-16354	we	_	
30-37	16355-16360	found	_	
30-38	16361-16362	a	_	
30-39	16363-16374	significant	_	
30-40	16375-16382	inverse	_	
30-41	16383-16394	correlation	_	
30-42	16395-16402	between	_	
30-43	16403-16415	PFC-thalamic	_	
30-44	16416-16423	network	_	
30-45	16424-16442	under-connectivity	_	
30-46	16443-16446	and	_	
30-47	16447-16461	motor-thalamic	_	
30-48	16462-16469	network	_	
30-49	16470-16488	hyper-connectivity	_	
30-50	16489-16491	in	_	
30-51	16492-16500	patients	_	
30-52	16501-16505	with	_	
30-53	16506-16515	psychosis	_	
30-54	16516-16517	(	_	
30-55	16517-16518	r	_	
30-56	16518-16519	=	_	
30-57	16519-16520	-	_	
30-58	16520-16523	.40	_	
30-59	16523-16524	,	_	
30-60	16525-16526	p	_	
30-61	16526-16527	<	_	
30-62	16527-16531	.001	_	
30-63	16531-16532	)	_	
30-64	16532-16533	.	_	
30-65	16534-16541	However	_	
30-66	16541-16542	,	_	
30-67	16543-16545	in	_	
30-68	16546-16554	contrast	_	
30-69	16555-16557	to	_	
30-70	16558-16567	Anticevic	_	
30-71	16568-16570	et	_	
30-72	16571-16573	al	_	
30-73	16573-16574	.	_	
30-74	16575-16576	(	_	
30-75	16576-16580	2013	_	
30-76	16580-16581	)	_	
30-77	16581-16582	,	_	
30-78	16583-16587	this	_	
30-79	16588-16600	relationship	_	
30-80	16601-16604	was	_	
30-81	16605-16608	not	_	
30-82	16609-16616	present	_	
30-83	16617-16619	in	_	
30-84	16620-16627	healthy	_	
30-85	16628-16636	subjects	_	
30-86	16637-16638	(	_	
30-87	16638-16639	r	_	
30-88	16639-16640	=	_	
30-89	16640-16641	-	_	
30-90	16641-16644	.11	_	
30-91	16644-16645	,	_	
30-92	16646-16647	p	_	
30-93	16647-16648	=	_	
30-94	16648-16652	.264	_	
30-95	16652-16653	)	_	
30-96	16653-16654	.	_	
30-97	16655-16657	As	_	
30-98	16658-16663	shown	_	
30-99	16664-16666	in	_	
30-100	16667-16673	Figure	_	
30-101	16674-16676	1C	_	
30-102	16676-16677	,	_	
30-103	16678-16681	the	_	
30-104	16682-16693	correlation	_	
30-105	16694-16697	was	_	
30-106	16698-16711	significantly	_	
30-107	16712-16719	greater	_	
30-108	16720-16722	in	_	
30-109	16723-16726	the	_	
30-110	16727-16736	psychosis	_	
30-111	16737-16742	group	_	
30-112	16743-16751	compared	_	
30-113	16752-16754	to	_	
30-114	16755-16762	healthy	_	
30-115	16763-16771	subjects	_	
30-116	16772-16773	(	_	
30-117	16773-16779	Fisher	_	
30-118	16780-16781	Z	_	
30-119	16781-16782	=	_	
30-120	16782-16786	2.42	_	
30-121	16786-16787	,	_	
30-122	16788-16789	p	_	
30-123	16789-16790	=	_	
30-124	16790-16794	.016	_	
30-125	16794-16795	)	_	
30-126	16795-16796	.	_	
30-127	16797-16819	Somatosensory-thalamic	_	
30-128	16820-16832	connectivity	_	
30-129	16833-16836	was	_	
30-130	16837-16846	unrelated	_	
30-131	16847-16849	to	_	
30-132	16850-16862	PFC-thalamic	_	
30-133	16863-16875	connectivity	_	
30-134	16876-16878	in	_	
30-135	16879-16883	both	_	
30-136	16884-16893	psychosis	_	
30-137	16894-16895	(	_	
30-138	16895-16896	r	_	
30-139	16896-16897	=	_	
30-140	16897-16898	-	_	
30-141	16898-16901	.02	_	
30-142	16901-16902	,	_	
30-143	16903-16904	p	_	
30-144	16904-16905	=	_	
30-145	16905-16909	.816	_	
30-146	16909-16910	)	_	
30-147	16911-16914	and	_	
30-148	16915-16922	healthy	_	
30-149	16923-16931	subjects	_	
30-150	16932-16933	(	_	
30-151	16933-16934	r	_	
30-152	16934-16935	=	_	
30-153	16935-16938	.01	_	
30-154	16938-16939	,	_	
30-155	16940-16941	p	_	
30-156	16941-16942	=	_	
30-157	16942-16946	.906	_	
30-158	16946-16947	)	_	

#Text=Additional analyses examining the relationship between thalamocortical functional connectivity and diagnosis, antipsychotic medication, clinical symptoms, and cognitive functioning were also performed. As shown in Supplemental Figure S4, after adjusting for age, sex, and illness stage, PFC-thalamic network connectivity was lower in non-affective psychosis patients compared to affective psychosis at the trend significance level (F(1,143)=3.11, p=.080). In contrast, there were no differences between affective and non-affective psychosis in motor (F(1,143)=0.03, p=.869) and somatosensory (F1,143)=0.34, p=.562) network connectivity. Among patients, antipsychotic dose, PANSS positive, negative, and general scores, and overall cognitive function (i.e. SCIP global Z-score) did not correlate with functional connectivity of any thalamocortical network (all r values<|.11|, p>.217).
31-1	16948-16958	Additional	_	
31-2	16959-16967	analyses	_	
31-3	16968-16977	examining	_	
31-4	16978-16981	the	_	
31-5	16982-16994	relationship	_	
31-6	16995-17002	between	_	
31-7	17003-17018	thalamocortical	_	
31-8	17019-17029	functional	_	
31-9	17030-17042	connectivity	_	
31-10	17043-17046	and	_	
31-11	17047-17056	diagnosis	_	
31-12	17056-17057	,	_	
31-13	17058-17071	antipsychotic	_	
31-14	17072-17082	medication	_	
31-15	17082-17083	,	_	
31-16	17084-17092	clinical	_	
31-17	17093-17101	symptoms	_	
31-18	17101-17102	,	_	
31-19	17103-17106	and	_	
31-20	17107-17116	cognitive	_	
31-21	17117-17128	functioning	_	
31-22	17129-17133	were	_	
31-23	17134-17138	also	_	
31-24	17139-17148	performed	_	
31-25	17148-17149	.	_	
31-26	17150-17152	As	_	
31-27	17153-17158	shown	_	
31-28	17159-17161	in	_	
31-29	17162-17174	Supplemental	_	
31-30	17175-17181	Figure	_	
31-31	17182-17184	S4	_	
31-32	17184-17185	,	_	
31-33	17186-17191	after	_	
31-34	17192-17201	adjusting	_	
31-35	17202-17205	for	_	
31-36	17206-17209	age	_	
31-37	17209-17210	,	_	
31-38	17211-17214	sex	_	
31-39	17214-17215	,	_	
31-40	17216-17219	and	_	
31-41	17220-17227	illness	_	
31-42	17228-17233	stage	_	
31-43	17233-17234	,	_	
31-44	17235-17247	PFC-thalamic	_	
31-45	17248-17255	network	_	
31-46	17256-17268	connectivity	_	
31-47	17269-17272	was	_	
31-48	17273-17278	lower	_	
31-49	17279-17281	in	_	
31-50	17282-17295	non-affective	_	
31-51	17296-17305	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[13]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[14]	
31-52	17306-17314	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[13]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[14]	
31-53	17315-17323	compared	_	
31-54	17324-17326	to	_	
31-55	17327-17336	affective	_	
31-56	17337-17346	psychosis	_	
31-57	17347-17349	at	_	
31-58	17350-17353	the	_	
31-59	17354-17359	trend	_	
31-60	17360-17372	significance	_	
31-61	17373-17378	level	_	
31-62	17379-17380	(	_	
31-63	17380-17381	F	_	
31-64	17381-17382	(	_	
31-65	17382-17387	1,143	_	
31-66	17387-17388	)	_	
31-67	17388-17389	=	_	
31-68	17389-17393	3.11	_	
31-69	17393-17394	,	_	
31-70	17395-17396	p	_	
31-71	17396-17397	=	_	
31-72	17397-17401	.080	_	
31-73	17401-17402	)	_	
31-74	17402-17403	.	_	
31-75	17404-17406	In	_	
31-76	17407-17415	contrast	_	
31-77	17415-17416	,	_	
31-78	17417-17422	there	_	
31-79	17423-17427	were	_	
31-80	17428-17430	no	_	
31-81	17431-17442	differences	_	
31-82	17443-17450	between	_	
31-83	17451-17460	affective	_	
31-84	17461-17464	and	_	
31-85	17465-17478	non-affective	_	
31-86	17479-17488	psychosis	_	
31-87	17489-17491	in	_	
31-88	17492-17497	motor	_	
31-89	17498-17499	(	_	
31-90	17499-17500	F	_	
31-91	17500-17501	(	_	
31-92	17501-17506	1,143	_	
31-93	17506-17507	)	_	
31-94	17507-17508	=	_	
31-95	17508-17512	0.03	_	
31-96	17512-17513	,	_	
31-97	17514-17515	p	_	
31-98	17515-17516	=	_	
31-99	17516-17520	.869	_	
31-100	17520-17521	)	_	
31-101	17522-17525	and	_	
31-102	17526-17539	somatosensory	_	
31-103	17540-17541	(	_	
31-104	17541-17547	F1,143	_	
31-105	17547-17548	)	_	
31-106	17548-17549	=	_	
31-107	17549-17553	0.34	_	
31-108	17553-17554	,	_	
31-109	17555-17556	p	_	
31-110	17556-17557	=	_	
31-111	17557-17561	.562	_	
31-112	17561-17562	)	_	
31-113	17563-17570	network	_	
31-114	17571-17583	connectivity	_	
31-115	17583-17584	.	_	
31-116	17585-17590	Among	_	
31-117	17591-17599	patients	_	
31-118	17599-17600	,	_	
31-119	17601-17614	antipsychotic	_	
31-120	17615-17619	dose	_	
31-121	17619-17620	,	_	
31-122	17621-17626	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
31-123	17627-17635	positive	_	
31-124	17635-17636	,	_	
31-125	17637-17645	negative	_	
31-126	17645-17646	,	_	
31-127	17647-17650	and	_	
31-128	17651-17658	general	_	
31-129	17659-17665	scores	_	
31-130	17665-17666	,	_	
31-131	17667-17670	and	_	
31-132	17671-17678	overall	_	
31-133	17679-17688	cognitive	_	
31-134	17689-17697	function	_	
31-135	17698-17699	(	_	
31-136	17699-17702	i.e	_	
31-137	17702-17703	.	_	
31-138	17704-17708	SCIP	_	
31-139	17709-17715	global	_	
31-140	17716-17723	Z-score	_	
31-141	17723-17724	)	_	
31-142	17725-17728	did	_	
31-143	17729-17732	not	_	
31-144	17733-17742	correlate	_	
31-145	17743-17747	with	_	
31-146	17748-17758	functional	_	
31-147	17759-17771	connectivity	_	
31-148	17772-17774	of	_	
31-149	17775-17778	any	_	
31-150	17779-17794	thalamocortical	_	
31-151	17795-17802	network	_	
31-152	17803-17804	(	_	
31-153	17804-17807	all	_	
31-154	17808-17809	r	_	
31-155	17810-17816	values	_	
31-156	17816-17817	<	_	
31-157	17817-17818	|	_	
31-158	17818-17821	.11	_	
31-159	17821-17822	|	_	
31-160	17822-17823	,	_	
31-161	17824-17825	p	_	
31-162	17825-17826	>	_	
31-163	17826-17830	.217	_	
31-164	17830-17831	)	_	
31-165	17831-17832	.	_	

#Text=Thalamocortical Functional Connectivity: Thalamus ROI Seed-based Analysis
32-1	17833-17848	Thalamocortical	_	
32-2	17849-17859	Functional	_	
32-3	17860-17872	Connectivity	_	
32-4	17872-17873	:	_	
32-5	17874-17882	Thalamus	_	
32-6	17883-17886	ROI	_	
32-7	17887-17897	Seed-based	_	
32-8	17898-17906	Analysis	_	

#Text=The ‘cortical ROI-to-thalamus ROI’ analysis was followed up with seed-based analyses using the thalamic PFC, motor, and somatosensory sub-regions as seeds to better localize thalamic dysconnectivity with the rest of the brain. Functional connectivity of the thalamus PFC, motor, and somatosensory seeds in healthy subjects and individuals with psychosis are shown rendered on the cortical surface and cerebellum in Figure 2, and on serial axial slices covering the entire brain in Supplemental Figure S5 (cortical and cerebellum renderings were created using Caret v5.65; http://brainmap.wustl.edu/caret.html).
33-1	17907-17910	The	_	
33-2	17911-17912	‘	_	
33-3	17912-17920	cortical	_	
33-4	17921-17936	ROI-to-thalamus	_	
33-5	17937-17940	ROI	_	
33-6	17940-17941	’	_	
33-7	17942-17950	analysis	_	
33-8	17951-17954	was	_	
33-9	17955-17963	followed	_	
33-10	17964-17966	up	_	
33-11	17967-17971	with	_	
33-12	17972-17982	seed-based	_	
33-13	17983-17991	analyses	_	
33-14	17992-17997	using	_	
33-15	17998-18001	the	_	
33-16	18002-18010	thalamic	_	
33-17	18011-18014	PFC	_	
33-18	18014-18015	,	_	
33-19	18016-18021	motor	_	
33-20	18021-18022	,	_	
33-21	18023-18026	and	_	
33-22	18027-18040	somatosensory	_	
33-23	18041-18052	sub-regions	_	
33-24	18053-18055	as	_	
33-25	18056-18061	seeds	_	
33-26	18062-18064	to	_	
33-27	18065-18071	better	_	
33-28	18072-18080	localize	_	
33-29	18081-18089	thalamic	_	
33-30	18090-18105	dysconnectivity	_	
33-31	18106-18110	with	_	
33-32	18111-18114	the	_	
33-33	18115-18119	rest	_	
33-34	18120-18122	of	_	
33-35	18123-18126	the	_	
33-36	18127-18132	brain	_	
33-37	18132-18133	.	_	
33-38	18134-18144	Functional	_	
33-39	18145-18157	connectivity	_	
33-40	18158-18160	of	_	
33-41	18161-18164	the	_	
33-42	18165-18173	thalamus	_	
33-43	18174-18177	PFC	_	
33-44	18177-18178	,	_	
33-45	18179-18184	motor	_	
33-46	18184-18185	,	_	
33-47	18186-18189	and	_	
33-48	18190-18203	somatosensory	_	
33-49	18204-18209	seeds	_	
33-50	18210-18212	in	_	
33-51	18213-18220	healthy	_	
33-52	18221-18229	subjects	_	
33-53	18230-18233	and	_	
33-54	18234-18245	individuals	_	
33-55	18246-18250	with	_	
33-56	18251-18260	psychosis	_	
33-57	18261-18264	are	_	
33-58	18265-18270	shown	_	
33-59	18271-18279	rendered	_	
33-60	18280-18282	on	_	
33-61	18283-18286	the	_	
33-62	18287-18295	cortical	_	
33-63	18296-18303	surface	_	
33-64	18304-18307	and	_	
33-65	18308-18318	cerebellum	_	
33-66	18319-18321	in	_	
33-67	18322-18328	Figure	_	
33-68	18329-18330	2	_	
33-69	18330-18331	,	_	
33-70	18332-18335	and	_	
33-71	18336-18338	on	_	
33-72	18339-18345	serial	_	
33-73	18346-18351	axial	_	
33-74	18352-18358	slices	_	
33-75	18359-18367	covering	_	
33-76	18368-18371	the	_	
33-77	18372-18378	entire	_	
33-78	18379-18384	brain	_	
33-79	18385-18387	in	_	
33-80	18388-18400	Supplemental	_	
33-81	18401-18407	Figure	_	
33-82	18408-18410	S5	_	
33-83	18411-18412	(	_	
33-84	18412-18420	cortical	_	
33-85	18421-18424	and	_	
33-86	18425-18435	cerebellum	_	
33-87	18436-18446	renderings	_	
33-88	18447-18451	were	_	
33-89	18452-18459	created	_	
33-90	18460-18465	using	_	
33-91	18466-18471	Caret	_	
33-92	18472-18477	v5.65	_	
33-93	18477-18478	;	_	
33-94	18479-18483	http	_	
33-95	18483-18484	:	_	
33-96	18484-18485	/	_	
33-97	18485-18486	/	_	
33-98	18486-18504	brainmap.wustl.edu	_	
33-99	18504-18505	/	_	
33-100	18505-18515	caret.html	_	
33-101	18515-18516	)	_	
33-102	18516-18517	.	_	

#Text=In healthy subjects, the thalamic PFC seed was functionally connected to dorsolateral PFC, inferior frontal gyrus/anterior insula, anterior cingulate cortex (ACC), inferior parietal lobule (supramarginal and angular gyri), mid cingulate, left transverse temporal gyrus, and posterior quadrangle of the cerebellum. Sub-cortically, significant connectivity was detected with the caudate, especially the head of the caudate, and putamen (see Supplemental Figure S5). This pattern of connectivity bears a striking resemblance to the fronto-parietal “executive control” network (e.g.). Functional connectivity of the motor and somatosensory thalamus seeds was restricted almost exclusively to primary and secondary motor and somatosensory cortex, striatum, and cerebellum. In psychotic disorders, functional connectivity of the thalamus PFC seed was restricted to the medial PFC and ACC; inferior frontal gyrus/anterior insula; mid-cingulate; and left transverse temporal gyrus (see Figure 2 and Supplemental Figure S5). Connectivity with the cerebellum was notably absent. In contrast, connectivity of the motor thalamus seed was more extensive and there was greater overlap between motor and somatosensory seeds in midline cortical areas. Functional connectivity patterns were very similar in chronic and early stage psychosis patients.
34-1	18518-18520	In	_	
34-2	18521-18528	healthy	_	
34-3	18529-18537	subjects	_	
34-4	18537-18538	,	_	
34-5	18539-18542	the	_	
34-6	18543-18551	thalamic	_	
34-7	18552-18555	PFC	_	
34-8	18556-18560	seed	_	
34-9	18561-18564	was	_	
34-10	18565-18577	functionally	_	
34-11	18578-18587	connected	_	
34-12	18588-18590	to	_	
34-13	18591-18603	dorsolateral	_	
34-14	18604-18607	PFC	_	
34-15	18607-18608	,	_	
34-16	18609-18617	inferior	_	
34-17	18618-18625	frontal	_	
34-18	18626-18631	gyrus	_	
34-19	18631-18632	/	_	
34-20	18632-18640	anterior	_	
34-21	18641-18647	insula	_	
34-22	18647-18648	,	_	
34-23	18649-18657	anterior	_	
34-24	18658-18667	cingulate	_	
34-25	18668-18674	cortex	_	
34-26	18675-18676	(	_	
34-27	18676-18679	ACC	_	
34-28	18679-18680	)	_	
34-29	18680-18681	,	_	
34-30	18682-18690	inferior	_	
34-31	18691-18699	parietal	_	
34-32	18700-18706	lobule	_	
34-33	18707-18708	(	_	
34-34	18708-18721	supramarginal	_	
34-35	18722-18725	and	_	
34-36	18726-18733	angular	_	
34-37	18734-18738	gyri	_	
34-38	18738-18739	)	_	
34-39	18739-18740	,	_	
34-40	18741-18744	mid	_	
34-41	18745-18754	cingulate	_	
34-42	18754-18755	,	_	
34-43	18756-18760	left	_	
34-44	18761-18771	transverse	_	
34-45	18772-18780	temporal	_	
34-46	18781-18786	gyrus	_	
34-47	18786-18787	,	_	
34-48	18788-18791	and	_	
34-49	18792-18801	posterior	_	
34-50	18802-18812	quadrangle	_	
34-51	18813-18815	of	_	
34-52	18816-18819	the	_	
34-53	18820-18830	cerebellum	_	
34-54	18830-18831	.	_	
34-55	18832-18846	Sub-cortically	_	
34-56	18846-18847	,	_	
34-57	18848-18859	significant	_	
34-58	18860-18872	connectivity	_	
34-59	18873-18876	was	_	
34-60	18877-18885	detected	_	
34-61	18886-18890	with	_	
34-62	18891-18894	the	_	
34-63	18895-18902	caudate	_	
34-64	18902-18903	,	_	
34-65	18904-18914	especially	_	
34-66	18915-18918	the	_	
34-67	18919-18923	head	_	
34-68	18924-18926	of	_	
34-69	18927-18930	the	_	
34-70	18931-18938	caudate	_	
34-71	18938-18939	,	_	
34-72	18940-18943	and	_	
34-73	18944-18951	putamen	_	
34-74	18952-18953	(	_	
34-75	18953-18956	see	_	
34-76	18957-18969	Supplemental	_	
34-77	18970-18976	Figure	_	
34-78	18977-18979	S5	_	
34-79	18979-18980	)	_	
34-80	18980-18981	.	_	
34-81	18982-18986	This	_	
34-82	18987-18994	pattern	_	
34-83	18995-18997	of	_	
34-84	18998-19010	connectivity	_	
34-85	19011-19016	bears	_	
34-86	19017-19018	a	_	
34-87	19019-19027	striking	_	
34-88	19028-19039	resemblance	_	
34-89	19040-19042	to	_	
34-90	19043-19046	the	_	
34-91	19047-19062	fronto-parietal	_	
34-92	19063-19064	“	_	
34-93	19064-19073	executive	_	
34-94	19074-19081	control	_	
34-95	19081-19082	”	_	
34-96	19083-19090	network	_	
34-97	19091-19092	(	_	
34-98	19092-19095	e.g	_	
34-99	19095-19096	.	_	
34-100	19096-19097	)	_	
34-101	19097-19098	.	_	
34-102	19099-19109	Functional	_	
34-103	19110-19122	connectivity	_	
34-104	19123-19125	of	_	
34-105	19126-19129	the	_	
34-106	19130-19135	motor	_	
34-107	19136-19139	and	_	
34-108	19140-19153	somatosensory	_	
34-109	19154-19162	thalamus	_	
34-110	19163-19168	seeds	_	
34-111	19169-19172	was	_	
34-112	19173-19183	restricted	_	
34-113	19184-19190	almost	_	
34-114	19191-19202	exclusively	_	
34-115	19203-19205	to	_	
34-116	19206-19213	primary	_	
34-117	19214-19217	and	_	
34-118	19218-19227	secondary	_	
34-119	19228-19233	motor	_	
34-120	19234-19237	and	_	
34-121	19238-19251	somatosensory	_	
34-122	19252-19258	cortex	_	
34-123	19258-19259	,	_	
34-124	19260-19268	striatum	_	
34-125	19268-19269	,	_	
34-126	19270-19273	and	_	
34-127	19274-19284	cerebellum	_	
34-128	19284-19285	.	_	
34-129	19286-19288	In	_	
34-130	19289-19298	psychotic	_	
34-131	19299-19308	disorders	_	
34-132	19308-19309	,	_	
34-133	19310-19320	functional	_	
34-134	19321-19333	connectivity	_	
34-135	19334-19336	of	_	
34-136	19337-19340	the	_	
34-137	19341-19349	thalamus	_	
34-138	19350-19353	PFC	_	
34-139	19354-19358	seed	_	
34-140	19359-19362	was	_	
34-141	19363-19373	restricted	_	
34-142	19374-19376	to	_	
34-143	19377-19380	the	_	
34-144	19381-19387	medial	_	
34-145	19388-19391	PFC	_	
34-146	19392-19395	and	_	
34-147	19396-19399	ACC	_	
34-148	19399-19400	;	_	
34-149	19401-19409	inferior	_	
34-150	19410-19417	frontal	_	
34-151	19418-19423	gyrus	_	
34-152	19423-19424	/	_	
34-153	19424-19432	anterior	_	
34-154	19433-19439	insula	_	
34-155	19439-19440	;	_	
34-156	19441-19454	mid-cingulate	_	
34-157	19454-19455	;	_	
34-158	19456-19459	and	_	
34-159	19460-19464	left	_	
34-160	19465-19475	transverse	_	
34-161	19476-19484	temporal	_	
34-162	19485-19490	gyrus	_	
34-163	19491-19492	(	_	
34-164	19492-19495	see	_	
34-165	19496-19502	Figure	_	
34-166	19503-19504	2	_	
34-167	19505-19508	and	_	
34-168	19509-19521	Supplemental	_	
34-169	19522-19528	Figure	_	
34-170	19529-19531	S5	_	
34-171	19531-19532	)	_	
34-172	19532-19533	.	_	
34-173	19534-19546	Connectivity	_	
34-174	19547-19551	with	_	
34-175	19552-19555	the	_	
34-176	19556-19566	cerebellum	_	
34-177	19567-19570	was	_	
34-178	19571-19578	notably	_	
34-179	19579-19585	absent	_	
34-180	19585-19586	.	_	
34-181	19587-19589	In	_	
34-182	19590-19598	contrast	_	
34-183	19598-19599	,	_	
34-184	19600-19612	connectivity	_	
34-185	19613-19615	of	_	
34-186	19616-19619	the	_	
34-187	19620-19625	motor	_	
34-188	19626-19634	thalamus	_	
34-189	19635-19639	seed	_	
34-190	19640-19643	was	_	
34-191	19644-19648	more	_	
34-192	19649-19658	extensive	_	
34-193	19659-19662	and	_	
34-194	19663-19668	there	_	
34-195	19669-19672	was	_	
34-196	19673-19680	greater	_	
34-197	19681-19688	overlap	_	
34-198	19689-19696	between	_	
34-199	19697-19702	motor	_	
34-200	19703-19706	and	_	
34-201	19707-19720	somatosensory	_	
34-202	19721-19726	seeds	_	
34-203	19727-19729	in	_	
34-204	19730-19737	midline	_	
34-205	19738-19746	cortical	_	
34-206	19747-19752	areas	_	
34-207	19752-19753	.	_	
34-208	19754-19764	Functional	_	
34-209	19765-19777	connectivity	_	
34-210	19778-19786	patterns	_	
34-211	19787-19791	were	_	
34-212	19792-19796	very	_	
34-213	19797-19804	similar	_	
34-214	19805-19807	in	_	
34-215	19808-19815	chronic	_	
34-216	19816-19819	and	_	
34-217	19820-19825	early	_	
34-218	19826-19831	stage	_	
34-219	19832-19841	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[15]	
34-220	19842-19850	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[15]	
34-221	19850-19851	.	_	

#Text=Direct comparison between healthy subjects and psychosis patients confirmed that some of the qualitative differences observed between groups were statistically significant (see Figure 3 and Table 2). As shown in Figure 3, thalamus PFC seed connectivity with medial superior frontal gyrus extending laterally to middle frontal gyrus was reduced in psychosis. Thalamic PFC seed connectivity with cerebellum was reduced bilaterally. Chronic patients demonstrated less connectivity with medial and lateral aspects of the superior frontal gyrus, left cerebellum, and left inferior parietal lobule. No differences between healthy subjects and early stage psychosis patients were observed at the a-priori defined statistical threshold. However, relaxing the voxel-wise threshold to p=.05, while still maintaining a cluster-level corrected threshold of the pFWE-corrected=.05, revealed a very similar pattern of thalamic dysconnectivity in early stage psychosis. In contrast to the thalamus PFC seed, psychosis patients exhibited greater motor thalamus seed connectivity with a cluster that included midline Brodmann’s areas 6 and 4 and left precentral gyrus corresponding to Brodmann’s area 44. In chronic patients, hyper-connectivity of the thalamus motor seed localized to the right lateral precentral gyrus corresponding to Brodmann’s area 6, midline cortical areas corresponding to medial aspects of Brodmann’s areas 4 and 6, and left postcentral gyrus corresponding to Brodmann’s area 5. No significant differences between healthy subjects and early stage psychosis patients were observed at the corrected significance level. However, relaxing the voxel-wise threshold to p=.05, while still maintaining a whole-brain cluster-level corrected threshold of pFWE-corrected=.05, revealed a similar pattern of thalamus motor seed hyper-connectivity in early stage psychosis; elevated connectivity with medial aspects of precentral and postcentral gyrus, and lateral precentral gyrus. With respect to the thalamus somatosensory seed, no differences in functional connectivity were detected between healthy subjects and psychosis patients. In order to better appreciate the similar patterns of thalamic dysconnectivity in chronic and early stage psychosis, the results of the voxel-wise contrasts comparing each illness stage group to healthy subjects are also presented in Supplemental Figure S6 without statistical thresholding.
35-1	19852-19858	Direct	_	
35-2	19859-19869	comparison	_	
35-3	19870-19877	between	_	
35-4	19878-19885	healthy	_	
35-5	19886-19894	subjects	_	
35-6	19895-19898	and	_	
35-7	19899-19908	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[16]	
35-8	19909-19917	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[16]	
35-9	19918-19927	confirmed	_	
35-10	19928-19932	that	_	
35-11	19933-19937	some	_	
35-12	19938-19940	of	_	
35-13	19941-19944	the	_	
35-14	19945-19956	qualitative	_	
35-15	19957-19968	differences	_	
35-16	19969-19977	observed	_	
35-17	19978-19985	between	_	
35-18	19986-19992	groups	_	
35-19	19993-19997	were	_	
35-20	19998-20011	statistically	_	
35-21	20012-20023	significant	_	
35-22	20024-20025	(	_	
35-23	20025-20028	see	_	
35-24	20029-20035	Figure	_	
35-25	20036-20037	3	_	
35-26	20038-20041	and	_	
35-27	20042-20047	Table	_	
35-28	20048-20049	2	_	
35-29	20049-20050	)	_	
35-30	20050-20051	.	_	
35-31	20052-20054	As	_	
35-32	20055-20060	shown	_	
35-33	20061-20063	in	_	
35-34	20064-20070	Figure	_	
35-35	20071-20072	3	_	
35-36	20072-20073	,	_	
35-37	20074-20082	thalamus	_	
35-38	20083-20086	PFC	_	
35-39	20087-20091	seed	_	
35-40	20092-20104	connectivity	_	
35-41	20105-20109	with	_	
35-42	20110-20116	medial	_	
35-43	20117-20125	superior	_	
35-44	20126-20133	frontal	_	
35-45	20134-20139	gyrus	_	
35-46	20140-20149	extending	_	
35-47	20150-20159	laterally	_	
35-48	20160-20162	to	_	
35-49	20163-20169	middle	_	
35-50	20170-20177	frontal	_	
35-51	20178-20183	gyrus	_	
35-52	20184-20187	was	_	
35-53	20188-20195	reduced	_	
35-54	20196-20198	in	_	
35-55	20199-20208	psychosis	_	
35-56	20208-20209	.	_	
35-57	20210-20218	Thalamic	_	
35-58	20219-20222	PFC	_	
35-59	20223-20227	seed	_	
35-60	20228-20240	connectivity	_	
35-61	20241-20245	with	_	
35-62	20246-20256	cerebellum	_	
35-63	20257-20260	was	_	
35-64	20261-20268	reduced	_	
35-65	20269-20280	bilaterally	_	
35-66	20280-20281	.	_	
35-67	20282-20289	Chronic	_	
35-68	20290-20298	patients	_	
35-69	20299-20311	demonstrated	_	
35-70	20312-20316	less	_	
35-71	20317-20329	connectivity	_	
35-72	20330-20334	with	_	
35-73	20335-20341	medial	_	
35-74	20342-20345	and	_	
35-75	20346-20353	lateral	_	
35-76	20354-20361	aspects	_	
35-77	20362-20364	of	_	
35-78	20365-20368	the	_	
35-79	20369-20377	superior	_	
35-80	20378-20385	frontal	_	
35-81	20386-20391	gyrus	_	
35-82	20391-20392	,	_	
35-83	20393-20397	left	_	
35-84	20398-20408	cerebellum	_	
35-85	20408-20409	,	_	
35-86	20410-20413	and	_	
35-87	20414-20418	left	_	
35-88	20419-20427	inferior	_	
35-89	20428-20436	parietal	_	
35-90	20437-20443	lobule	_	
35-91	20443-20444	.	_	
35-92	20445-20447	No	_	
35-93	20448-20459	differences	_	
35-94	20460-20467	between	_	
35-95	20468-20475	healthy	_	
35-96	20476-20484	subjects	_	
35-97	20485-20488	and	_	
35-98	20489-20494	early	_	
35-99	20495-20500	stage	_	
35-100	20501-20510	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[17]	
35-101	20511-20519	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[17]	
35-102	20520-20524	were	_	
35-103	20525-20533	observed	_	
35-104	20534-20536	at	_	
35-105	20537-20540	the	_	
35-106	20541-20549	a-priori	_	
35-107	20550-20557	defined	_	
35-108	20558-20569	statistical	_	
35-109	20570-20579	threshold	_	
35-110	20579-20580	.	_	
35-111	20581-20588	However	_	
35-112	20588-20589	,	_	
35-113	20590-20598	relaxing	_	
35-114	20599-20602	the	_	
35-115	20603-20613	voxel-wise	_	
35-116	20614-20623	threshold	_	
35-117	20624-20626	to	_	
35-118	20627-20628	p	_	
35-119	20628-20629	=	_	
35-120	20629-20632	.05	_	
35-121	20632-20633	,	_	
35-122	20634-20639	while	_	
35-123	20640-20645	still	_	
35-124	20646-20657	maintaining	_	
35-125	20658-20659	a	_	
35-126	20660-20673	cluster-level	_	
35-127	20674-20683	corrected	_	
35-128	20684-20693	threshold	_	
35-129	20694-20696	of	_	
35-130	20697-20700	the	_	
35-131	20701-20715	pFWE-corrected	_	
35-132	20715-20716	=	_	
35-133	20716-20719	.05	_	
35-134	20719-20720	,	_	
35-135	20721-20729	revealed	_	
35-136	20730-20731	a	_	
35-137	20732-20736	very	_	
35-138	20737-20744	similar	_	
35-139	20745-20752	pattern	_	
35-140	20753-20755	of	_	
35-141	20756-20764	thalamic	_	
35-142	20765-20780	dysconnectivity	_	
35-143	20781-20783	in	_	
35-144	20784-20789	early	_	
35-145	20790-20795	stage	_	
35-146	20796-20805	psychosis	_	
35-147	20805-20806	.	_	
35-148	20807-20809	In	_	
35-149	20810-20818	contrast	_	
35-150	20819-20821	to	_	
35-151	20822-20825	the	_	
35-152	20826-20834	thalamus	_	
35-153	20835-20838	PFC	_	
35-154	20839-20843	seed	_	
35-155	20843-20844	,	_	
35-156	20845-20854	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]	
35-157	20855-20863	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]	
35-158	20864-20873	exhibited	_	
35-159	20874-20881	greater	_	
35-160	20882-20887	motor	_	
35-161	20888-20896	thalamus	_	
35-162	20897-20901	seed	_	
35-163	20902-20914	connectivity	_	
35-164	20915-20919	with	_	
35-165	20920-20921	a	_	
35-166	20922-20929	cluster	_	
35-167	20930-20934	that	_	
35-168	20935-20943	included	_	
35-169	20944-20951	midline	_	
35-170	20952-20960	Brodmann	_	
35-171	20960-20961	’	_	
35-172	20961-20962	s	_	
35-173	20963-20968	areas	_	
35-174	20969-20970	6	_	
35-175	20971-20974	and	_	
35-176	20975-20976	4	_	
35-177	20977-20980	and	_	
35-178	20981-20985	left	_	
35-179	20986-20996	precentral	_	
35-180	20997-21002	gyrus	_	
35-181	21003-21016	corresponding	_	
35-182	21017-21019	to	_	
35-183	21020-21028	Brodmann	_	
35-184	21028-21029	’	_	
35-185	21029-21030	s	_	
35-186	21031-21035	area	_	
35-187	21036-21038	44	_	
35-188	21038-21039	.	_	
35-189	21040-21042	In	_	
35-190	21043-21050	chronic	_	
35-191	21051-21059	patients	_	
35-192	21059-21060	,	_	
35-193	21061-21079	hyper-connectivity	_	
35-194	21080-21082	of	_	
35-195	21083-21086	the	_	
35-196	21087-21095	thalamus	_	
35-197	21096-21101	motor	_	
35-198	21102-21106	seed	_	
35-199	21107-21116	localized	_	
35-200	21117-21119	to	_	
35-201	21120-21123	the	_	
35-202	21124-21129	right	_	
35-203	21130-21137	lateral	_	
35-204	21138-21148	precentral	_	
35-205	21149-21154	gyrus	_	
35-206	21155-21168	corresponding	_	
35-207	21169-21171	to	_	
35-208	21172-21180	Brodmann	_	
35-209	21180-21181	’	_	
35-210	21181-21182	s	_	
35-211	21183-21187	area	_	
35-212	21188-21189	6	_	
35-213	21189-21190	,	_	
35-214	21191-21198	midline	_	
35-215	21199-21207	cortical	_	
35-216	21208-21213	areas	_	
35-217	21214-21227	corresponding	_	
35-218	21228-21230	to	_	
35-219	21231-21237	medial	_	
35-220	21238-21245	aspects	_	
35-221	21246-21248	of	_	
35-222	21249-21257	Brodmann	_	
35-223	21257-21258	’	_	
35-224	21258-21259	s	_	
35-225	21260-21265	areas	_	
35-226	21266-21267	4	_	
35-227	21268-21271	and	_	
35-228	21272-21273	6	_	
35-229	21273-21274	,	_	
35-230	21275-21278	and	_	
35-231	21279-21283	left	_	
35-232	21284-21295	postcentral	_	
35-233	21296-21301	gyrus	_	
35-234	21302-21315	corresponding	_	
35-235	21316-21318	to	_	
35-236	21319-21327	Brodmann	_	
35-237	21327-21328	’	_	
35-238	21328-21329	s	_	
35-239	21330-21334	area	_	
35-240	21335-21336	5	_	
35-241	21336-21337	.	_	
35-242	21338-21340	No	_	
35-243	21341-21352	significant	_	
35-244	21353-21364	differences	_	
35-245	21365-21372	between	_	
35-246	21373-21380	healthy	_	
35-247	21381-21389	subjects	_	
35-248	21390-21393	and	_	
35-249	21394-21399	early	_	
35-250	21400-21405	stage	_	
35-251	21406-21415	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[19]	
35-252	21416-21424	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[19]	
35-253	21425-21429	were	_	
35-254	21430-21438	observed	_	
35-255	21439-21441	at	_	
35-256	21442-21445	the	_	
35-257	21446-21455	corrected	_	
35-258	21456-21468	significance	_	
35-259	21469-21474	level	_	
35-260	21474-21475	.	_	
35-261	21476-21483	However	_	
35-262	21483-21484	,	_	
35-263	21485-21493	relaxing	_	
35-264	21494-21497	the	_	
35-265	21498-21508	voxel-wise	_	
35-266	21509-21518	threshold	_	
35-267	21519-21521	to	_	
35-268	21522-21523	p	_	
35-269	21523-21524	=	_	
35-270	21524-21527	.05	_	
35-271	21527-21528	,	_	
35-272	21529-21534	while	_	
35-273	21535-21540	still	_	
35-274	21541-21552	maintaining	_	
35-275	21553-21554	a	_	
35-276	21555-21566	whole-brain	_	
35-277	21567-21580	cluster-level	_	
35-278	21581-21590	corrected	_	
35-279	21591-21600	threshold	_	
35-280	21601-21603	of	_	
35-281	21604-21618	pFWE-corrected	_	
35-282	21618-21619	=	_	
35-283	21619-21622	.05	_	
35-284	21622-21623	,	_	
35-285	21624-21632	revealed	_	
35-286	21633-21634	a	_	
35-287	21635-21642	similar	_	
35-288	21643-21650	pattern	_	
35-289	21651-21653	of	_	
35-290	21654-21662	thalamus	_	
35-291	21663-21668	motor	_	
35-292	21669-21673	seed	_	
35-293	21674-21692	hyper-connectivity	_	
35-294	21693-21695	in	_	
35-295	21696-21701	early	_	
35-296	21702-21707	stage	_	
35-297	21708-21717	psychosis	_	
35-298	21717-21718	;	_	
35-299	21719-21727	elevated	_	
35-300	21728-21740	connectivity	_	
35-301	21741-21745	with	_	
35-302	21746-21752	medial	_	
35-303	21753-21760	aspects	_	
35-304	21761-21763	of	_	
35-305	21764-21774	precentral	_	
35-306	21775-21778	and	_	
35-307	21779-21790	postcentral	_	
35-308	21791-21796	gyrus	_	
35-309	21796-21797	,	_	
35-310	21798-21801	and	_	
35-311	21802-21809	lateral	_	
35-312	21810-21820	precentral	_	
35-313	21821-21826	gyrus	_	
35-314	21826-21827	.	_	
35-315	21828-21832	With	_	
35-316	21833-21840	respect	_	
35-317	21841-21843	to	_	
35-318	21844-21847	the	_	
35-319	21848-21856	thalamus	_	
35-320	21857-21870	somatosensory	_	
35-321	21871-21875	seed	_	
35-322	21875-21876	,	_	
35-323	21877-21879	no	_	
35-324	21880-21891	differences	_	
35-325	21892-21894	in	_	
35-326	21895-21905	functional	_	
35-327	21906-21918	connectivity	_	
35-328	21919-21923	were	_	
35-329	21924-21932	detected	_	
35-330	21933-21940	between	_	
35-331	21941-21948	healthy	_	
35-332	21949-21957	subjects	_	
35-333	21958-21961	and	_	
35-334	21962-21971	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[20]	
35-335	21972-21980	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[20]	
35-336	21980-21981	.	_	
35-337	21982-21984	In	_	
35-338	21985-21990	order	_	
35-339	21991-21993	to	_	
35-340	21994-22000	better	_	
35-341	22001-22011	appreciate	_	
35-342	22012-22015	the	_	
35-343	22016-22023	similar	_	
35-344	22024-22032	patterns	_	
35-345	22033-22035	of	_	
35-346	22036-22044	thalamic	_	
35-347	22045-22060	dysconnectivity	_	
35-348	22061-22063	in	_	
35-349	22064-22071	chronic	_	
35-350	22072-22075	and	_	
35-351	22076-22081	early	_	
35-352	22082-22087	stage	_	
35-353	22088-22097	psychosis	_	
35-354	22097-22098	,	_	
35-355	22099-22102	the	_	
35-356	22103-22110	results	_	
35-357	22111-22113	of	_	
35-358	22114-22117	the	_	
35-359	22118-22128	voxel-wise	_	
35-360	22129-22138	contrasts	_	
35-361	22139-22148	comparing	_	
35-362	22149-22153	each	_	
35-363	22154-22161	illness	_	
35-364	22162-22167	stage	_	
35-365	22168-22173	group	_	
35-366	22174-22176	to	_	
35-367	22177-22184	healthy	_	
35-368	22185-22193	subjects	_	
35-369	22194-22197	are	_	
35-370	22198-22202	also	_	
35-371	22203-22212	presented	_	
35-372	22213-22215	in	_	
35-373	22216-22228	Supplemental	_	
35-374	22229-22235	Figure	_	
35-375	22236-22238	S6	_	
35-376	22239-22246	without	_	
35-377	22247-22258	statistical	_	
35-378	22259-22271	thresholding	_	
35-379	22271-22272	.	_	

#Text=Exploratory analyses were performed examining the relationship between thalamic functional connectivity and cognition, clinical symptoms, and psychotic disorder diagnosis. Functional connectivity, in beta units, was extracted from the clusters identified in the healthy subjects vs. psychosis contrasts and averaged to create two values per subject; one indicating average PFC thalamic under-connectivity, the other indicating average motor thalamus hyper-connectivity. In ES terms, thalamus PFC seed hypo-connectivity was similar in chronic and early stage patients (ES=−0.94 and −0.87, respectively), as was thalamus motor seed hyper-connectivity (ES=0.78 and 0.85, respectively). After controlling for group, average connectivity in the PFC thalamus seed regions demonstrating reduced connectivity in psychosis correlated with SCIP Global z-score of cognitive functioning across all subjects (partial r=.14, p=.029). This relationship was strongest for the verbal learning sub-test (partial r=.18, p=.006). Scatterplots depicting these correlations are presented in Supplemental Figure S7. Motor thalamus hyper-connectivity was unrelated to cognitive functioning (partial r=-.06, p=.319). Neither PFC hypo-connectivity nor motor thalamus seed hyper-connectivity was related to positive, negative, and general symptoms from the PANSS (all r values<.|14|, p>.101). Consistent with the cortical ROI-to-ROI analysis presented earlier, PFC-thalamic seed connectivity was lower in non-affective psychosis compared to affective psychosis at the trend significance level after controlling for age, sex, and illness stage (F(1,143)=2.86, p=.093) (see Supplementary Figure S8). Motor functional connectivity did not differ between psychotic disorders (F(1,143)=0.12, p=.730).
36-1	22273-22284	Exploratory	_	
36-2	22285-22293	analyses	_	
36-3	22294-22298	were	_	
36-4	22299-22308	performed	_	
36-5	22309-22318	examining	_	
36-6	22319-22322	the	_	
36-7	22323-22335	relationship	_	
36-8	22336-22343	between	_	
36-9	22344-22352	thalamic	_	
36-10	22353-22363	functional	_	
36-11	22364-22376	connectivity	_	
36-12	22377-22380	and	_	
36-13	22381-22390	cognition	_	
36-14	22390-22391	,	_	
36-15	22392-22400	clinical	_	
36-16	22401-22409	symptoms	_	
36-17	22409-22410	,	_	
36-18	22411-22414	and	_	
36-19	22415-22424	psychotic	_	
36-20	22425-22433	disorder	_	
36-21	22434-22443	diagnosis	_	
36-22	22443-22444	.	_	
36-23	22445-22455	Functional	_	
36-24	22456-22468	connectivity	_	
36-25	22468-22469	,	_	
36-26	22470-22472	in	_	
36-27	22473-22477	beta	_	
36-28	22478-22483	units	_	
36-29	22483-22484	,	_	
36-30	22485-22488	was	_	
36-31	22489-22498	extracted	_	
36-32	22499-22503	from	_	
36-33	22504-22507	the	_	
36-34	22508-22516	clusters	_	
36-35	22517-22527	identified	_	
36-36	22528-22530	in	_	
36-37	22531-22534	the	_	
36-38	22535-22542	healthy	_	
36-39	22543-22551	subjects	_	
36-40	22552-22554	vs	_	
36-41	22554-22555	.	_	
36-42	22556-22565	psychosis	_	
36-43	22566-22575	contrasts	_	
36-44	22576-22579	and	_	
36-45	22580-22588	averaged	_	
36-46	22589-22591	to	_	
36-47	22592-22598	create	_	
36-48	22599-22602	two	_	
36-49	22603-22609	values	_	
36-50	22610-22613	per	_	
36-51	22614-22621	subject	_	
36-52	22621-22622	;	_	
36-53	22623-22626	one	_	
36-54	22627-22637	indicating	_	
36-55	22638-22645	average	_	
36-56	22646-22649	PFC	_	
36-57	22650-22658	thalamic	_	
36-58	22659-22677	under-connectivity	_	
36-59	22677-22678	,	_	
36-60	22679-22682	the	_	
36-61	22683-22688	other	_	
36-62	22689-22699	indicating	_	
36-63	22700-22707	average	_	
36-64	22708-22713	motor	_	
36-65	22714-22722	thalamus	_	
36-66	22723-22741	hyper-connectivity	_	
36-67	22741-22742	.	_	
36-68	22743-22745	In	_	
36-69	22746-22748	ES	_	
36-70	22749-22754	terms	_	
36-71	22754-22755	,	_	
36-72	22756-22764	thalamus	_	
36-73	22765-22768	PFC	_	
36-74	22769-22773	seed	_	
36-75	22774-22791	hypo-connectivity	_	
36-76	22792-22795	was	_	
36-77	22796-22803	similar	_	
36-78	22804-22806	in	_	
36-79	22807-22814	chronic	_	
36-80	22815-22818	and	_	
36-81	22819-22824	early	_	
36-82	22825-22830	stage	_	
36-83	22831-22839	patients	_	
36-84	22840-22841	(	_	
36-85	22841-22843	ES	_	
36-86	22843-22844	=	_	
36-87	22844-22845	−	_	
36-88	22845-22849	0.94	_	
36-89	22850-22853	and	_	
36-90	22854-22855	−	_	
36-91	22855-22859	0.87	_	
36-92	22859-22860	,	_	
36-93	22861-22873	respectively	_	
36-94	22873-22874	)	_	
36-95	22874-22875	,	_	
36-96	22876-22878	as	_	
36-97	22879-22882	was	_	
36-98	22883-22891	thalamus	_	
36-99	22892-22897	motor	_	
36-100	22898-22902	seed	_	
36-101	22903-22921	hyper-connectivity	_	
36-102	22922-22923	(	_	
36-103	22923-22925	ES	_	
36-104	22925-22926	=	_	
36-105	22926-22930	0.78	_	
36-106	22931-22934	and	_	
36-107	22935-22939	0.85	_	
36-108	22939-22940	,	_	
36-109	22941-22953	respectively	_	
36-110	22953-22954	)	_	
36-111	22954-22955	.	_	
36-112	22956-22961	After	_	
36-113	22962-22973	controlling	_	
36-114	22974-22977	for	_	
36-115	22978-22983	group	_	
36-116	22983-22984	,	_	
36-117	22985-22992	average	_	
36-118	22993-23005	connectivity	_	
36-119	23006-23008	in	_	
36-120	23009-23012	the	_	
36-121	23013-23016	PFC	_	
36-122	23017-23025	thalamus	_	
36-123	23026-23030	seed	_	
36-124	23031-23038	regions	_	
36-125	23039-23052	demonstrating	_	
36-126	23053-23060	reduced	_	
36-127	23061-23073	connectivity	_	
36-128	23074-23076	in	_	
36-129	23077-23086	psychosis	_	
36-130	23087-23097	correlated	_	
36-131	23098-23102	with	_	
36-132	23103-23107	SCIP	_	
36-133	23108-23114	Global	_	
36-134	23115-23122	z-score	_	
36-135	23123-23125	of	_	
36-136	23126-23135	cognitive	_	
36-137	23136-23147	functioning	_	
36-138	23148-23154	across	_	
36-139	23155-23158	all	_	
36-140	23159-23167	subjects	_	
36-141	23168-23169	(	_	
36-142	23169-23176	partial	_	
36-143	23177-23178	r	_	
36-144	23178-23179	=	_	
36-145	23179-23182	.14	_	
36-146	23182-23183	,	_	
36-147	23184-23185	p	_	
36-148	23185-23186	=	_	
36-149	23186-23190	.029	_	
36-150	23190-23191	)	_	
36-151	23191-23192	.	_	
36-152	23193-23197	This	_	
36-153	23198-23210	relationship	_	
36-154	23211-23214	was	_	
36-155	23215-23224	strongest	_	
36-156	23225-23228	for	_	
36-157	23229-23232	the	_	
36-158	23233-23239	verbal	_	
36-159	23240-23248	learning	_	
36-160	23249-23257	sub-test	_	
36-161	23258-23259	(	_	
36-162	23259-23266	partial	_	
36-163	23267-23268	r	_	
36-164	23268-23269	=	_	
36-165	23269-23272	.18	_	
36-166	23272-23273	,	_	
36-167	23274-23275	p	_	
36-168	23275-23276	=	_	
36-169	23276-23280	.006	_	
36-170	23280-23281	)	_	
36-171	23281-23282	.	_	
36-172	23283-23295	Scatterplots	_	
36-173	23296-23305	depicting	_	
36-174	23306-23311	these	_	
36-175	23312-23324	correlations	_	
36-176	23325-23328	are	_	
36-177	23329-23338	presented	_	
36-178	23339-23341	in	_	
36-179	23342-23354	Supplemental	_	
36-180	23355-23361	Figure	_	
36-181	23362-23364	S7	_	
36-182	23364-23365	.	_	
36-183	23366-23371	Motor	_	
36-184	23372-23380	thalamus	_	
36-185	23381-23399	hyper-connectivity	_	
36-186	23400-23403	was	_	
36-187	23404-23413	unrelated	_	
36-188	23414-23416	to	_	
36-189	23417-23426	cognitive	_	
36-190	23427-23438	functioning	_	
36-191	23439-23440	(	_	
36-192	23440-23447	partial	_	
36-193	23448-23449	r	_	
36-194	23449-23450	=	_	
36-195	23450-23451	-	_	
36-196	23451-23454	.06	_	
36-197	23454-23455	,	_	
36-198	23456-23457	p	_	
36-199	23457-23458	=	_	
36-200	23458-23462	.319	_	
36-201	23462-23463	)	_	
36-202	23463-23464	.	_	
36-203	23465-23472	Neither	_	
36-204	23473-23476	PFC	_	
36-205	23477-23494	hypo-connectivity	_	
36-206	23495-23498	nor	_	
36-207	23499-23504	motor	_	
36-208	23505-23513	thalamus	_	
36-209	23514-23518	seed	_	
36-210	23519-23537	hyper-connectivity	_	
36-211	23538-23541	was	_	
36-212	23542-23549	related	_	
36-213	23550-23552	to	_	
36-214	23553-23561	positive	_	
36-215	23561-23562	,	_	
36-216	23563-23571	negative	_	
36-217	23571-23572	,	_	
36-218	23573-23576	and	_	
36-219	23577-23584	general	_	
36-220	23585-23593	symptoms	_	
36-221	23594-23598	from	_	
36-222	23599-23602	the	_	
36-223	23603-23608	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
36-224	23609-23610	(	_	
36-225	23610-23613	all	_	
36-226	23614-23615	r	_	
36-227	23616-23622	values	_	
36-228	23622-23623	<	_	
36-229	23623-23624	.	_	
36-230	23624-23625	|	_	
36-231	23625-23627	14	_	
36-232	23627-23628	|	_	
36-233	23628-23629	,	_	
36-234	23630-23631	p	_	
36-235	23631-23632	>	_	
36-236	23632-23636	.101	_	
36-237	23636-23637	)	_	
36-238	23637-23638	.	_	
36-239	23639-23649	Consistent	_	
36-240	23650-23654	with	_	
36-241	23655-23658	the	_	
36-242	23659-23667	cortical	_	
36-243	23668-23678	ROI-to-ROI	_	
36-244	23679-23687	analysis	_	
36-245	23688-23697	presented	_	
36-246	23698-23705	earlier	_	
36-247	23705-23706	,	_	
36-248	23707-23719	PFC-thalamic	_	
36-249	23720-23724	seed	_	
36-250	23725-23737	connectivity	_	
36-251	23738-23741	was	_	
36-252	23742-23747	lower	_	
36-253	23748-23750	in	_	
36-254	23751-23764	non-affective	_	
36-255	23765-23774	psychosis	_	
36-256	23775-23783	compared	_	
36-257	23784-23786	to	_	
36-258	23787-23796	affective	_	
36-259	23797-23806	psychosis	_	
36-260	23807-23809	at	_	
36-261	23810-23813	the	_	
36-262	23814-23819	trend	_	
36-263	23820-23832	significance	_	
36-264	23833-23838	level	_	
36-265	23839-23844	after	_	
36-266	23845-23856	controlling	_	
36-267	23857-23860	for	_	
36-268	23861-23864	age	_	
36-269	23864-23865	,	_	
36-270	23866-23869	sex	_	
36-271	23869-23870	,	_	
36-272	23871-23874	and	_	
36-273	23875-23882	illness	_	
36-274	23883-23888	stage	_	
36-275	23889-23890	(	_	
36-276	23890-23891	F	_	
36-277	23891-23892	(	_	
36-278	23892-23897	1,143	_	
36-279	23897-23898	)	_	
36-280	23898-23899	=	_	
36-281	23899-23903	2.86	_	
36-282	23903-23904	,	_	
36-283	23905-23906	p	_	
36-284	23906-23907	=	_	
36-285	23907-23911	.093	_	
36-286	23911-23912	)	_	
36-287	23913-23914	(	_	
36-288	23914-23917	see	_	
36-289	23918-23931	Supplementary	_	
36-290	23932-23938	Figure	_	
36-291	23939-23941	S8	_	
36-292	23941-23942	)	_	
36-293	23942-23943	.	_	
36-294	23944-23949	Motor	_	
36-295	23950-23960	functional	_	
36-296	23961-23973	connectivity	_	
36-297	23974-23977	did	_	
36-298	23978-23981	not	_	
36-299	23982-23988	differ	_	
36-300	23989-23996	between	_	
36-301	23997-24006	psychotic	_	
36-302	24007-24016	disorders	_	
36-303	24017-24018	(	_	
36-304	24018-24019	F	_	
36-305	24019-24020	(	_	
36-306	24020-24025	1,143	_	
36-307	24025-24026	)	_	
36-308	24026-24027	=	_	
36-309	24027-24031	0.12	_	
36-310	24031-24032	,	_	
36-311	24033-24034	p	_	
36-312	24034-24035	=	_	
36-313	24035-24039	.730	_	
36-314	24039-24040	)	_	
36-315	24040-24041	.	_	

#Text=DISCUSSION
37-1	24042-24052	DISCUSSION	_	

#Text=We confirmed that the combination of reduced PFC-thalamic connectivity and somatomotor-thalamic hyper-connectivity observed in prior investigations of chronic patients is present in the early stage of psychosis. Models of the etiology of psychotic disorders have oscillated over time between neurodegenerative and neurodevelopmental models. Mounting evidence indicates that both processes are likely involved; some abnormalities are detected early in the course of psychotic illnesses and remain relatively static, whereas other abnormalities emerge over time and progressively worsen. Based on earlier findings in chronic patients, we hypothesized that reduced PFC-thalamic connectivity and increased somatomotor-thalamic in psychosis may result from abnormal late brain maturation that derails the normal development of PFC-thalamic circuitry and refinement of somatomotor-thalamic connectivity. The current results obtained from a sample of early stage patients are consistent with a neurodevelopmental explanation for thalamocortical dysconnectivity. Nonetheless, our results, while consistent with neurodevelopmental models, cannot definitively confirm that thalamocortical network abnormalities result from atypical neurodevelopment. It remains possible that thalamocortical dysconnectivity emerges prior to or at the onset of psychosis. Recent findings from a cross-sectional investigation showing reduced dorsal caudate connectivity with PFC and thalamus in individuals at high risk for psychosis further support a developmental basis for thalamic dysconnectivity. Longitudinal investigations of high-risk/prodromal patients will be useful in further pinpointing the timing and clarifying the functional relevance of cortico-striatal-thalamic dysconnectivity.
38-1	24053-24055	We	_	
38-2	24056-24065	confirmed	_	
38-3	24066-24070	that	_	
38-4	24071-24074	the	_	
38-5	24075-24086	combination	_	
38-6	24087-24089	of	_	
38-7	24090-24097	reduced	_	
38-8	24098-24110	PFC-thalamic	_	
38-9	24111-24123	connectivity	_	
38-10	24124-24127	and	_	
38-11	24128-24148	somatomotor-thalamic	_	
38-12	24149-24167	hyper-connectivity	_	
38-13	24168-24176	observed	_	
38-14	24177-24179	in	_	
38-15	24180-24185	prior	_	
38-16	24186-24200	investigations	_	
38-17	24201-24203	of	_	
38-18	24204-24211	chronic	_	
38-19	24212-24220	patients	_	
38-20	24221-24223	is	_	
38-21	24224-24231	present	_	
38-22	24232-24234	in	_	
38-23	24235-24238	the	_	
38-24	24239-24244	early	_	
38-25	24245-24250	stage	_	
38-26	24251-24253	of	_	
38-27	24254-24263	psychosis	_	
38-28	24263-24264	.	_	
38-29	24265-24271	Models	_	
38-30	24272-24274	of	_	
38-31	24275-24278	the	_	
38-32	24279-24287	etiology	_	
38-33	24288-24290	of	_	
38-34	24291-24300	psychotic	_	
38-35	24301-24310	disorders	_	
38-36	24311-24315	have	_	
38-37	24316-24326	oscillated	_	
38-38	24327-24331	over	_	
38-39	24332-24336	time	_	
38-40	24337-24344	between	_	
38-41	24345-24362	neurodegenerative	_	
38-42	24363-24366	and	_	
38-43	24367-24385	neurodevelopmental	_	
38-44	24386-24392	models	_	
38-45	24392-24393	.	_	
38-46	24394-24402	Mounting	_	
38-47	24403-24411	evidence	_	
38-48	24412-24421	indicates	_	
38-49	24422-24426	that	_	
38-50	24427-24431	both	_	
38-51	24432-24441	processes	_	
38-52	24442-24445	are	_	
38-53	24446-24452	likely	_	
38-54	24453-24461	involved	_	
38-55	24461-24462	;	_	
38-56	24463-24467	some	_	
38-57	24468-24481	abnormalities	_	
38-58	24482-24485	are	_	
38-59	24486-24494	detected	_	
38-60	24495-24500	early	_	
38-61	24501-24503	in	_	
38-62	24504-24507	the	_	
38-63	24508-24514	course	_	
38-64	24515-24517	of	_	
38-65	24518-24527	psychotic	_	
38-66	24528-24537	illnesses	_	
38-67	24538-24541	and	_	
38-68	24542-24548	remain	_	
38-69	24549-24559	relatively	_	
38-70	24560-24566	static	_	
38-71	24566-24567	,	_	
38-72	24568-24575	whereas	_	
38-73	24576-24581	other	_	
38-74	24582-24595	abnormalities	_	
38-75	24596-24602	emerge	_	
38-76	24603-24607	over	_	
38-77	24608-24612	time	_	
38-78	24613-24616	and	_	
38-79	24617-24630	progressively	_	
38-80	24631-24637	worsen	_	
38-81	24637-24638	.	_	
38-82	24639-24644	Based	_	
38-83	24645-24647	on	_	
38-84	24648-24655	earlier	_	
38-85	24656-24664	findings	_	
38-86	24665-24667	in	_	
38-87	24668-24675	chronic	_	
38-88	24676-24684	patients	_	
38-89	24684-24685	,	_	
38-90	24686-24688	we	_	
38-91	24689-24701	hypothesized	_	
38-92	24702-24706	that	_	
38-93	24707-24714	reduced	_	
38-94	24715-24727	PFC-thalamic	_	
38-95	24728-24740	connectivity	_	
38-96	24741-24744	and	_	
38-97	24745-24754	increased	_	
38-98	24755-24775	somatomotor-thalamic	_	
38-99	24776-24778	in	_	
38-100	24779-24788	psychosis	_	
38-101	24789-24792	may	_	
38-102	24793-24799	result	_	
38-103	24800-24804	from	_	
38-104	24805-24813	abnormal	_	
38-105	24814-24818	late	_	
38-106	24819-24824	brain	_	
38-107	24825-24835	maturation	_	
38-108	24836-24840	that	_	
38-109	24841-24848	derails	_	
38-110	24849-24852	the	_	
38-111	24853-24859	normal	_	
38-112	24860-24871	development	_	
38-113	24872-24874	of	_	
38-114	24875-24887	PFC-thalamic	_	
38-115	24888-24897	circuitry	_	
38-116	24898-24901	and	_	
38-117	24902-24912	refinement	_	
38-118	24913-24915	of	_	
38-119	24916-24936	somatomotor-thalamic	_	
38-120	24937-24949	connectivity	_	
38-121	24949-24950	.	_	
38-122	24951-24954	The	_	
38-123	24955-24962	current	_	
38-124	24963-24970	results	_	
38-125	24971-24979	obtained	_	
38-126	24980-24984	from	_	
38-127	24985-24986	a	_	
38-128	24987-24993	sample	_	
38-129	24994-24996	of	_	
38-130	24997-25002	early	_	
38-131	25003-25008	stage	_	
38-132	25009-25017	patients	_	
38-133	25018-25021	are	_	
38-134	25022-25032	consistent	_	
38-135	25033-25037	with	_	
38-136	25038-25039	a	_	
38-137	25040-25058	neurodevelopmental	_	
38-138	25059-25070	explanation	_	
38-139	25071-25074	for	_	
38-140	25075-25090	thalamocortical	_	
38-141	25091-25106	dysconnectivity	_	
38-142	25106-25107	.	_	
38-143	25108-25119	Nonetheless	_	
38-144	25119-25120	,	_	
38-145	25121-25124	our	_	
38-146	25125-25132	results	_	
38-147	25132-25133	,	_	
38-148	25134-25139	while	_	
38-149	25140-25150	consistent	_	
38-150	25151-25155	with	_	
38-151	25156-25174	neurodevelopmental	_	
38-152	25175-25181	models	_	
38-153	25181-25182	,	_	
38-154	25183-25189	cannot	_	
38-155	25190-25202	definitively	_	
38-156	25203-25210	confirm	_	
38-157	25211-25215	that	_	
38-158	25216-25231	thalamocortical	_	
38-159	25232-25239	network	_	
38-160	25240-25253	abnormalities	_	
38-161	25254-25260	result	_	
38-162	25261-25265	from	_	
38-163	25266-25274	atypical	_	
38-164	25275-25291	neurodevelopment	_	
38-165	25291-25292	.	_	
38-166	25293-25295	It	_	
38-167	25296-25303	remains	_	
38-168	25304-25312	possible	_	
38-169	25313-25317	that	_	
38-170	25318-25333	thalamocortical	_	
38-171	25334-25349	dysconnectivity	_	
38-172	25350-25357	emerges	_	
38-173	25358-25363	prior	_	
38-174	25364-25366	to	_	
38-175	25367-25369	or	_	
38-176	25370-25372	at	_	
38-177	25373-25376	the	_	
38-178	25377-25382	onset	_	
38-179	25383-25385	of	_	
38-180	25386-25395	psychosis	_	
38-181	25395-25396	.	_	
38-182	25397-25403	Recent	_	
38-183	25404-25412	findings	_	
38-184	25413-25417	from	_	
38-185	25418-25419	a	_	
38-186	25420-25435	cross-sectional	_	
38-187	25436-25449	investigation	_	
38-188	25450-25457	showing	_	
38-189	25458-25465	reduced	_	
38-190	25466-25472	dorsal	_	
38-191	25473-25480	caudate	_	
38-192	25481-25493	connectivity	_	
38-193	25494-25498	with	_	
38-194	25499-25502	PFC	_	
38-195	25503-25506	and	_	
38-196	25507-25515	thalamus	_	
38-197	25516-25518	in	_	
38-198	25519-25530	individuals	_	
38-199	25531-25533	at	_	
38-200	25534-25538	high	_	
38-201	25539-25543	risk	_	
38-202	25544-25547	for	_	
38-203	25548-25557	psychosis	_	
38-204	25558-25565	further	_	
38-205	25566-25573	support	_	
38-206	25574-25575	a	_	
38-207	25576-25589	developmental	_	
38-208	25590-25595	basis	_	
38-209	25596-25599	for	_	
38-210	25600-25608	thalamic	_	
38-211	25609-25624	dysconnectivity	_	
38-212	25624-25625	.	_	
38-213	25626-25638	Longitudinal	_	
38-214	25639-25653	investigations	_	
38-215	25654-25656	of	_	
38-216	25657-25666	high-risk	_	
38-217	25666-25667	/	_	
38-218	25667-25676	prodromal	_	
38-219	25677-25685	patients	_	
38-220	25686-25690	will	_	
38-221	25691-25693	be	_	
38-222	25694-25700	useful	_	
38-223	25701-25703	in	_	
38-224	25704-25711	further	_	
38-225	25712-25723	pinpointing	_	
38-226	25724-25727	the	_	
38-227	25728-25734	timing	_	
38-228	25735-25738	and	_	
38-229	25739-25749	clarifying	_	
38-230	25750-25753	the	_	
38-231	25754-25764	functional	_	
38-232	25765-25774	relevance	_	
38-233	25775-25777	of	_	
38-234	25778-25803	cortico-striatal-thalamic	_	
38-235	25804-25819	dysconnectivity	_	
38-236	25819-25820	.	_	

#Text=The present investigation also clarifies the anatomical specificity of thalamic circuitry abnormalities. Prior studies investigated either connectivity of large swaths of cortex with the thalamus or connectivity of the whole thalamus with the rest of the brain. The former approach provides excellent anatomical specificity within the thalamus, but at the cost of cortical specificity (e.g.), while the second approach provides better specificity within the cortex and rest of the brain, but by treating the thalamus as a homogeneous structure obscures network specific abnormalities (e.g.). Using a combination of ROI-to-ROI and seed-to-voxel approaches, we found that the anterior/medial-dorsal region of the thalamus is functionally connected to medial and dorsolateral PFC, mid cingulate, inferior parietal lobule, striatum, primarily the caudate, and cerebellum. The connectivity profile of the anterior/medial-dorsal thalamus bears a striking resemblance to the fronto-parietal or ‘executive control’ network that has been linked to a range of ‘higher’ cognitive functions often impaired in psychotic disorders, including working memory, cognitive flexibility, initiation, and inhibition. Consistent with our findings, human lesion and animal electrophysiology studies support a role for the mediodorsal thalamus in executive cognitive functions and memory. Both task-based and resting-state imaging studies have repeatedly found abnormal executive control network function in psychotic disorders; however, most investigations focused on cortical components and cortico-cortical connectivity of this network. Recently, reduced PFC-caudate was identified in first episode psychosis. The current results deepen our understanding of executive control network dysfunction in psychosis by showing that dysconnectivity within this network extends to the thalamus, is present in the early stage of the illness, and is related, albeit modestly, to cognition. Additionally, reduced thalamic connectivity with the cerebellum is particularly noteworthy as it further supports cortico-thalamo-cerebellum circuitry models of psychosis and is consistent with the growing appreciation of the cerebellum’s role in cognition.
39-1	25821-25824	The	_	
39-2	25825-25832	present	_	
39-3	25833-25846	investigation	_	
39-4	25847-25851	also	_	
39-5	25852-25861	clarifies	_	
39-6	25862-25865	the	_	
39-7	25866-25876	anatomical	_	
39-8	25877-25888	specificity	_	
39-9	25889-25891	of	_	
39-10	25892-25900	thalamic	_	
39-11	25901-25910	circuitry	_	
39-12	25911-25924	abnormalities	_	
39-13	25924-25925	.	_	
39-14	25926-25931	Prior	_	
39-15	25932-25939	studies	_	
39-16	25940-25952	investigated	_	
39-17	25953-25959	either	_	
39-18	25960-25972	connectivity	_	
39-19	25973-25975	of	_	
39-20	25976-25981	large	_	
39-21	25982-25988	swaths	_	
39-22	25989-25991	of	_	
39-23	25992-25998	cortex	_	
39-24	25999-26003	with	_	
39-25	26004-26007	the	_	
39-26	26008-26016	thalamus	_	
39-27	26017-26019	or	_	
39-28	26020-26032	connectivity	_	
39-29	26033-26035	of	_	
39-30	26036-26039	the	_	
39-31	26040-26045	whole	_	
39-32	26046-26054	thalamus	_	
39-33	26055-26059	with	_	
39-34	26060-26063	the	_	
39-35	26064-26068	rest	_	
39-36	26069-26071	of	_	
39-37	26072-26075	the	_	
39-38	26076-26081	brain	_	
39-39	26081-26082	.	_	
39-40	26083-26086	The	_	
39-41	26087-26093	former	_	
39-42	26094-26102	approach	_	
39-43	26103-26111	provides	_	
39-44	26112-26121	excellent	_	
39-45	26122-26132	anatomical	_	
39-46	26133-26144	specificity	_	
39-47	26145-26151	within	_	
39-48	26152-26155	the	_	
39-49	26156-26164	thalamus	_	
39-50	26164-26165	,	_	
39-51	26166-26169	but	_	
39-52	26170-26172	at	_	
39-53	26173-26176	the	_	
39-54	26177-26181	cost	_	
39-55	26182-26184	of	_	
39-56	26185-26193	cortical	_	
39-57	26194-26205	specificity	_	
39-58	26206-26207	(	_	
39-59	26207-26210	e.g	_	
39-60	26210-26211	.	_	
39-61	26211-26212	)	_	
39-62	26212-26213	,	_	
39-63	26214-26219	while	_	
39-64	26220-26223	the	_	
39-65	26224-26230	second	_	
39-66	26231-26239	approach	_	
39-67	26240-26248	provides	_	
39-68	26249-26255	better	_	
39-69	26256-26267	specificity	_	
39-70	26268-26274	within	_	
39-71	26275-26278	the	_	
39-72	26279-26285	cortex	_	
39-73	26286-26289	and	_	
39-74	26290-26294	rest	_	
39-75	26295-26297	of	_	
39-76	26298-26301	the	_	
39-77	26302-26307	brain	_	
39-78	26307-26308	,	_	
39-79	26309-26312	but	_	
39-80	26313-26315	by	_	
39-81	26316-26324	treating	_	
39-82	26325-26328	the	_	
39-83	26329-26337	thalamus	_	
39-84	26338-26340	as	_	
39-85	26341-26342	a	_	
39-86	26343-26354	homogeneous	_	
39-87	26355-26364	structure	_	
39-88	26365-26373	obscures	_	
39-89	26374-26381	network	_	
39-90	26382-26390	specific	_	
39-91	26391-26404	abnormalities	_	
39-92	26405-26406	(	_	
39-93	26406-26409	e.g	_	
39-94	26409-26410	.	_	
39-95	26410-26411	)	_	
39-96	26411-26412	.	_	
39-97	26413-26418	Using	_	
39-98	26419-26420	a	_	
39-99	26421-26432	combination	_	
39-100	26433-26435	of	_	
39-101	26436-26446	ROI-to-ROI	_	
39-102	26447-26450	and	_	
39-103	26451-26464	seed-to-voxel	_	
39-104	26465-26475	approaches	_	
39-105	26475-26476	,	_	
39-106	26477-26479	we	_	
39-107	26480-26485	found	_	
39-108	26486-26490	that	_	
39-109	26491-26494	the	_	
39-110	26495-26503	anterior	_	
39-111	26503-26504	/	_	
39-112	26504-26517	medial-dorsal	_	
39-113	26518-26524	region	_	
39-114	26525-26527	of	_	
39-115	26528-26531	the	_	
39-116	26532-26540	thalamus	_	
39-117	26541-26543	is	_	
39-118	26544-26556	functionally	_	
39-119	26557-26566	connected	_	
39-120	26567-26569	to	_	
39-121	26570-26576	medial	_	
39-122	26577-26580	and	_	
39-123	26581-26593	dorsolateral	_	
39-124	26594-26597	PFC	_	
39-125	26597-26598	,	_	
39-126	26599-26602	mid	_	
39-127	26603-26612	cingulate	_	
39-128	26612-26613	,	_	
39-129	26614-26622	inferior	_	
39-130	26623-26631	parietal	_	
39-131	26632-26638	lobule	_	
39-132	26638-26639	,	_	
39-133	26640-26648	striatum	_	
39-134	26648-26649	,	_	
39-135	26650-26659	primarily	_	
39-136	26660-26663	the	_	
39-137	26664-26671	caudate	_	
39-138	26671-26672	,	_	
39-139	26673-26676	and	_	
39-140	26677-26687	cerebellum	_	
39-141	26687-26688	.	_	
39-142	26689-26692	The	_	
39-143	26693-26705	connectivity	_	
39-144	26706-26713	profile	_	
39-145	26714-26716	of	_	
39-146	26717-26720	the	_	
39-147	26721-26729	anterior	_	
39-148	26729-26730	/	_	
39-149	26730-26743	medial-dorsal	_	
39-150	26744-26752	thalamus	_	
39-151	26753-26758	bears	_	
39-152	26759-26760	a	_	
39-153	26761-26769	striking	_	
39-154	26770-26781	resemblance	_	
39-155	26782-26784	to	_	
39-156	26785-26788	the	_	
39-157	26789-26804	fronto-parietal	_	
39-158	26805-26807	or	_	
39-159	26808-26809	‘	_	
39-160	26809-26818	executive	_	
39-161	26819-26826	control	_	
39-162	26826-26827	’	_	
39-163	26828-26835	network	_	
39-164	26836-26840	that	_	
39-165	26841-26844	has	_	
39-166	26845-26849	been	_	
39-167	26850-26856	linked	_	
39-168	26857-26859	to	_	
39-169	26860-26861	a	_	
39-170	26862-26867	range	_	
39-171	26868-26870	of	_	
39-172	26871-26872	‘	_	
39-173	26872-26878	higher	_	
39-174	26878-26879	’	_	
39-175	26880-26889	cognitive	_	
39-176	26890-26899	functions	_	
39-177	26900-26905	often	_	
39-178	26906-26914	impaired	_	
39-179	26915-26917	in	_	
39-180	26918-26927	psychotic	_	
39-181	26928-26937	disorders	_	
39-182	26937-26938	,	_	
39-183	26939-26948	including	_	
39-184	26949-26956	working	_	
39-185	26957-26963	memory	_	
39-186	26963-26964	,	_	
39-187	26965-26974	cognitive	_	
39-188	26975-26986	flexibility	_	
39-189	26986-26987	,	_	
39-190	26988-26998	initiation	_	
39-191	26998-26999	,	_	
39-192	27000-27003	and	_	
39-193	27004-27014	inhibition	_	
39-194	27014-27015	.	_	
39-195	27016-27026	Consistent	_	
39-196	27027-27031	with	_	
39-197	27032-27035	our	_	
39-198	27036-27044	findings	_	
39-199	27044-27045	,	_	
39-200	27046-27051	human	_	
39-201	27052-27058	lesion	_	
39-202	27059-27062	and	_	
39-203	27063-27069	animal	_	
39-204	27070-27087	electrophysiology	_	
39-205	27088-27095	studies	_	
39-206	27096-27103	support	_	
39-207	27104-27105	a	_	
39-208	27106-27110	role	_	
39-209	27111-27114	for	_	
39-210	27115-27118	the	_	
39-211	27119-27130	mediodorsal	_	
39-212	27131-27139	thalamus	_	
39-213	27140-27142	in	_	
39-214	27143-27152	executive	_	
39-215	27153-27162	cognitive	_	
39-216	27163-27172	functions	_	
39-217	27173-27176	and	_	
39-218	27177-27183	memory	_	
39-219	27183-27184	.	_	
39-220	27185-27189	Both	_	
39-221	27190-27200	task-based	_	
39-222	27201-27204	and	_	
39-223	27205-27218	resting-state	_	
39-224	27219-27226	imaging	_	
39-225	27227-27234	studies	_	
39-226	27235-27239	have	_	
39-227	27240-27250	repeatedly	_	
39-228	27251-27256	found	_	
39-229	27257-27265	abnormal	_	
39-230	27266-27275	executive	_	
39-231	27276-27283	control	_	
39-232	27284-27291	network	_	
39-233	27292-27300	function	_	
39-234	27301-27303	in	_	
39-235	27304-27313	psychotic	_	
39-236	27314-27323	disorders	_	
39-237	27323-27324	;	_	
39-238	27325-27332	however	_	
39-239	27332-27333	,	_	
39-240	27334-27338	most	_	
39-241	27339-27353	investigations	_	
39-242	27354-27361	focused	_	
39-243	27362-27364	on	_	
39-244	27365-27373	cortical	_	
39-245	27374-27384	components	_	
39-246	27385-27388	and	_	
39-247	27389-27405	cortico-cortical	_	
39-248	27406-27418	connectivity	_	
39-249	27419-27421	of	_	
39-250	27422-27426	this	_	
39-251	27427-27434	network	_	
39-252	27434-27435	.	_	
39-253	27436-27444	Recently	_	
39-254	27444-27445	,	_	
39-255	27446-27453	reduced	_	
39-256	27454-27465	PFC-caudate	_	
39-257	27466-27469	was	_	
39-258	27470-27480	identified	_	
39-259	27481-27483	in	_	
39-260	27484-27489	first	_	
39-261	27490-27497	episode	_	
39-262	27498-27507	psychosis	_	
39-263	27507-27508	.	_	
39-264	27509-27512	The	_	
39-265	27513-27520	current	_	
39-266	27521-27528	results	_	
39-267	27529-27535	deepen	_	
39-268	27536-27539	our	_	
39-269	27540-27553	understanding	_	
39-270	27554-27556	of	_	
39-271	27557-27566	executive	_	
39-272	27567-27574	control	_	
39-273	27575-27582	network	_	
39-274	27583-27594	dysfunction	_	
39-275	27595-27597	in	_	
39-276	27598-27607	psychosis	_	
39-277	27608-27610	by	_	
39-278	27611-27618	showing	_	
39-279	27619-27623	that	_	
39-280	27624-27639	dysconnectivity	_	
39-281	27640-27646	within	_	
39-282	27647-27651	this	_	
39-283	27652-27659	network	_	
39-284	27660-27667	extends	_	
39-285	27668-27670	to	_	
39-286	27671-27674	the	_	
39-287	27675-27683	thalamus	_	
39-288	27683-27684	,	_	
39-289	27685-27687	is	_	
39-290	27688-27695	present	_	
39-291	27696-27698	in	_	
39-292	27699-27702	the	_	
39-293	27703-27708	early	_	
39-294	27709-27714	stage	_	
39-295	27715-27717	of	_	
39-296	27718-27721	the	_	
39-297	27722-27729	illness	_	
39-298	27729-27730	,	_	
39-299	27731-27734	and	_	
39-300	27735-27737	is	_	
39-301	27738-27745	related	_	
39-302	27745-27746	,	_	
39-303	27747-27753	albeit	_	
39-304	27754-27762	modestly	_	
39-305	27762-27763	,	_	
39-306	27764-27766	to	_	
39-307	27767-27776	cognition	_	
39-308	27776-27777	.	_	
39-309	27778-27790	Additionally	_	
39-310	27790-27791	,	_	
39-311	27792-27799	reduced	_	
39-312	27800-27808	thalamic	_	
39-313	27809-27821	connectivity	_	
39-314	27822-27826	with	_	
39-315	27827-27830	the	_	
39-316	27831-27841	cerebellum	_	
39-317	27842-27844	is	_	
39-318	27845-27857	particularly	_	
39-319	27858-27868	noteworthy	_	
39-320	27869-27871	as	_	
39-321	27872-27874	it	_	
39-322	27875-27882	further	_	
39-323	27883-27891	supports	_	
39-324	27892-27918	cortico-thalamo-cerebellum	_	
39-325	27919-27928	circuitry	_	
39-326	27929-27935	models	_	
39-327	27936-27938	of	_	
39-328	27939-27948	psychosis	_	
39-329	27949-27952	and	_	
39-330	27953-27955	is	_	
39-331	27956-27966	consistent	_	
39-332	27967-27971	with	_	
39-333	27972-27975	the	_	
39-334	27976-27983	growing	_	
39-335	27984-27996	appreciation	_	
39-336	27997-27999	of	_	
39-337	28000-28003	the	_	
39-338	28004-28014	cerebellum	_	
39-339	28014-28015	’	_	
39-340	28015-28016	s	_	
39-341	28017-28021	role	_	
39-342	28022-28024	in	_	
39-343	28025-28034	cognition	_	
39-344	28034-28035	.	_	

#Text=Consistent with a prior investigation, we found that PFC-thalamic hypo-connectivity and motor-thalamic hyper-connectivity were inversely correlated in psychosis suggesting that they are related. Anatomical investigations of non-human primates have found that there is greater connectivity between mediodorsal thalamus and motor cortical areas than is often appreciated. Direct microinjection of GABA agonists into the mediodorsal nucleus leads to increased motor activity and reduced dopamine metabolism in the PFC. Interestingly, a recent rodent electrophysiology investigation found that modest inhibition of mediodorsal nucleus activity disrupts PFC-thalamic functional connectivity and impairs cognition. Combined, these findings suggest that disruption of mediodorsal thalamus function may lead to reduced PFC-thalamic functional connectivity and a corresponding increase in motor-thalamic connectivity. Human neuroimaging and animal electrophysiology investigations examining the inter-relationships between thalamic networks and the impact of selective cortical and thalamic lesions on multiple thalamic networks will help clarify the mechanisms underlying thalamocortical deficits in psychosis.
40-1	28036-28046	Consistent	_	
40-2	28047-28051	with	_	
40-3	28052-28053	a	_	
40-4	28054-28059	prior	_	
40-5	28060-28073	investigation	_	
40-6	28073-28074	,	_	
40-7	28075-28077	we	_	
40-8	28078-28083	found	_	
40-9	28084-28088	that	_	
40-10	28089-28101	PFC-thalamic	_	
40-11	28102-28119	hypo-connectivity	_	
40-12	28120-28123	and	_	
40-13	28124-28138	motor-thalamic	_	
40-14	28139-28157	hyper-connectivity	_	
40-15	28158-28162	were	_	
40-16	28163-28172	inversely	_	
40-17	28173-28183	correlated	_	
40-18	28184-28186	in	_	
40-19	28187-28196	psychosis	_	
40-20	28197-28207	suggesting	_	
40-21	28208-28212	that	_	
40-22	28213-28217	they	_	
40-23	28218-28221	are	_	
40-24	28222-28229	related	_	
40-25	28229-28230	.	_	
40-26	28231-28241	Anatomical	_	
40-27	28242-28256	investigations	_	
40-28	28257-28259	of	_	
40-29	28260-28269	non-human	_	
40-30	28270-28278	primates	_	
40-31	28279-28283	have	_	
40-32	28284-28289	found	_	
40-33	28290-28294	that	_	
40-34	28295-28300	there	_	
40-35	28301-28303	is	_	
40-36	28304-28311	greater	_	
40-37	28312-28324	connectivity	_	
40-38	28325-28332	between	_	
40-39	28333-28344	mediodorsal	_	
40-40	28345-28353	thalamus	_	
40-41	28354-28357	and	_	
40-42	28358-28363	motor	_	
40-43	28364-28372	cortical	_	
40-44	28373-28378	areas	_	
40-45	28379-28383	than	_	
40-46	28384-28386	is	_	
40-47	28387-28392	often	_	
40-48	28393-28404	appreciated	_	
40-49	28404-28405	.	_	
40-50	28406-28412	Direct	_	
40-51	28413-28427	microinjection	_	
40-52	28428-28430	of	_	
40-53	28431-28435	GABA	_	
40-54	28436-28444	agonists	_	
40-55	28445-28449	into	_	
40-56	28450-28453	the	_	
40-57	28454-28465	mediodorsal	_	
40-58	28466-28473	nucleus	_	
40-59	28474-28479	leads	_	
40-60	28480-28482	to	_	
40-61	28483-28492	increased	_	
40-62	28493-28498	motor	_	
40-63	28499-28507	activity	_	
40-64	28508-28511	and	_	
40-65	28512-28519	reduced	_	
40-66	28520-28528	dopamine	_	
40-67	28529-28539	metabolism	_	
40-68	28540-28542	in	_	
40-69	28543-28546	the	_	
40-70	28547-28550	PFC	_	
40-71	28550-28551	.	_	
40-72	28552-28565	Interestingly	_	
40-73	28565-28566	,	_	
40-74	28567-28568	a	_	
40-75	28569-28575	recent	_	
40-76	28576-28582	rodent	_	
40-77	28583-28600	electrophysiology	_	
40-78	28601-28614	investigation	_	
40-79	28615-28620	found	_	
40-80	28621-28625	that	_	
40-81	28626-28632	modest	_	
40-82	28633-28643	inhibition	_	
40-83	28644-28646	of	_	
40-84	28647-28658	mediodorsal	_	
40-85	28659-28666	nucleus	_	
40-86	28667-28675	activity	_	
40-87	28676-28684	disrupts	_	
40-88	28685-28697	PFC-thalamic	_	
40-89	28698-28708	functional	_	
40-90	28709-28721	connectivity	_	
40-91	28722-28725	and	_	
40-92	28726-28733	impairs	_	
40-93	28734-28743	cognition	_	
40-94	28743-28744	.	_	
40-95	28745-28753	Combined	_	
40-96	28753-28754	,	_	
40-97	28755-28760	these	_	
40-98	28761-28769	findings	_	
40-99	28770-28777	suggest	_	
40-100	28778-28782	that	_	
40-101	28783-28793	disruption	_	
40-102	28794-28796	of	_	
40-103	28797-28808	mediodorsal	_	
40-104	28809-28817	thalamus	_	
40-105	28818-28826	function	_	
40-106	28827-28830	may	_	
40-107	28831-28835	lead	_	
40-108	28836-28838	to	_	
40-109	28839-28846	reduced	_	
40-110	28847-28859	PFC-thalamic	_	
40-111	28860-28870	functional	_	
40-112	28871-28883	connectivity	_	
40-113	28884-28887	and	_	
40-114	28888-28889	a	_	
40-115	28890-28903	corresponding	_	
40-116	28904-28912	increase	_	
40-117	28913-28915	in	_	
40-118	28916-28930	motor-thalamic	_	
40-119	28931-28943	connectivity	_	
40-120	28943-28944	.	_	
40-121	28945-28950	Human	_	
40-122	28951-28963	neuroimaging	_	
40-123	28964-28967	and	_	
40-124	28968-28974	animal	_	
40-125	28975-28992	electrophysiology	_	
40-126	28993-29007	investigations	_	
40-127	29008-29017	examining	_	
40-128	29018-29021	the	_	
40-129	29022-29041	inter-relationships	_	
40-130	29042-29049	between	_	
40-131	29050-29058	thalamic	_	
40-132	29059-29067	networks	_	
40-133	29068-29071	and	_	
40-134	29072-29075	the	_	
40-135	29076-29082	impact	_	
40-136	29083-29085	of	_	
40-137	29086-29095	selective	_	
40-138	29096-29104	cortical	_	
40-139	29105-29108	and	_	
40-140	29109-29117	thalamic	_	
40-141	29118-29125	lesions	_	
40-142	29126-29128	on	_	
40-143	29129-29137	multiple	_	
40-144	29138-29146	thalamic	_	
40-145	29147-29155	networks	_	
40-146	29156-29160	will	_	
40-147	29161-29165	help	_	
40-148	29166-29173	clarify	_	
40-149	29174-29177	the	_	
40-150	29178-29188	mechanisms	_	
40-151	29189-29199	underlying	_	
40-152	29200-29215	thalamocortical	_	
40-153	29216-29224	deficits	_	
40-154	29225-29227	in	_	
40-155	29228-29237	psychosis	_	
40-156	29237-29238	.	_	

#Text=Our investigation has several limitations. First, it is unclear if functional dysconnectivity is a consequence of compromised anatomical connectivity. Altered thalamocortical structural connectivity has been reported in schizophrenia. However, brain regions exhibiting strong functional coupling do not always share a direct anatomical pathway suggesting functional connectivity likely represents polysnaptic connectivity. Multi-modal investigations will be helpful in clarifying the nature of thalamocortical dysconnectivity. Anatomical connectivity methods may also improve localization of thalamic sub-regions which are difficult to delineate using conventional anatomical imaging. The relatively small number of psychotic bipolar patients included in our sample is another limitation. The finding that reduced thalamic-PFC connectivity was more prominent in non-affective psychosis should be considered preliminary, especially given evidence that other brain areas, such as the ventral anterior cingulate, exhibit similar patterns of dysconnectivity in psychotic bipolar disorder and schizophrenia. Similarly, our sample sizes were too small to examine diagnosis by illness stage effects. This may prove important given evidence that cognitive impairment is more severe in non-affective psychosis at the early stage of the illness, in contrast to the chronic stage when affective and non-affective psychosis patients exhibit a similar degree of impairment.
41-1	29239-29242	Our	_	
41-2	29243-29256	investigation	_	
41-3	29257-29260	has	_	
41-4	29261-29268	several	_	
41-5	29269-29280	limitations	_	
41-6	29280-29281	.	_	
41-7	29282-29287	First	_	
41-8	29287-29288	,	_	
41-9	29289-29291	it	_	
41-10	29292-29294	is	_	
41-11	29295-29302	unclear	_	
41-12	29303-29305	if	_	
41-13	29306-29316	functional	_	
41-14	29317-29332	dysconnectivity	_	
41-15	29333-29335	is	_	
41-16	29336-29337	a	_	
41-17	29338-29349	consequence	_	
41-18	29350-29352	of	_	
41-19	29353-29364	compromised	_	
41-20	29365-29375	anatomical	_	
41-21	29376-29388	connectivity	_	
41-22	29388-29389	.	_	
41-23	29390-29397	Altered	_	
41-24	29398-29413	thalamocortical	_	
41-25	29414-29424	structural	_	
41-26	29425-29437	connectivity	_	
41-27	29438-29441	has	_	
41-28	29442-29446	been	_	
41-29	29447-29455	reported	_	
41-30	29456-29458	in	_	
41-31	29459-29472	schizophrenia	_	
41-32	29472-29473	.	_	
41-33	29474-29481	However	_	
41-34	29481-29482	,	_	
41-35	29483-29488	brain	_	
41-36	29489-29496	regions	_	
41-37	29497-29507	exhibiting	_	
41-38	29508-29514	strong	_	
41-39	29515-29525	functional	_	
41-40	29526-29534	coupling	_	
41-41	29535-29537	do	_	
41-42	29538-29541	not	_	
41-43	29542-29548	always	_	
41-44	29549-29554	share	_	
41-45	29555-29556	a	_	
41-46	29557-29563	direct	_	
41-47	29564-29574	anatomical	_	
41-48	29575-29582	pathway	_	
41-49	29583-29593	suggesting	_	
41-50	29594-29604	functional	_	
41-51	29605-29617	connectivity	_	
41-52	29618-29624	likely	_	
41-53	29625-29635	represents	_	
41-54	29636-29647	polysnaptic	_	
41-55	29648-29660	connectivity	_	
41-56	29660-29661	.	_	
41-57	29662-29673	Multi-modal	_	
41-58	29674-29688	investigations	_	
41-59	29689-29693	will	_	
41-60	29694-29696	be	_	
41-61	29697-29704	helpful	_	
41-62	29705-29707	in	_	
41-63	29708-29718	clarifying	_	
41-64	29719-29722	the	_	
41-65	29723-29729	nature	_	
41-66	29730-29732	of	_	
41-67	29733-29748	thalamocortical	_	
41-68	29749-29764	dysconnectivity	_	
41-69	29764-29765	.	_	
41-70	29766-29776	Anatomical	_	
41-71	29777-29789	connectivity	_	
41-72	29790-29797	methods	_	
41-73	29798-29801	may	_	
41-74	29802-29806	also	_	
41-75	29807-29814	improve	_	
41-76	29815-29827	localization	_	
41-77	29828-29830	of	_	
41-78	29831-29839	thalamic	_	
41-79	29840-29851	sub-regions	_	
41-80	29852-29857	which	_	
41-81	29858-29861	are	_	
41-82	29862-29871	difficult	_	
41-83	29872-29874	to	_	
41-84	29875-29884	delineate	_	
41-85	29885-29890	using	_	
41-86	29891-29903	conventional	_	
41-87	29904-29914	anatomical	_	
41-88	29915-29922	imaging	_	
41-89	29922-29923	.	_	
41-90	29924-29927	The	_	
41-91	29928-29938	relatively	_	
41-92	29939-29944	small	_	
41-93	29945-29951	number	_	
41-94	29952-29954	of	_	
41-95	29955-29964	psychotic	_	
41-96	29965-29972	bipolar	_	
41-97	29973-29981	patients	_	
41-98	29982-29990	included	_	
41-99	29991-29993	in	_	
41-100	29994-29997	our	_	
41-101	29998-30004	sample	_	
41-102	30005-30007	is	_	
41-103	30008-30015	another	_	
41-104	30016-30026	limitation	_	
41-105	30026-30027	.	_	
41-106	30028-30031	The	_	
41-107	30032-30039	finding	_	
41-108	30040-30044	that	_	
41-109	30045-30052	reduced	_	
41-110	30053-30065	thalamic-PFC	_	
41-111	30066-30078	connectivity	_	
41-112	30079-30082	was	_	
41-113	30083-30087	more	_	
41-114	30088-30097	prominent	_	
41-115	30098-30100	in	_	
41-116	30101-30114	non-affective	_	
41-117	30115-30124	psychosis	_	
41-118	30125-30131	should	_	
41-119	30132-30134	be	_	
41-120	30135-30145	considered	_	
41-121	30146-30157	preliminary	_	
41-122	30157-30158	,	_	
41-123	30159-30169	especially	_	
41-124	30170-30175	given	_	
41-125	30176-30184	evidence	_	
41-126	30185-30189	that	_	
41-127	30190-30195	other	_	
41-128	30196-30201	brain	_	
41-129	30202-30207	areas	_	
41-130	30207-30208	,	_	
41-131	30209-30213	such	_	
41-132	30214-30216	as	_	
41-133	30217-30220	the	_	
41-134	30221-30228	ventral	_	
41-135	30229-30237	anterior	_	
41-136	30238-30247	cingulate	_	
41-137	30247-30248	,	_	
41-138	30249-30256	exhibit	_	
41-139	30257-30264	similar	_	
41-140	30265-30273	patterns	_	
41-141	30274-30276	of	_	
41-142	30277-30292	dysconnectivity	_	
41-143	30293-30295	in	_	
41-144	30296-30305	psychotic	_	
41-145	30306-30313	bipolar	_	
41-146	30314-30322	disorder	_	
41-147	30323-30326	and	_	
41-148	30327-30340	schizophrenia	_	
41-149	30340-30341	.	_	
41-150	30342-30351	Similarly	_	
41-151	30351-30352	,	_	
41-152	30353-30356	our	_	
41-153	30357-30363	sample	_	
41-154	30364-30369	sizes	_	
41-155	30370-30374	were	_	
41-156	30375-30378	too	_	
41-157	30379-30384	small	_	
41-158	30385-30387	to	_	
41-159	30388-30395	examine	_	
41-160	30396-30405	diagnosis	_	
41-161	30406-30408	by	_	
41-162	30409-30416	illness	_	
41-163	30417-30422	stage	_	
41-164	30423-30430	effects	_	
41-165	30430-30431	.	_	
41-166	30432-30436	This	_	
41-167	30437-30440	may	_	
41-168	30441-30446	prove	_	
41-169	30447-30456	important	_	
41-170	30457-30462	given	_	
41-171	30463-30471	evidence	_	
41-172	30472-30476	that	_	
41-173	30477-30486	cognitive	_	
41-174	30487-30497	impairment	_	
41-175	30498-30500	is	_	
41-176	30501-30505	more	_	
41-177	30506-30512	severe	_	
41-178	30513-30515	in	_	
41-179	30516-30529	non-affective	_	
41-180	30530-30539	psychosis	_	
41-181	30540-30542	at	_	
41-182	30543-30546	the	_	
41-183	30547-30552	early	_	
41-184	30553-30558	stage	_	
41-185	30559-30561	of	_	
41-186	30562-30565	the	_	
41-187	30566-30573	illness	_	
41-188	30573-30574	,	_	
41-189	30575-30577	in	_	
41-190	30578-30586	contrast	_	
41-191	30587-30589	to	_	
41-192	30590-30593	the	_	
41-193	30594-30601	chronic	_	
41-194	30602-30607	stage	_	
41-195	30608-30612	when	_	
41-196	30613-30622	affective	_	
41-197	30623-30626	and	_	
41-198	30627-30640	non-affective	_	
41-199	30641-30650	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[21]	
41-200	30651-30659	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[21]	
41-201	30660-30667	exhibit	_	
41-202	30668-30669	a	_	
41-203	30670-30677	similar	_	
41-204	30678-30684	degree	_	
41-205	30685-30687	of	_	
41-206	30688-30698	impairment	_	
41-207	30698-30699	.	_	

#Text=In conclusion, we confirmed that the combination of PFC-thalamic hypo-connectivity and somatomotor-thalamic hyper-connectivity is present at both the chronic and early stages of psychotic disorders. These two features are related, lower PFC-thalamic connectivity correlates with motor-thalamic hyper-connectivity, suggesting they result from a common pathophysiological mechanism. Moreover, thalamic hypo-connectivity is characterized by reduced connectivity between the anterior/medial-dorsal thalamus and the ‘executive control’ network and correlated with cognitive functioning. Future studies are required to: 1) clarify the relationship between thalamocortical functional dysconnectivity and anatomical connectivity; 2) confirm that thalamic dysconnectivity, especially reduced connectivity with the PFC and executive control network, is more severe in non-affective psychosis; and 3) determine if there is diagnosis by illness stage interactions.
42-1	30700-30702	In	_	
42-2	30703-30713	conclusion	_	
42-3	30713-30714	,	_	
42-4	30715-30717	we	_	
42-5	30718-30727	confirmed	_	
42-6	30728-30732	that	_	
42-7	30733-30736	the	_	
42-8	30737-30748	combination	_	
42-9	30749-30751	of	_	
42-10	30752-30764	PFC-thalamic	_	
42-11	30765-30782	hypo-connectivity	_	
42-12	30783-30786	and	_	
42-13	30787-30807	somatomotor-thalamic	_	
42-14	30808-30826	hyper-connectivity	_	
42-15	30827-30829	is	_	
42-16	30830-30837	present	_	
42-17	30838-30840	at	_	
42-18	30841-30845	both	_	
42-19	30846-30849	the	_	
42-20	30850-30857	chronic	_	
42-21	30858-30861	and	_	
42-22	30862-30867	early	_	
42-23	30868-30874	stages	_	
42-24	30875-30877	of	_	
42-25	30878-30887	psychotic	_	
42-26	30888-30897	disorders	_	
42-27	30897-30898	.	_	
42-28	30899-30904	These	_	
42-29	30905-30908	two	_	
42-30	30909-30917	features	_	
42-31	30918-30921	are	_	
42-32	30922-30929	related	_	
42-33	30929-30930	,	_	
42-34	30931-30936	lower	_	
42-35	30937-30949	PFC-thalamic	_	
42-36	30950-30962	connectivity	_	
42-37	30963-30973	correlates	_	
42-38	30974-30978	with	_	
42-39	30979-30993	motor-thalamic	_	
42-40	30994-31012	hyper-connectivity	_	
42-41	31012-31013	,	_	
42-42	31014-31024	suggesting	_	
42-43	31025-31029	they	_	
42-44	31030-31036	result	_	
42-45	31037-31041	from	_	
42-46	31042-31043	a	_	
42-47	31044-31050	common	_	
42-48	31051-31069	pathophysiological	_	
42-49	31070-31079	mechanism	_	
42-50	31079-31080	.	_	
42-51	31081-31089	Moreover	_	
42-52	31089-31090	,	_	
42-53	31091-31099	thalamic	_	
42-54	31100-31117	hypo-connectivity	_	
42-55	31118-31120	is	_	
42-56	31121-31134	characterized	_	
42-57	31135-31137	by	_	
42-58	31138-31145	reduced	_	
42-59	31146-31158	connectivity	_	
42-60	31159-31166	between	_	
42-61	31167-31170	the	_	
42-62	31171-31179	anterior	_	
42-63	31179-31180	/	_	
42-64	31180-31193	medial-dorsal	_	
42-65	31194-31202	thalamus	_	
42-66	31203-31206	and	_	
42-67	31207-31210	the	_	
42-68	31211-31212	‘	_	
42-69	31212-31221	executive	_	
42-70	31222-31229	control	_	
42-71	31229-31230	’	_	
42-72	31231-31238	network	_	
42-73	31239-31242	and	_	
42-74	31243-31253	correlated	_	
42-75	31254-31258	with	_	
42-76	31259-31268	cognitive	_	
42-77	31269-31280	functioning	_	
42-78	31280-31281	.	_	
42-79	31282-31288	Future	_	
42-80	31289-31296	studies	_	
42-81	31297-31300	are	_	
42-82	31301-31309	required	_	
42-83	31310-31312	to	_	
42-84	31312-31313	:	_	
42-85	31314-31315	1	_	
42-86	31315-31316	)	_	
42-87	31317-31324	clarify	_	
42-88	31325-31328	the	_	
42-89	31329-31341	relationship	_	
42-90	31342-31349	between	_	
42-91	31350-31365	thalamocortical	_	
42-92	31366-31376	functional	_	
42-93	31377-31392	dysconnectivity	_	
42-94	31393-31396	and	_	
42-95	31397-31407	anatomical	_	
42-96	31408-31420	connectivity	_	
42-97	31420-31421	;	_	
42-98	31422-31423	2	_	
42-99	31423-31424	)	_	
42-100	31425-31432	confirm	_	
42-101	31433-31437	that	_	
42-102	31438-31446	thalamic	_	
42-103	31447-31462	dysconnectivity	_	
42-104	31462-31463	,	_	
42-105	31464-31474	especially	_	
42-106	31475-31482	reduced	_	
42-107	31483-31495	connectivity	_	
42-108	31496-31500	with	_	
42-109	31501-31504	the	_	
42-110	31505-31508	PFC	_	
42-111	31509-31512	and	_	
42-112	31513-31522	executive	_	
42-113	31523-31530	control	_	
42-114	31531-31538	network	_	
42-115	31538-31539	,	_	
42-116	31540-31542	is	_	
42-117	31543-31547	more	_	
42-118	31548-31554	severe	_	
42-119	31555-31557	in	_	
42-120	31558-31571	non-affective	_	
42-121	31572-31581	psychosis	_	
42-122	31581-31582	;	_	
42-123	31583-31586	and	_	
42-124	31587-31588	3	_	
42-125	31588-31589	)	_	
42-126	31590-31599	determine	_	
42-127	31600-31602	if	_	
42-128	31603-31608	there	_	
42-129	31609-31611	is	_	
42-130	31612-31621	diagnosis	_	
42-131	31622-31624	by	_	
42-132	31625-31632	illness	_	
42-133	31633-31638	stage	_	
42-134	31639-31651	interactions	_	
42-135	31651-31652	.	_	

#Text=Supplementary Material
43-1	31653-31666	Supplementary	_	
43-2	31667-31675	Material	_	

#Text=Disclosures: No commercial support was received for the preparation of this manuscript. All authors report no biomedical financial interests or potential conflicts of interest.
44-1	31676-31687	Disclosures	_	
44-2	31687-31688	:	_	
44-3	31689-31691	No	_	
44-4	31692-31702	commercial	_	
44-5	31703-31710	support	_	
44-6	31711-31714	was	_	
44-7	31715-31723	received	_	
44-8	31724-31727	for	_	
44-9	31728-31731	the	_	
44-10	31732-31743	preparation	_	
44-11	31744-31746	of	_	
44-12	31747-31751	this	_	
44-13	31752-31762	manuscript	_	
44-14	31762-31763	.	_	
44-15	31764-31767	All	_	
44-16	31768-31775	authors	_	
44-17	31776-31782	report	_	
44-18	31783-31785	no	_	
44-19	31786-31796	biomedical	_	
44-20	31797-31806	financial	_	
44-21	31807-31816	interests	_	
44-22	31817-31819	or	_	
44-23	31820-31829	potential	_	
44-24	31830-31839	conflicts	_	
44-25	31840-31842	of	_	
44-26	31843-31851	interest	_	
44-27	31851-31852	.	_	

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
45-1	31853-31857	This	_	
45-2	31858-31860	is	_	
45-3	31861-31862	a	_	
45-4	31863-31866	PDF	_	
45-5	31867-31871	file	_	
45-6	31872-31874	of	_	
45-7	31875-31877	an	_	
45-8	31878-31886	unedited	_	
45-9	31887-31897	manuscript	_	
45-10	31898-31902	that	_	
45-11	31903-31906	has	_	
45-12	31907-31911	been	_	
45-13	31912-31920	accepted	_	
45-14	31921-31924	for	_	
45-15	31925-31936	publication	_	
45-16	31936-31937	.	_	
45-17	31938-31940	As	_	
45-18	31941-31942	a	_	
45-19	31943-31950	service	_	
45-20	31951-31953	to	_	
45-21	31954-31957	our	_	
45-22	31958-31967	customers	_	
45-23	31968-31970	we	_	
45-24	31971-31974	are	_	
45-25	31975-31984	providing	_	
45-26	31985-31989	this	_	
45-27	31990-31995	early	_	
45-28	31996-32003	version	_	
45-29	32004-32006	of	_	
45-30	32007-32010	the	_	
45-31	32011-32021	manuscript	_	
45-32	32021-32022	.	_	
45-33	32023-32026	The	_	
45-34	32027-32037	manuscript	_	
45-35	32038-32042	will	_	
45-36	32043-32050	undergo	_	
45-37	32051-32062	copyediting	_	
45-38	32062-32063	,	_	
45-39	32064-32075	typesetting	_	
45-40	32075-32076	,	_	
45-41	32077-32080	and	_	
45-42	32081-32087	review	_	
45-43	32088-32090	of	_	
45-44	32091-32094	the	_	
45-45	32095-32104	resulting	_	
45-46	32105-32110	proof	_	
45-47	32111-32117	before	_	
45-48	32118-32120	it	_	
45-49	32121-32123	is	_	
45-50	32124-32133	published	_	
45-51	32134-32136	in	_	
45-52	32137-32140	its	_	
45-53	32141-32146	final	_	
45-54	32147-32154	citable	_	
45-55	32155-32159	form	_	
45-56	32159-32160	.	_	
45-57	32161-32167	Please	_	
45-58	32168-32172	note	_	
45-59	32173-32177	that	_	
45-60	32178-32184	during	_	
45-61	32185-32188	the	_	
45-62	32189-32199	production	_	
45-63	32200-32207	process	_	
45-64	32208-32214	errors	_	
45-65	32215-32218	may	_	
45-66	32219-32221	be	_	
45-67	32222-32232	discovered	_	
45-68	32233-32238	which	_	
45-69	32239-32244	could	_	
45-70	32245-32251	affect	_	
45-71	32252-32255	the	_	
45-72	32256-32263	content	_	
45-73	32263-32264	,	_	
45-74	32265-32268	and	_	
45-75	32269-32272	all	_	
45-76	32273-32278	legal	_	
45-77	32279-32290	disclaimers	_	
45-78	32291-32295	that	_	
45-79	32296-32301	apply	_	
45-80	32302-32304	to	_	
45-81	32305-32308	the	_	
45-82	32309-32316	journal	_	
45-83	32317-32324	pertain	_	
45-84	32324-32325	.	_	

#Text=“Cognitive dysmetria” as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?
46-1	32326-32327	“	_	
46-2	32327-32336	Cognitive	_	
46-3	32337-32346	dysmetria	_	
46-4	32346-32347	”	_	
46-5	32348-32350	as	_	
46-6	32351-32353	an	_	
46-7	32354-32365	integrative	_	
46-8	32366-32372	theory	_	
46-9	32373-32375	of	_	
46-10	32376-32389	schizophrenia	_	
46-11	32389-32390	:	_	
46-12	32391-32392	a	_	
46-13	32393-32404	dysfunction	_	
46-14	32405-32407	in	_	
46-15	32408-32439	cortical-subcortical-cerebellar	_	
46-16	32440-32449	circuitry	_	
46-17	32449-32450	?	_	

#Text=Testing models of thalamic dysfunction in schizophrenia using neuroimaging
47-1	32451-32458	Testing	_	
47-2	32459-32465	models	_	
47-3	32466-32468	of	_	
47-4	32469-32477	thalamic	_	
47-5	32478-32489	dysfunction	_	
47-6	32490-32492	in	_	
47-7	32493-32506	schizophrenia	_	
47-8	32507-32512	using	_	
47-9	32513-32525	neuroimaging	_	

#Text=Thalamic pathology in schizophrenia
48-1	32526-32534	Thalamic	_	
48-2	32535-32544	pathology	_	
48-3	32545-32547	in	_	
48-4	32548-32561	schizophrenia	_	

#Text=The functional neuroanatomy of bipolar disorder
49-1	32562-32565	The	_	
49-2	32566-32576	functional	_	
49-3	32577-32589	neuroanatomy	_	
49-4	32590-32592	of	_	
49-5	32593-32600	bipolar	_	
49-6	32601-32609	disorder	_	

#Text=The thalamus and schizophrenia: current status of research
50-1	32611-32614	The	_	
50-2	32615-32623	thalamus	_	
50-3	32624-32627	and	_	
50-4	32628-32641	schizophrenia	_	
50-5	32641-32642	:	_	
50-6	32643-32650	current	_	
50-7	32651-32657	status	_	
50-8	32658-32660	of	_	
50-9	32661-32669	research	_	

#Text=Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis
51-1	32670-32682	Morphometric	_	
51-2	32683-32694	post-mortem	_	
51-3	32695-32702	studies	_	
51-4	32703-32705	in	_	
51-5	32706-32713	bipolar	_	
51-6	32714-32722	disorder	_	
51-7	32722-32723	:	_	
51-8	32724-32732	possible	_	
51-9	32733-32744	association	_	
51-10	32745-32749	with	_	
51-11	32750-32759	oxidative	_	
51-12	32760-32766	stress	_	
51-13	32767-32770	and	_	
51-14	32771-32780	apoptosis	_	

#Text=Resting-State Networks In Schizophrenia
52-1	32781-32794	Resting-State	_	
52-2	32795-32803	Networks	_	
52-3	32804-32806	In	_	
52-4	32807-32820	Schizophrenia	_	

#Text=Resting-state fMRI: a review of methods and clinical applications
53-1	32821-32834	Resting-state	_	
53-2	32835-32839	fMRI	_	
53-3	32839-32840	:	_	
53-4	32841-32842	a	_	
53-5	32843-32849	review	_	
53-6	32850-32852	of	_	
53-7	32853-32860	methods	_	
53-8	32861-32864	and	_	
53-9	32865-32873	clinical	_	
53-10	32874-32886	applications	_	

#Text=Thalamocortical dysconnectivity in schizophrenia
54-1	32887-32902	Thalamocortical	_	
54-2	32903-32918	dysconnectivity	_	
54-3	32919-32921	in	_	
54-4	32922-32935	schizophrenia	_	

#Text=Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in schizophrenia
55-1	32936-32949	Low-frequency	_	
55-2	32950-32954	BOLD	_	
55-3	32955-32967	fluctuations	_	
55-4	32968-32979	demonstrate	_	
55-5	32980-32987	altered	_	
55-6	32988-33003	thalamocortical	_	
55-7	33004-33016	connectivity	_	
55-8	33017-33019	in	_	
55-9	33020-33033	schizophrenia	_	

#Text=Characterizing Thalamo-Cortical Disturbances in Schizophrenia and Bipolar Illness
56-1	33034-33048	Characterizing	_	
56-2	33049-33065	Thalamo-Cortical	_	
56-3	33066-33078	Disturbances	_	
56-4	33079-33081	in	_	
56-5	33082-33095	Schizophrenia	_	
56-6	33096-33099	and	_	
56-7	33100-33107	Bipolar	_	
56-8	33108-33115	Illness	_	

#Text=Mapping small-world properties through development in the human brain: disruption in schizophrenia
57-1	33116-33123	Mapping	_	
57-2	33124-33135	small-world	_	
57-3	33136-33146	properties	_	
57-4	33147-33154	through	_	
57-5	33155-33166	development	_	
57-6	33167-33169	in	_	
57-7	33170-33173	the	_	
57-8	33174-33179	human	_	
57-9	33180-33185	brain	_	
57-10	33185-33186	:	_	
57-11	33187-33197	disruption	_	
57-12	33198-33200	in	_	
57-13	33201-33214	schizophrenia	_	

#Text=Thalamocortical connectivity during resting state in schizophrenia
58-1	33215-33230	Thalamocortical	_	
58-2	33231-33243	connectivity	_	
58-3	33244-33250	during	_	
58-4	33251-33258	resting	_	
58-5	33259-33264	state	_	
58-6	33265-33267	in	_	
58-7	33268-33281	schizophrenia	_	

#Text=Maturing thalamocortical functional connectivity across development
59-1	33282-33290	Maturing	_	
59-2	33291-33306	thalamocortical	_	
59-3	33307-33317	functional	_	
59-4	33318-33330	connectivity	_	
59-5	33331-33337	across	_	
59-6	33338-33349	development	_	

#Text=Intrinsic functional relations between human cerebral cortex and thalamus
60-1	33350-33359	Intrinsic	_	
60-2	33360-33370	functional	_	
60-3	33371-33380	relations	_	
60-4	33381-33388	between	_	
60-5	33389-33394	human	_	
60-6	33395-33403	cerebral	_	
60-7	33404-33410	cortex	_	
60-8	33411-33414	and	_	
60-9	33415-33423	thalamus	_	

#Text=Noninvasive functional and structural connectivity mapping of the human thalamocortical system
61-1	33424-33435	Noninvasive	_	
61-2	33436-33446	functional	_	
61-3	33447-33450	and	_	
61-4	33451-33461	structural	_	
61-5	33462-33474	connectivity	_	
61-6	33475-33482	mapping	_	
61-7	33483-33485	of	_	
61-8	33486-33489	the	_	
61-9	33490-33495	human	_	
61-10	33496-33511	thalamocortical	_	
61-11	33512-33518	system	_	

#Text=Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging
62-1	33519-33531	Non-invasive	_	
62-2	33532-33539	mapping	_	
62-3	33540-33542	of	_	
62-4	33543-33554	connections	_	
62-5	33555-33562	between	_	
62-6	33563-33568	human	_	
62-7	33569-33577	thalamus	_	
62-8	33578-33581	and	_	
62-9	33582-33588	cortex	_	
62-10	33589-33594	using	_	
62-11	33595-33604	diffusion	_	
62-12	33605-33612	imaging	_	

#Text=Intact relational memory and normal hippocampal structure in the early stage of psychosis
63-1	33613-33619	Intact	_	
63-2	33620-33630	relational	_	
63-3	33631-33637	memory	_	
63-4	33638-33641	and	_	
63-5	33642-33648	normal	_	
63-6	33649-33660	hippocampal	_	
63-7	33661-33670	structure	_	
63-8	33671-33673	in	_	
63-9	33674-33677	the	_	
63-10	33678-33683	early	_	
63-11	33684-33689	stage	_	
63-12	33690-33692	of	_	
63-13	33693-33702	psychosis	_	

#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
64-1	33705-33708	The	_	
64-2	33709-33717	positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[22]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[23]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
64-3	33718-33721	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[22]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[23]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
64-4	33722-33730	negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[22]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[23]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
64-5	33731-33739	syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[22]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[23]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
64-6	33740-33745	scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[22]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[23]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
64-7	33746-33747	(	_	
64-8	33747-33752	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
64-9	33752-33753	)	_	
64-10	33754-33757	for	_	
64-11	33758-33771	schizophrenia	_	

#Text=Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks
65-1	33773-33777	Conn	_	
65-2	33777-33778	:	_	
65-3	33779-33780	a	_	
65-4	33781-33791	functional	_	
65-5	33792-33804	connectivity	_	
65-6	33805-33812	toolbox	_	
65-7	33813-33816	for	_	
65-8	33817-33827	correlated	_	
65-9	33828-33831	and	_	
65-10	33832-33846	anticorrelated	_	
65-11	33847-33852	brain	_	
65-12	33853-33861	networks	_	

#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
66-1	33862-33870	Spurious	_	
66-2	33871-33874	but	_	
66-3	33875-33885	systematic	_	
66-4	33886-33898	correlations	_	
66-5	33899-33901	in	_	
66-6	33902-33912	functional	_	
66-7	33913-33925	connectivity	_	
66-8	33926-33929	MRI	_	
66-9	33930-33938	networks	_	
66-10	33939-33944	arise	_	
66-11	33945-33949	from	_	
66-12	33950-33957	subject	_	
66-13	33958-33964	motion	_	

#Text=Reduction of motion-related artifacts in resting state fMRI using aCompCor
67-1	33965-33974	Reduction	_	
67-2	33975-33977	of	_	
67-3	33978-33992	motion-related	_	
67-4	33993-34002	artifacts	_	
67-5	34003-34005	in	_	
67-6	34006-34013	resting	_	
67-7	34014-34019	state	_	
67-8	34020-34024	fMRI	_	
67-9	34025-34030	using	_	
67-10	34031-34039	aCompCor	_	

#Text=The nuisance of nuisance regression: spectral misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise and obscures functional connectivity
68-1	34040-34043	The	_	
68-2	34044-34052	nuisance	_	
68-3	34053-34055	of	_	
68-4	34056-34064	nuisance	_	
68-5	34065-34075	regression	_	
68-6	34075-34076	:	_	
68-7	34077-34085	spectral	_	
68-8	34086-34102	misspecification	_	
68-9	34103-34105	in	_	
68-10	34106-34107	a	_	
68-11	34108-34114	common	_	
68-12	34115-34123	approach	_	
68-13	34124-34126	to	_	
68-14	34127-34140	resting-state	_	
68-15	34141-34145	fMRI	_	
68-16	34146-34159	preprocessing	_	
68-17	34160-34172	reintroduces	_	
68-18	34173-34178	noise	_	
68-19	34179-34182	and	_	
68-20	34183-34191	obscures	_	
68-21	34192-34202	functional	_	
68-22	34203-34215	connectivity	_	

#Text=International consensus study of antipsychotic dosing
69-1	34216-34229	International	_	
69-2	34230-34239	consensus	_	
69-3	34240-34245	study	_	
69-4	34246-34248	of	_	
69-5	34249-34262	antipsychotic	_	
69-6	34263-34269	dosing	_	

#Text=Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions
70-1	34270-34283	Meta-analytic	_	
70-2	34284-34292	evidence	_	
70-3	34293-34296	for	_	
70-4	34297-34298	a	_	
70-5	34299-34312	superordinate	_	
70-6	34313-34322	cognitive	_	
70-7	34323-34330	control	_	
70-8	34331-34338	network	_	
70-9	34339-34349	subserving	_	
70-10	34350-34357	diverse	_	
70-11	34358-34367	executive	_	
70-12	34368-34377	functions	_	

#Text=Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?
71-1	34378-34391	Neurotoxicity	_	
71-2	34391-34392	,	_	
71-3	34393-34408	neuroplasticity	_	
71-4	34408-34409	,	_	
71-5	34410-34413	and	_	
71-6	34414-34422	magnetic	_	
71-7	34423-34432	resonance	_	
71-8	34433-34440	imaging	_	
71-9	34441-34452	morphometry	_	
71-10	34452-34453	:	_	
71-11	34454-34458	what	_	
71-12	34459-34461	is	_	
71-13	34462-34471	happening	_	
71-14	34472-34474	in	_	
71-15	34475-34478	the	_	
71-16	34479-34492	schizophrenic	_	
71-17	34493-34498	brain	_	
71-18	34498-34499	?	_	

#Text=The course of neuropsychological impairment and brain structure abnormalities in psychotic disorders
72-1	34500-34503	The	_	
72-2	34504-34510	course	_	
72-3	34511-34513	of	_	
72-4	34514-34532	neuropsychological	_	
72-5	34533-34543	impairment	_	
72-6	34544-34547	and	_	
72-7	34548-34553	brain	_	
72-8	34554-34563	structure	_	
72-9	34564-34577	abnormalities	_	
72-10	34578-34580	in	_	
72-11	34581-34590	psychotic	_	
72-12	34591-34600	disorders	_	

#Text=Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder
73-1	34601-34610	Evolution	_	
73-2	34611-34613	of	_	
73-3	34614-34632	neuropsychological	_	
73-4	34633-34644	dysfunction	_	
73-5	34645-34651	during	_	
73-6	34652-34655	the	_	
73-7	34656-34662	course	_	
73-8	34663-34665	of	_	
73-9	34666-34679	schizophrenia	_	
73-10	34680-34683	and	_	
73-11	34684-34691	bipolar	_	
73-12	34692-34700	disorder	_	

#Text=Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis
74-1	34701-34708	Altered	_	
74-2	34709-34717	striatal	_	
74-3	34718-34728	functional	_	
74-4	34729-34741	connectivity	_	
74-5	34742-34744	in	_	
74-6	34745-34753	subjects	_	
74-7	34754-34758	with	_	
74-8	34759-34761	an	_	
74-9	34762-34769	at-risk	_	
74-10	34770-34776	mental	_	
74-11	34777-34782	state	_	
74-12	34783-34786	for	_	
74-13	34787-34796	psychosis	_	

#Text=Decreasing activity of the medio-dorsal thalamus in vivo impairs prefrontal-dependent cognitive behaviors
75-1	34797-34807	Decreasing	_	
75-2	34808-34816	activity	_	
75-3	34817-34819	of	_	
75-4	34820-34823	the	_	
75-5	34824-34836	medio-dorsal	_	
75-6	34837-34845	thalamus	_	
75-7	34846-34848	in	_	
75-8	34849-34853	vivo	_	
75-9	34854-34861	impairs	_	
75-10	34862-34882	prefrontal-dependent	_	
75-11	34883-34892	cognitive	_	
75-12	34893-34902	behaviors	_	

#Text=Cognitive, affective and behavioural disturbances following vascular thalamic lesions: a review
76-1	34903-34912	Cognitive	_	
76-2	34912-34913	,	_	
76-3	34914-34923	affective	_	
76-4	34924-34927	and	_	
76-5	34928-34939	behavioural	_	
76-6	34940-34952	disturbances	_	
76-7	34953-34962	following	_	
76-8	34963-34971	vascular	_	
76-9	34972-34980	thalamic	_	
76-10	34981-34988	lesions	_	
76-11	34988-34989	:	_	
76-12	34990-34991	a	_	
76-13	34992-34998	review	_	

#Text=Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions
77-1	34999-35007	Deficits	_	
77-2	35008-35010	of	_	
77-3	35011-35017	memory	_	
77-4	35017-35018	,	_	
77-5	35019-35028	executive	_	
77-6	35029-35040	functioning	_	
77-7	35041-35044	and	_	
77-8	35045-35054	attention	_	
77-9	35055-35064	following	_	
77-10	35065-35075	infarction	_	
77-11	35076-35078	in	_	
77-12	35079-35082	the	_	
77-13	35083-35091	thalamus	_	
77-14	35091-35092	;	_	
77-15	35093-35094	a	_	
77-16	35095-35100	study	_	
77-17	35101-35103	of	_	
77-18	35104-35106	22	_	
77-19	35107-35112	cases	_	
77-20	35113-35117	with	_	
77-21	35118-35127	localised	_	
77-22	35128-35135	lesions	_	

#Text=Delayed-alternation performance after kainic acid lesions of the thalamic mediodorsal nucleus and the ventral tegmental area in the rat
78-1	35136-35155	Delayed-alternation	_	
78-2	35156-35167	performance	_	
78-3	35168-35173	after	_	
78-4	35174-35180	kainic	_	
78-5	35181-35185	acid	_	
78-6	35186-35193	lesions	_	
78-7	35194-35196	of	_	
78-8	35197-35200	the	_	
78-9	35201-35209	thalamic	_	
78-10	35210-35221	mediodorsal	_	
78-11	35222-35229	nucleus	_	
78-12	35230-35233	and	_	
78-13	35234-35237	the	_	
78-14	35238-35245	ventral	_	
78-15	35246-35255	tegmental	_	
78-16	35256-35260	area	_	
78-17	35261-35263	in	_	
78-18	35264-35267	the	_	
78-19	35268-35271	rat	_	

#Text=Neurotoxic lesions of the dorsomedial thalamus impair the acquisition but not the performance of delayed matching to place by rats: a deficit in shifting response rules
79-1	35272-35282	Neurotoxic	_	
79-2	35283-35290	lesions	_	
79-3	35291-35293	of	_	
79-4	35294-35297	the	_	
79-5	35298-35309	dorsomedial	_	
79-6	35310-35318	thalamus	_	
79-7	35319-35325	impair	_	
79-8	35326-35329	the	_	
79-9	35330-35341	acquisition	_	
79-10	35342-35345	but	_	
79-11	35346-35349	not	_	
79-12	35350-35353	the	_	
79-13	35354-35365	performance	_	
79-14	35366-35368	of	_	
79-15	35369-35376	delayed	_	
79-16	35377-35385	matching	_	
79-17	35386-35388	to	_	
79-18	35389-35394	place	_	
79-19	35395-35397	by	_	
79-20	35398-35402	rats	_	
79-21	35402-35403	:	_	
79-22	35404-35405	a	_	
79-23	35406-35413	deficit	_	
79-24	35414-35416	in	_	
79-25	35417-35425	shifting	_	
79-26	35426-35434	response	_	
79-27	35435-35440	rules	_	

#Text=Patterns of impaired verbal, spatial, and object working memory after thalamic lesions
80-1	35441-35449	Patterns	_	
80-2	35450-35452	of	_	
80-3	35453-35461	impaired	_	
80-4	35462-35468	verbal	_	
80-5	35468-35469	,	_	
80-6	35470-35477	spatial	_	
80-7	35477-35478	,	_	
80-8	35479-35482	and	_	
80-9	35483-35489	object	_	
80-10	35490-35497	working	_	
80-11	35498-35504	memory	_	
80-12	35505-35510	after	_	
80-13	35511-35519	thalamic	_	
80-14	35520-35527	lesions	_	

#Text=Functional resting-state networks are differentially affected in schizophrenia
81-1	35528-35538	Functional	_	
81-2	35539-35552	resting-state	_	
81-3	35553-35561	networks	_	
81-4	35562-35565	are	_	
81-5	35566-35580	differentially	_	
81-6	35581-35589	affected	_	
81-7	35590-35592	in	_	
81-8	35593-35606	schizophrenia	_	

#Text=Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder
82-1	35607-35617	Disruption	_	
82-2	35618-35620	of	_	
82-3	35621-35629	cortical	_	
82-4	35630-35641	association	_	
82-5	35642-35650	networks	_	
82-6	35651-35653	in	_	
82-7	35654-35667	schizophrenia	_	
82-8	35668-35671	and	_	
82-9	35672-35681	psychotic	_	
82-10	35682-35689	bipolar	_	
82-11	35690-35698	disorder	_	

#Text=Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia
83-1	35699-35712	Meta-analysis	_	
83-2	35713-35715	of	_	
83-3	35716-35718	41	_	
83-4	35719-35729	functional	_	
83-5	35730-35742	neuroimaging	_	
83-6	35743-35750	studies	_	
83-7	35751-35753	of	_	
83-8	35754-35763	executive	_	
83-9	35764-35772	function	_	
83-10	35773-35775	in	_	
83-11	35776-35789	schizophrenia	_	

#Text=Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis
84-1	35790-35800	Functional	_	
84-2	35801-35816	dysconnectivity	_	
84-3	35817-35819	of	_	
84-4	35820-35835	corticostriatal	_	
84-5	35836-35845	circuitry	_	
84-6	35846-35848	as	_	
84-7	35849-35850	a	_	
84-8	35851-35855	risk	_	
84-9	35856-35865	phenotype	_	
84-10	35866-35869	for	_	
84-11	35870-35879	psychosis	_	

#Text=The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging
85-1	35880-35883	The	_	
85-2	35884-35894	cerebellum	_	
85-3	35895-35898	and	_	
85-4	35899-35908	cognitive	_	
85-5	35909-35917	function	_	
85-6	35917-35918	:	_	
85-7	35919-35921	25	_	
85-8	35922-35927	years	_	
85-9	35928-35930	of	_	
85-10	35931-35938	insight	_	
85-11	35939-35943	from	_	
85-12	35944-35951	anatomy	_	
85-13	35952-35955	and	_	
85-14	35956-35968	neuroimaging	_	

#Text=Mediodorsal nucleus: areal, laminar, and tangential distribution of afferents and efferents in the frontal lobe of rhesus monkeys
86-1	35969-35980	Mediodorsal	_	
86-2	35981-35988	nucleus	_	
86-3	35988-35989	:	_	
86-4	35990-35995	areal	_	
86-5	35995-35996	,	_	
86-6	35997-36004	laminar	_	
86-7	36004-36005	,	_	
86-8	36006-36009	and	_	
86-9	36010-36020	tangential	_	
86-10	36021-36033	distribution	_	
86-11	36034-36036	of	_	
86-12	36037-36046	afferents	_	
86-13	36047-36050	and	_	
86-14	36051-36060	efferents	_	
86-15	36061-36063	in	_	
86-16	36064-36067	the	_	
86-17	36068-36075	frontal	_	
86-18	36076-36080	lobe	_	
86-19	36081-36083	of	_	
86-20	36084-36090	rhesus	_	
86-21	36091-36098	monkeys	_	

#Text=Reevaluation of the primary motor cortex connections with the thalamus in primates
87-1	36099-36111	Reevaluation	_	
87-2	36112-36114	of	_	
87-3	36115-36118	the	_	
87-4	36119-36126	primary	_	
87-5	36127-36132	motor	_	
87-6	36133-36139	cortex	_	
87-7	36140-36151	connections	_	
87-8	36152-36156	with	_	
87-9	36157-36160	the	_	
87-10	36161-36169	thalamus	_	
87-11	36170-36172	in	_	
87-12	36173-36181	primates	_	

#Text=Origin of thalamic inputs to the primary, premotor, and supplementary motor cortical areas and to area 46 in macaque monkeys: a multiple retrograde tracing study
88-1	36182-36188	Origin	_	
88-2	36189-36191	of	_	
88-3	36192-36200	thalamic	_	
88-4	36201-36207	inputs	_	
88-5	36208-36210	to	_	
88-6	36211-36214	the	_	
88-7	36215-36222	primary	_	
88-8	36222-36223	,	_	
88-9	36224-36232	premotor	_	
88-10	36232-36233	,	_	
88-11	36234-36237	and	_	
88-12	36238-36251	supplementary	_	
88-13	36252-36257	motor	_	
88-14	36258-36266	cortical	_	
88-15	36267-36272	areas	_	
88-16	36273-36276	and	_	
88-17	36277-36279	to	_	
88-18	36280-36284	area	_	
88-19	36285-36287	46	_	
88-20	36288-36290	in	_	
88-21	36291-36298	macaque	_	
88-22	36299-36306	monkeys	_	
88-23	36306-36307	:	_	
88-24	36308-36309	a	_	
88-25	36310-36318	multiple	_	
88-26	36319-36329	retrograde	_	
88-27	36330-36337	tracing	_	
88-28	36338-36343	study	_	

#Text=The mediodorsal nucleus of the thalamus in rats--II. Behavioral and neurochemical effects of GABA agonists
89-1	36344-36347	The	_	
89-2	36348-36359	mediodorsal	_	
89-3	36360-36367	nucleus	_	
89-4	36368-36370	of	_	
89-5	36371-36374	the	_	
89-6	36375-36383	thalamus	_	
89-7	36384-36386	in	_	
89-8	36387-36391	rats	_	
89-9	36391-36392	-	_	
89-10	36392-36393	-	_	
89-11	36393-36395	II	_	
89-12	36395-36396	.	_	
89-13	36397-36407	Behavioral	_	
89-14	36408-36411	and	_	
89-15	36412-36425	neurochemical	_	
89-16	36426-36433	effects	_	
89-17	36434-36436	of	_	
89-18	36437-36441	GABA	_	
89-19	36442-36450	agonists	_	

#Text=Investigation of anatomical thalamo-cortical connectivity and FMRI activation in schizophrenia
90-1	36451-36464	Investigation	_	
90-2	36465-36467	of	_	
90-3	36468-36478	anatomical	_	
90-4	36479-36495	thalamo-cortical	_	
90-5	36496-36508	connectivity	_	
90-6	36509-36512	and	_	
90-7	36513-36517	FMRI	_	
90-8	36518-36528	activation	_	
90-9	36529-36531	in	_	
90-10	36532-36545	schizophrenia	_	

#Text=Predicting human resting-state functional connectivity from structural connectivity
91-1	36546-36556	Predicting	_	
91-2	36557-36562	human	_	
91-3	36563-36576	resting-state	_	
91-4	36577-36587	functional	_	
91-5	36588-36600	connectivity	_	
91-6	36601-36605	from	_	
91-7	36606-36616	structural	_	
91-8	36617-36629	connectivity	_	

#Text=Characterization and propagation of uncertainty in diffusion-weighted MR imaging
92-1	36630-36646	Characterization	_	
92-2	36647-36650	and	_	
92-3	36651-36662	propagation	_	
92-4	36663-36665	of	_	
92-5	36666-36677	uncertainty	_	
92-6	36678-36680	in	_	
92-7	36681-36699	diffusion-weighted	_	
92-8	36700-36702	MR	_	
92-9	36703-36710	imaging	_	

#Text=Ventral anterior cingulate connectivity distinguished nonpsychotic bipolar illness from psychotic bipolar disorder and schizophrenia
93-1	36711-36718	Ventral	_	
93-2	36719-36727	anterior	_	
93-3	36728-36737	cingulate	_	
93-4	36738-36750	connectivity	_	
93-5	36751-36764	distinguished	_	
93-6	36765-36777	nonpsychotic	_	
93-7	36778-36785	bipolar	_	
93-8	36786-36793	illness	_	
93-9	36794-36798	from	_	
93-10	36799-36808	psychotic	_	
93-11	36809-36816	bipolar	_	
93-12	36817-36825	disorder	_	
93-13	36826-36829	and	_	
93-14	36830-36843	schizophrenia	_	

#Text=Thalamocortical functional connectivity in chronic and early stage psychosis. Panel A: Within the entire sample of 253 subjects, connectivity of 6 a-priori defined cortical areas (left) correlated with distinct, largely non-overlapping regions of the thalamus (middle). The thalamus was parceled into functional ROIs using the ‘winner-take-all’ approach in which each voxel in the thalamus is classified according to which cortical ROI it is most strongly connected to (right). Connectivity between each cortical ROI and its corresponding thalamic functional ROI was then calculated for each subject. Panel B: Thalamic-cortical network functional connectivity varied between groups (repeated measures ANOVA network × group interaction: F(10,490)=3.20, p=.001). Follow-up univariate ANOVAs indicated that, compared to healthy subjects, PFC-thalamic network connectivity was reduced in both chronic (p=.002) and early stage (p=.020) psychosis, whereas connectivity in the motor-thalamic and somatosensory-thalamic networks was increased in chronic (p=.00006 and p=.006, respectively) and early stage psychosis (p=.027 and p=.014, respectively). Panel C: PFC-thalamic network connectivity inversely correlated with motor-thalamic network connectivity in patients with psychosis (r=-.40, p=.0000006), but not healthy subjects (r=-.11, p=.264). Direct comparison between groups indicated that the correlation was significantly greater in the psychosis group compared to healthy subjects (Fischer Z=2.42, p=.016).
94-1	36844-36859	Thalamocortical	_	
94-2	36860-36870	functional	_	
94-3	36871-36883	connectivity	_	
94-4	36884-36886	in	_	
94-5	36887-36894	chronic	_	
94-6	36895-36898	and	_	
94-7	36899-36904	early	_	
94-8	36905-36910	stage	_	
94-9	36911-36920	psychosis	_	
94-10	36920-36921	.	_	
94-11	36922-36927	Panel	_	
94-12	36928-36929	A	_	
94-13	36929-36930	:	_	
94-14	36931-36937	Within	_	
94-15	36938-36941	the	_	
94-16	36942-36948	entire	_	
94-17	36949-36955	sample	_	
94-18	36956-36958	of	_	
94-19	36959-36962	253	_	
94-20	36963-36971	subjects	_	
94-21	36971-36972	,	_	
94-22	36973-36985	connectivity	_	
94-23	36986-36988	of	_	
94-24	36989-36990	6	_	
94-25	36991-36999	a-priori	_	
94-26	37000-37007	defined	_	
94-27	37008-37016	cortical	_	
94-28	37017-37022	areas	_	
94-29	37023-37024	(	_	
94-30	37024-37028	left	_	
94-31	37028-37029	)	_	
94-32	37030-37040	correlated	_	
94-33	37041-37045	with	_	
94-34	37046-37054	distinct	_	
94-35	37054-37055	,	_	
94-36	37056-37063	largely	_	
94-37	37064-37079	non-overlapping	_	
94-38	37080-37087	regions	_	
94-39	37088-37090	of	_	
94-40	37091-37094	the	_	
94-41	37095-37103	thalamus	_	
94-42	37104-37105	(	_	
94-43	37105-37111	middle	_	
94-44	37111-37112	)	_	
94-45	37112-37113	.	_	
94-46	37114-37117	The	_	
94-47	37118-37126	thalamus	_	
94-48	37127-37130	was	_	
94-49	37131-37139	parceled	_	
94-50	37140-37144	into	_	
94-51	37145-37155	functional	_	
94-52	37156-37160	ROIs	_	
94-53	37161-37166	using	_	
94-54	37167-37170	the	_	
94-55	37171-37172	‘	_	
94-56	37172-37187	winner-take-all	_	
94-57	37187-37188	’	_	
94-58	37189-37197	approach	_	
94-59	37198-37200	in	_	
94-60	37201-37206	which	_	
94-61	37207-37211	each	_	
94-62	37212-37217	voxel	_	
94-63	37218-37220	in	_	
94-64	37221-37224	the	_	
94-65	37225-37233	thalamus	_	
94-66	37234-37236	is	_	
94-67	37237-37247	classified	_	
94-68	37248-37257	according	_	
94-69	37258-37260	to	_	
94-70	37261-37266	which	_	
94-71	37267-37275	cortical	_	
94-72	37276-37279	ROI	_	
94-73	37280-37282	it	_	
94-74	37283-37285	is	_	
94-75	37286-37290	most	_	
94-76	37291-37299	strongly	_	
94-77	37300-37309	connected	_	
94-78	37310-37312	to	_	
94-79	37313-37314	(	_	
94-80	37314-37319	right	_	
94-81	37319-37320	)	_	
94-82	37320-37321	.	_	
94-83	37322-37334	Connectivity	_	
94-84	37335-37342	between	_	
94-85	37343-37347	each	_	
94-86	37348-37356	cortical	_	
94-87	37357-37360	ROI	_	
94-88	37361-37364	and	_	
94-89	37365-37368	its	_	
94-90	37369-37382	corresponding	_	
94-91	37383-37391	thalamic	_	
94-92	37392-37402	functional	_	
94-93	37403-37406	ROI	_	
94-94	37407-37410	was	_	
94-95	37411-37415	then	_	
94-96	37416-37426	calculated	_	
94-97	37427-37430	for	_	
94-98	37431-37435	each	_	
94-99	37436-37443	subject	_	
94-100	37443-37444	.	_	
94-101	37445-37450	Panel	_	
94-102	37451-37452	B	_	
94-103	37452-37453	:	_	
94-104	37454-37471	Thalamic-cortical	_	
94-105	37472-37479	network	_	
94-106	37480-37490	functional	_	
94-107	37491-37503	connectivity	_	
94-108	37504-37510	varied	_	
94-109	37511-37518	between	_	
94-110	37519-37525	groups	_	
94-111	37526-37527	(	_	
94-112	37527-37535	repeated	_	
94-113	37536-37544	measures	_	
94-114	37545-37550	ANOVA	_	
94-115	37551-37558	network	_	
94-116	37559-37560	×	_	
94-117	37561-37566	group	_	
94-118	37567-37578	interaction	_	
94-119	37578-37579	:	_	
94-120	37580-37581	F	_	
94-121	37581-37582	(	_	
94-122	37582-37588	10,490	_	
94-123	37588-37589	)	_	
94-124	37589-37590	=	_	
94-125	37590-37594	3.20	_	
94-126	37594-37595	,	_	
94-127	37596-37597	p	_	
94-128	37597-37598	=	_	
94-129	37598-37602	.001	_	
94-130	37602-37603	)	_	
94-131	37603-37604	.	_	
94-132	37605-37614	Follow-up	_	
94-133	37615-37625	univariate	_	
94-134	37626-37632	ANOVAs	_	
94-135	37633-37642	indicated	_	
94-136	37643-37647	that	_	
94-137	37647-37648	,	_	
94-138	37649-37657	compared	_	
94-139	37658-37660	to	_	
94-140	37661-37668	healthy	_	
94-141	37669-37677	subjects	_	
94-142	37677-37678	,	_	
94-143	37679-37691	PFC-thalamic	_	
94-144	37692-37699	network	_	
94-145	37700-37712	connectivity	_	
94-146	37713-37716	was	_	
94-147	37717-37724	reduced	_	
94-148	37725-37727	in	_	
94-149	37728-37732	both	_	
94-150	37733-37740	chronic	_	
94-151	37741-37742	(	_	
94-152	37742-37743	p	_	
94-153	37743-37744	=	_	
94-154	37744-37748	.002	_	
94-155	37748-37749	)	_	
94-156	37750-37753	and	_	
94-157	37754-37759	early	_	
94-158	37760-37765	stage	_	
94-159	37766-37767	(	_	
94-160	37767-37768	p	_	
94-161	37768-37769	=	_	
94-162	37769-37773	.020	_	
94-163	37773-37774	)	_	
94-164	37775-37784	psychosis	_	
94-165	37784-37785	,	_	
94-166	37786-37793	whereas	_	
94-167	37794-37806	connectivity	_	
94-168	37807-37809	in	_	
94-169	37810-37813	the	_	
94-170	37814-37828	motor-thalamic	_	
94-171	37829-37832	and	_	
94-172	37833-37855	somatosensory-thalamic	_	
94-173	37856-37864	networks	_	
94-174	37865-37868	was	_	
94-175	37869-37878	increased	_	
94-176	37879-37881	in	_	
94-177	37882-37889	chronic	_	
94-178	37890-37891	(	_	
94-179	37891-37892	p	_	
94-180	37892-37893	=	_	
94-181	37893-37899	.00006	_	
94-182	37900-37903	and	_	
94-183	37904-37905	p	_	
94-184	37905-37906	=	_	
94-185	37906-37910	.006	_	
94-186	37910-37911	,	_	
94-187	37912-37924	respectively	_	
94-188	37924-37925	)	_	
94-189	37926-37929	and	_	
94-190	37930-37935	early	_	
94-191	37936-37941	stage	_	
94-192	37942-37951	psychosis	_	
94-193	37952-37953	(	_	
94-194	37953-37954	p	_	
94-195	37954-37955	=	_	
94-196	37955-37959	.027	_	
94-197	37960-37963	and	_	
94-198	37964-37965	p	_	
94-199	37965-37966	=	_	
94-200	37966-37970	.014	_	
94-201	37970-37971	,	_	
94-202	37972-37984	respectively	_	
94-203	37984-37985	)	_	
94-204	37985-37986	.	_	
94-205	37987-37992	Panel	_	
94-206	37993-37994	C	_	
94-207	37994-37995	:	_	
94-208	37996-38008	PFC-thalamic	_	
94-209	38009-38016	network	_	
94-210	38017-38029	connectivity	_	
94-211	38030-38039	inversely	_	
94-212	38040-38050	correlated	_	
94-213	38051-38055	with	_	
94-214	38056-38070	motor-thalamic	_	
94-215	38071-38078	network	_	
94-216	38079-38091	connectivity	_	
94-217	38092-38094	in	_	
94-218	38095-38103	patients	_	
94-219	38104-38108	with	_	
94-220	38109-38118	psychosis	_	
94-221	38119-38120	(	_	
94-222	38120-38121	r	_	
94-223	38121-38122	=	_	
94-224	38122-38123	-	_	
94-225	38123-38126	.40	_	
94-226	38126-38127	,	_	
94-227	38128-38129	p	_	
94-228	38129-38130	=	_	
94-229	38130-38138	.0000006	_	
94-230	38138-38139	)	_	
94-231	38139-38140	,	_	
94-232	38141-38144	but	_	
94-233	38145-38148	not	_	
94-234	38149-38156	healthy	_	
94-235	38157-38165	subjects	_	
94-236	38166-38167	(	_	
94-237	38167-38168	r	_	
94-238	38168-38169	=	_	
94-239	38169-38170	-	_	
94-240	38170-38173	.11	_	
94-241	38173-38174	,	_	
94-242	38175-38176	p	_	
94-243	38176-38177	=	_	
94-244	38177-38181	.264	_	
94-245	38181-38182	)	_	
94-246	38182-38183	.	_	
94-247	38184-38190	Direct	_	
94-248	38191-38201	comparison	_	
94-249	38202-38209	between	_	
94-250	38210-38216	groups	_	
94-251	38217-38226	indicated	_	
94-252	38227-38231	that	_	
94-253	38232-38235	the	_	
94-254	38236-38247	correlation	_	
94-255	38248-38251	was	_	
94-256	38252-38265	significantly	_	
94-257	38266-38273	greater	_	
94-258	38274-38276	in	_	
94-259	38277-38280	the	_	
94-260	38281-38290	psychosis	_	
94-261	38291-38296	group	_	
94-262	38297-38305	compared	_	
94-263	38306-38308	to	_	
94-264	38309-38316	healthy	_	
94-265	38317-38325	subjects	_	
94-266	38326-38327	(	_	
94-267	38327-38334	Fischer	_	
94-268	38335-38336	Z	_	
94-269	38336-38337	=	_	
94-270	38337-38341	2.42	_	
94-271	38341-38342	,	_	
94-272	38343-38344	p	_	
94-273	38344-38345	=	_	
94-274	38345-38349	.016	_	
94-275	38349-38350	)	_	
94-276	38350-38351	.	_	

#Text=Functional connectivity of PFC, motor, and somatosensory thalamus seeds in psychosis. Panel A: Functional connectivity of the ‘PFC’ thalamus seed in healthy subjects resembled the well-described “executive control” network (i.e. Niendam et al., 2012) and included the dorsolateral PFC, medial PFC/anterior cingulate, mid-cingulate, inferior parietal lobule, and cerebellum. This pattern was markedly attenuated in psychosis, including both chronic and early stage patients. Panel B: Functional connectivity of the thalamus ‘motor’ seed (warm colors) and ‘somatosensory’ seed (cool colors) included mainly motor and somatosensory areas and cerebellum. Qualitatively, functional connectivity of the thalamus motor and somatosensory seeds appeared more widespread and less segregated in psychosis patients (overlap in motor and somatosensory thalamus seed connectivity is shown in green).
95-1	38352-38362	Functional	_	
95-2	38363-38375	connectivity	_	
95-3	38376-38378	of	_	
95-4	38379-38382	PFC	_	
95-5	38382-38383	,	_	
95-6	38384-38389	motor	_	
95-7	38389-38390	,	_	
95-8	38391-38394	and	_	
95-9	38395-38408	somatosensory	_	
95-10	38409-38417	thalamus	_	
95-11	38418-38423	seeds	_	
95-12	38424-38426	in	_	
95-13	38427-38436	psychosis	_	
95-14	38436-38437	.	_	
95-15	38438-38443	Panel	_	
95-16	38444-38445	A	_	
95-17	38445-38446	:	_	
95-18	38447-38457	Functional	_	
95-19	38458-38470	connectivity	_	
95-20	38471-38473	of	_	
95-21	38474-38477	the	_	
95-22	38478-38479	‘	_	
95-23	38479-38482	PFC	_	
95-24	38482-38483	’	_	
95-25	38484-38492	thalamus	_	
95-26	38493-38497	seed	_	
95-27	38498-38500	in	_	
95-28	38501-38508	healthy	_	
95-29	38509-38517	subjects	_	
95-30	38518-38527	resembled	_	
95-31	38528-38531	the	_	
95-32	38532-38546	well-described	_	
95-33	38547-38548	“	_	
95-34	38548-38557	executive	_	
95-35	38558-38565	control	_	
95-36	38565-38566	”	_	
95-37	38567-38574	network	_	
95-38	38575-38576	(	_	
95-39	38576-38579	i.e	_	
95-40	38579-38580	.	_	
95-41	38581-38588	Niendam	_	
95-42	38589-38591	et	_	
95-43	38592-38594	al	_	
95-44	38594-38595	.	_	
95-45	38595-38596	,	_	
95-46	38597-38601	2012	_	
95-47	38601-38602	)	_	
95-48	38603-38606	and	_	
95-49	38607-38615	included	_	
95-50	38616-38619	the	_	
95-51	38620-38632	dorsolateral	_	
95-52	38633-38636	PFC	_	
95-53	38636-38637	,	_	
95-54	38638-38644	medial	_	
95-55	38645-38648	PFC	_	
95-56	38648-38649	/	_	
95-57	38649-38657	anterior	_	
95-58	38658-38667	cingulate	_	
95-59	38667-38668	,	_	
95-60	38669-38682	mid-cingulate	_	
95-61	38682-38683	,	_	
95-62	38684-38692	inferior	_	
95-63	38693-38701	parietal	_	
95-64	38702-38708	lobule	_	
95-65	38708-38709	,	_	
95-66	38710-38713	and	_	
95-67	38714-38724	cerebellum	_	
95-68	38724-38725	.	_	
95-69	38726-38730	This	_	
95-70	38731-38738	pattern	_	
95-71	38739-38742	was	_	
95-72	38743-38751	markedly	_	
95-73	38752-38762	attenuated	_	
95-74	38763-38765	in	_	
95-75	38766-38775	psychosis	_	
95-76	38775-38776	,	_	
95-77	38777-38786	including	_	
95-78	38787-38791	both	_	
95-79	38792-38799	chronic	_	
95-80	38800-38803	and	_	
95-81	38804-38809	early	_	
95-82	38810-38815	stage	_	
95-83	38816-38824	patients	_	
95-84	38824-38825	.	_	
95-85	38826-38831	Panel	_	
95-86	38832-38833	B	_	
95-87	38833-38834	:	_	
95-88	38835-38845	Functional	_	
95-89	38846-38858	connectivity	_	
95-90	38859-38861	of	_	
95-91	38862-38865	the	_	
95-92	38866-38874	thalamus	_	
95-93	38875-38876	‘	_	
95-94	38876-38881	motor	_	
95-95	38881-38882	’	_	
95-96	38883-38887	seed	_	
95-97	38888-38889	(	_	
95-98	38889-38893	warm	_	
95-99	38894-38900	colors	_	
95-100	38900-38901	)	_	
95-101	38902-38905	and	_	
95-102	38906-38907	‘	_	
95-103	38907-38920	somatosensory	_	
95-104	38920-38921	’	_	
95-105	38922-38926	seed	_	
95-106	38927-38928	(	_	
95-107	38928-38932	cool	_	
95-108	38933-38939	colors	_	
95-109	38939-38940	)	_	
95-110	38941-38949	included	_	
95-111	38950-38956	mainly	_	
95-112	38957-38962	motor	_	
95-113	38963-38966	and	_	
95-114	38967-38980	somatosensory	_	
95-115	38981-38986	areas	_	
95-116	38987-38990	and	_	
95-117	38991-39001	cerebellum	_	
95-118	39001-39002	.	_	
95-119	39003-39016	Qualitatively	_	
95-120	39016-39017	,	_	
95-121	39018-39028	functional	_	
95-122	39029-39041	connectivity	_	
95-123	39042-39044	of	_	
95-124	39045-39048	the	_	
95-125	39049-39057	thalamus	_	
95-126	39058-39063	motor	_	
95-127	39064-39067	and	_	
95-128	39068-39081	somatosensory	_	
95-129	39082-39087	seeds	_	
95-130	39088-39096	appeared	_	
95-131	39097-39101	more	_	
95-132	39102-39112	widespread	_	
95-133	39113-39116	and	_	
95-134	39117-39121	less	_	
95-135	39122-39132	segregated	_	
95-136	39133-39135	in	_	
95-137	39136-39145	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[25]	
95-138	39146-39154	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[25]	
95-139	39155-39156	(	_	
95-140	39156-39163	overlap	_	
95-141	39164-39166	in	_	
95-142	39167-39172	motor	_	
95-143	39173-39176	and	_	
95-144	39177-39190	somatosensory	_	
95-145	39191-39199	thalamus	_	
95-146	39200-39204	seed	_	
95-147	39205-39217	connectivity	_	
95-148	39218-39220	is	_	
95-149	39221-39226	shown	_	
95-150	39227-39229	in	_	
95-151	39230-39235	green	_	
95-152	39235-39236	)	_	
95-153	39236-39237	.	_	

#Text=Functional dysconnectivity of the thalamus PFC and motor seeds in psychosis. Compared to healthy subjects, functional connectivity of the PFC thalamus seed with lateral PFC (i.e. superior frontal gyrus), anterior medial PFC, and cerebellum was reduced in individuals with a psychotic disorder (warm colors). In contrast, functional connectivity of the thalamus motor seed was increased in patients with a psychotic disorder in medial and ventral-lateral primary motor cortex (cool colors). Chronic and early stage psychosis patients exhibited very similar patterns of functional connectivity abnormalities. All results thresholded at cluster-level corrected pFWE-corrected=.05 for voxel-wise p=.005 (p=.05 for the healthy subjects vs. early stage psychosis patients contrast).
96-1	39238-39248	Functional	_	
96-2	39249-39264	dysconnectivity	_	
96-3	39265-39267	of	_	
96-4	39268-39271	the	_	
96-5	39272-39280	thalamus	_	
96-6	39281-39284	PFC	_	
96-7	39285-39288	and	_	
96-8	39289-39294	motor	_	
96-9	39295-39300	seeds	_	
96-10	39301-39303	in	_	
96-11	39304-39313	psychosis	_	
96-12	39313-39314	.	_	
96-13	39315-39323	Compared	_	
96-14	39324-39326	to	_	
96-15	39327-39334	healthy	_	
96-16	39335-39343	subjects	_	
96-17	39343-39344	,	_	
96-18	39345-39355	functional	_	
96-19	39356-39368	connectivity	_	
96-20	39369-39371	of	_	
96-21	39372-39375	the	_	
96-22	39376-39379	PFC	_	
96-23	39380-39388	thalamus	_	
96-24	39389-39393	seed	_	
96-25	39394-39398	with	_	
96-26	39399-39406	lateral	_	
96-27	39407-39410	PFC	_	
96-28	39411-39412	(	_	
96-29	39412-39415	i.e	_	
96-30	39415-39416	.	_	
96-31	39417-39425	superior	_	
96-32	39426-39433	frontal	_	
96-33	39434-39439	gyrus	_	
96-34	39439-39440	)	_	
96-35	39440-39441	,	_	
96-36	39442-39450	anterior	_	
96-37	39451-39457	medial	_	
96-38	39458-39461	PFC	_	
96-39	39461-39462	,	_	
96-40	39463-39466	and	_	
96-41	39467-39477	cerebellum	_	
96-42	39478-39481	was	_	
96-43	39482-39489	reduced	_	
96-44	39490-39492	in	_	
96-45	39493-39504	individuals	_	
96-46	39505-39509	with	_	
96-47	39510-39511	a	_	
96-48	39512-39521	psychotic	_	
96-49	39522-39530	disorder	_	
96-50	39531-39532	(	_	
96-51	39532-39536	warm	_	
96-52	39537-39543	colors	_	
96-53	39543-39544	)	_	
96-54	39544-39545	.	_	
96-55	39546-39548	In	_	
96-56	39549-39557	contrast	_	
96-57	39557-39558	,	_	
96-58	39559-39569	functional	_	
96-59	39570-39582	connectivity	_	
96-60	39583-39585	of	_	
96-61	39586-39589	the	_	
96-62	39590-39598	thalamus	_	
96-63	39599-39604	motor	_	
96-64	39605-39609	seed	_	
96-65	39610-39613	was	_	
96-66	39614-39623	increased	_	
96-67	39624-39626	in	_	
96-68	39627-39635	patients	_	
96-69	39636-39640	with	_	
96-70	39641-39642	a	_	
96-71	39643-39652	psychotic	_	
96-72	39653-39661	disorder	_	
96-73	39662-39664	in	_	
96-74	39665-39671	medial	_	
96-75	39672-39675	and	_	
96-76	39676-39691	ventral-lateral	_	
96-77	39692-39699	primary	_	
96-78	39700-39705	motor	_	
96-79	39706-39712	cortex	_	
96-80	39713-39714	(	_	
96-81	39714-39718	cool	_	
96-82	39719-39725	colors	_	
96-83	39725-39726	)	_	
96-84	39726-39727	.	_	
96-85	39728-39735	Chronic	_	
96-86	39736-39739	and	_	
96-87	39740-39745	early	_	
96-88	39746-39751	stage	_	
96-89	39752-39761	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[26]	
96-90	39762-39770	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[26]	
96-91	39771-39780	exhibited	_	
96-92	39781-39785	very	_	
96-93	39786-39793	similar	_	
96-94	39794-39802	patterns	_	
96-95	39803-39805	of	_	
96-96	39806-39816	functional	_	
96-97	39817-39829	connectivity	_	
96-98	39830-39843	abnormalities	_	
96-99	39843-39844	.	_	
96-100	39845-39848	All	_	
96-101	39849-39856	results	_	
96-102	39857-39868	thresholded	_	
96-103	39869-39871	at	_	
96-104	39872-39885	cluster-level	_	
96-105	39886-39895	corrected	_	
96-106	39896-39910	pFWE-corrected	_	
96-107	39910-39911	=	_	
96-108	39911-39914	.05	_	
96-109	39915-39918	for	_	
96-110	39919-39929	voxel-wise	_	
96-111	39930-39931	p	_	
96-112	39931-39932	=	_	
96-113	39932-39936	.005	_	
96-114	39937-39938	(	_	
96-115	39938-39939	p	_	
96-116	39939-39940	=	_	
96-117	39940-39943	.05	_	
96-118	39944-39947	for	_	
96-119	39948-39951	the	_	
96-120	39952-39959	healthy	_	
96-121	39960-39968	subjects	_	
96-122	39969-39971	vs	_	
96-123	39971-39972	.	_	
96-124	39973-39978	early	_	
96-125	39979-39984	stage	_	
96-126	39985-39994	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[27]	
96-127	39995-40003	patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[27]	
96-128	40004-40012	contrast	_	
96-129	40012-40013	)	_	
96-130	40013-40014	.	_	

#Text=Sample Demographics
97-1	40015-40021	Sample	_	
97-2	40022-40034	Demographics	_	

#Text=Psychosis\tPost-Hoc\t \tHealthy Subjects\tChronic\tEarly Stage\tStatistics\t \tN=105\tN=95\tN=53\tF/t/x2\tp\t \tGender (male:female)\t61:44\t50:45\t39:14\t6.29\t.043\tCP>ESP (males)\t \tEthnicity (White:AA:Other)\t69:29:7\t57:31:7\t36:14:3\t1.17\t.882\t--\t \tAffective/Non-Affective Psychosis\t--\t17:78\t20:33\t7.14\t.008\t\t \t\tMean\tSD\tMean\tSD\tMean\tSD\t\t\t\t \t\t\t\t\t\t\t\t \tAge\t32.5\t11.3\t38.1\t11.8\t22.0\t3.7\t40.28\t<.001\tCP>HS>ESP\t \tPremorbid IQ\t109.9\t12.0\t96.8\t16.2\t101.3\t13.3\t21.19\t<.001\tHS>CP, ESP\t \tSCIP Global Cognition z-score\t0.0\t0.68\t−1.53\t0.94\t−0.68\t0.87\t77.06\t<.001\tHS>ESP>CP\t \t% of fMRI Volumes Exlcuded\t6.1\t11.4\t12.9\t16.4\t7.6\t12.5\t6.41\t.002\tCP>ESP, HS\t \tDuration of Illness (years)\t--\t--\t15.7\t11.1\t0.36\t0.5\t10.01\t<.001\t--\t \tPANSS Positive\t--\t--\t19.4\t7.0\t19.3\t8.1\t0.09\t.925\t--\t \tPANSS Negative\t--\t--\t14.6\t6.7\t15.3\t8.3\t0.53\t.597\t--\t \tPANSS General\t--\t--\t31.7\t8.0\t31.5\t8.6\t0.14\t.886\t--\t \tCPZ Equivalents\t--\t--\t464.6\t232.2\t325.4\t171.4\t3.15\t.002\t--
98-1	40036-40045	Psychosis	_	
98-2	40046-40054	Post-Hoc	_	
98-3	40057-40064	Healthy	_	
98-4	40065-40073	Subjects	_	
98-5	40074-40081	Chronic	_	
98-6	40082-40087	Early	_	
98-7	40088-40093	Stage	_	
98-8	40094-40104	Statistics	_	
98-9	40107-40108	N	_	
98-10	40108-40109	=	_	
98-11	40109-40112	105	_	
98-12	40113-40114	N	_	
98-13	40114-40115	=	_	
98-14	40115-40117	95	_	
98-15	40118-40119	N	_	
98-16	40119-40120	=	_	
98-17	40120-40122	53	_	
98-18	40123-40124	F	_	
98-19	40124-40125	/	_	
98-20	40125-40126	t	_	
98-21	40126-40127	/	_	
98-22	40127-40129	x2	_	
98-23	40130-40131	p	_	
98-24	40134-40140	Gender	_	
98-25	40141-40142	(	_	
98-26	40142-40146	male	_	
98-27	40146-40147	:	_	
98-28	40147-40153	female	_	
98-29	40153-40154	)	_	
98-30	40155-40157	61	_	
98-31	40157-40158	:	_	
98-32	40158-40160	44	_	
98-33	40161-40163	50	_	
98-34	40163-40164	:	_	
98-35	40164-40166	45	_	
98-36	40167-40169	39	_	
98-37	40169-40170	:	_	
98-38	40170-40172	14	_	
98-39	40173-40177	6.29	_	
98-40	40178-40182	.043	_	
98-41	40183-40185	CP	_	
98-42	40185-40186	>	_	
98-43	40186-40189	ESP	_	
98-44	40190-40191	(	_	
98-45	40191-40196	males	_	
98-46	40196-40197	)	_	
98-47	40200-40209	Ethnicity	_	
98-48	40210-40211	(	_	
98-49	40211-40216	White	_	
98-50	40216-40217	:	_	
98-51	40217-40219	AA	_	
98-52	40219-40220	:	_	
98-53	40220-40225	Other	_	
98-54	40225-40226	)	_	
98-55	40227-40229	69	_	
98-56	40229-40230	:	_	
98-57	40230-40232	29	_	
98-58	40232-40233	:	_	
98-59	40233-40234	7	_	
98-60	40235-40237	57	_	
98-61	40237-40238	:	_	
98-62	40238-40240	31	_	
98-63	40240-40241	:	_	
98-64	40241-40242	7	_	
98-65	40243-40245	36	_	
98-66	40245-40246	:	_	
98-67	40246-40248	14	_	
98-68	40248-40249	:	_	
98-69	40249-40250	3	_	
98-70	40251-40255	1.17	_	
98-71	40256-40260	.882	_	
98-72	40261-40262	-	_	
98-73	40262-40263	-	_	
98-74	40266-40275	Affective	_	
98-75	40275-40276	/	_	
98-76	40276-40289	Non-Affective	_	
98-77	40290-40299	Psychosis	_	
98-78	40300-40301	-	_	
98-79	40301-40302	-	_	
98-80	40303-40305	17	_	
98-81	40305-40306	:	_	
98-82	40306-40308	78	_	
98-83	40309-40311	20	_	
98-84	40311-40312	:	_	
98-85	40312-40314	33	_	
98-86	40315-40319	7.14	_	
98-87	40320-40324	.008	_	
98-88	40329-40333	Mean	_	
98-89	40334-40336	SD	_	
98-90	40337-40341	Mean	_	
98-91	40342-40344	SD	_	
98-92	40345-40349	Mean	_	
98-93	40350-40352	SD	_	
98-94	40367-40370	Age	_	
98-95	40371-40375	32.5	_	
98-96	40376-40380	11.3	_	
98-97	40381-40385	38.1	_	
98-98	40386-40390	11.8	_	
98-99	40391-40395	22.0	_	
98-100	40396-40399	3.7	_	
98-101	40400-40405	40.28	_	
98-102	40406-40407	<	_	
98-103	40407-40411	.001	_	
98-104	40412-40414	CP	_	
98-105	40414-40415	>	_	
98-106	40415-40417	HS	_	
98-107	40417-40418	>	_	
98-108	40418-40421	ESP	_	
98-109	40424-40433	Premorbid	_	
98-110	40434-40436	IQ	_	
98-111	40437-40442	109.9	_	
98-112	40443-40447	12.0	_	
98-113	40448-40452	96.8	_	
98-114	40453-40457	16.2	_	
98-115	40458-40463	101.3	_	
98-116	40464-40468	13.3	_	
98-117	40469-40474	21.19	_	
98-118	40475-40476	<	_	
98-119	40476-40480	.001	_	
98-120	40481-40483	HS	_	
98-121	40483-40484	>	_	
98-122	40484-40486	CP	_	
98-123	40486-40487	,	_	
98-124	40488-40491	ESP	_	
98-125	40494-40498	SCIP	_	
98-126	40499-40505	Global	_	
98-127	40506-40515	Cognition	_	
98-128	40516-40523	z-score	_	
98-129	40524-40527	0.0	_	
98-130	40528-40532	0.68	_	
98-131	40533-40534	−	_	
98-132	40534-40538	1.53	_	
98-133	40539-40543	0.94	_	
98-134	40544-40545	−	_	
98-135	40545-40549	0.68	_	
98-136	40550-40554	0.87	_	
98-137	40555-40560	77.06	_	
98-138	40561-40562	<	_	
98-139	40562-40566	.001	_	
98-140	40567-40569	HS	_	
98-141	40569-40570	>	_	
98-142	40570-40573	ESP	_	
98-143	40573-40574	>	_	
98-144	40574-40576	CP	_	
98-145	40579-40580	%	_	
98-146	40581-40583	of	_	
98-147	40584-40588	fMRI	_	
98-148	40589-40596	Volumes	_	
98-149	40597-40605	Exlcuded	_	
98-150	40606-40609	6.1	_	
98-151	40610-40614	11.4	_	
98-152	40615-40619	12.9	_	
98-153	40620-40624	16.4	_	
98-154	40625-40628	7.6	_	
98-155	40629-40633	12.5	_	
98-156	40634-40638	6.41	_	
98-157	40639-40643	.002	_	
98-158	40644-40646	CP	_	
98-159	40646-40647	>	_	
98-160	40647-40650	ESP	_	
98-161	40650-40651	,	_	
98-162	40652-40654	HS	_	
98-163	40657-40665	Duration	_	
98-164	40666-40668	of	_	
98-165	40669-40676	Illness	_	
98-166	40677-40678	(	_	
98-167	40678-40683	years	_	
98-168	40683-40684	)	_	
98-169	40685-40686	-	_	
98-170	40686-40687	-	_	
98-171	40688-40689	-	_	
98-172	40689-40690	-	_	
98-173	40691-40695	15.7	_	
98-174	40696-40700	11.1	_	
98-175	40701-40705	0.36	_	
98-176	40706-40709	0.5	_	
98-177	40710-40715	10.01	_	
98-178	40716-40717	<	_	
98-179	40717-40721	.001	_	
98-180	40722-40723	-	_	
98-181	40723-40724	-	_	
98-182	40727-40732	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
98-183	40733-40741	Positive	_	
98-184	40742-40743	-	_	
98-185	40743-40744	-	_	
98-186	40745-40746	-	_	
98-187	40746-40747	-	_	
98-188	40748-40752	19.4	_	
98-189	40753-40756	7.0	_	
98-190	40757-40761	19.3	_	
98-191	40762-40765	8.1	_	
98-192	40766-40770	0.09	_	
98-193	40771-40775	.925	_	
98-194	40776-40777	-	_	
98-195	40777-40778	-	_	
98-196	40781-40786	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
98-197	40787-40795	Negative	_	
98-198	40796-40797	-	_	
98-199	40797-40798	-	_	
98-200	40799-40800	-	_	
98-201	40800-40801	-	_	
98-202	40802-40806	14.6	_	
98-203	40807-40810	6.7	_	
98-204	40811-40815	15.3	_	
98-205	40816-40819	8.3	_	
98-206	40820-40824	0.53	_	
98-207	40825-40829	.597	_	
98-208	40830-40831	-	_	
98-209	40831-40832	-	_	
98-210	40835-40840	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
98-211	40841-40848	General	_	
98-212	40849-40850	-	_	
98-213	40850-40851	-	_	
98-214	40852-40853	-	_	
98-215	40853-40854	-	_	
98-216	40855-40859	31.7	_	
98-217	40860-40863	8.0	_	
98-218	40864-40868	31.5	_	
98-219	40869-40872	8.6	_	
98-220	40873-40877	0.14	_	
98-221	40878-40882	.886	_	
98-222	40883-40884	-	_	
98-223	40884-40885	-	_	
98-224	40888-40891	CPZ	_	
98-225	40892-40903	Equivalents	_	
98-226	40904-40905	-	_	
98-227	40905-40906	-	_	
98-228	40907-40908	-	_	
98-229	40908-40909	-	_	
98-230	40910-40915	464.6	_	
98-231	40916-40921	232.2	_	
98-232	40922-40927	325.4	_	
98-233	40928-40933	171.4	_	
98-234	40934-40938	3.15	_	
98-235	40939-40943	.002	_	
98-236	40944-40945	-	_	
98-237	40945-40946	-	_	

#Text=Abbreviations: CP=Chronic Psychosis; CPZ=Chlorpromazine; ESP=Early Stage Psychosis; HS=Healthy Subjects; PANSS=Positive and Negative Syndrome Scale; SCIP=Screen for Cognitive Impairment in Psychiatry
99-1	40950-40963	Abbreviations	_	
99-2	40963-40964	:	_	
99-3	40965-40967	CP	_	
99-4	40967-40968	=	_	
99-5	40968-40975	Chronic	_	
99-6	40976-40985	Psychosis	_	
99-7	40985-40986	;	_	
99-8	40987-40990	CPZ	_	
99-9	40990-40991	=	_	
99-10	40991-41005	Chlorpromazine	_	
99-11	41005-41006	;	_	
99-12	41007-41010	ESP	_	
99-13	41010-41011	=	_	
99-14	41011-41016	Early	_	
99-15	41017-41022	Stage	_	
99-16	41023-41032	Psychosis	_	
99-17	41032-41033	;	_	
99-18	41034-41036	HS	_	
99-19	41036-41037	=	_	
99-20	41037-41044	Healthy	_	
99-21	41045-41053	Subjects	_	
99-22	41053-41054	;	_	
99-23	41055-41060	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
99-24	41060-41061	=	_	
99-25	41061-41069	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[28]	
99-26	41070-41073	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[28]	
99-27	41074-41082	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[28]	
99-28	41083-41091	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[28]	
99-29	41092-41097	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[28]	
99-30	41097-41098	;	_	
99-31	41099-41103	SCIP	_	
99-32	41103-41104	=	_	
99-33	41104-41110	Screen	_	
99-34	41111-41114	for	_	
99-35	41115-41124	Cognitive	_	
99-36	41125-41135	Impairment	_	
99-37	41136-41138	in	_	
99-38	41139-41149	Psychiatry	_	

#Text=Group differences in functional connectivity of thalamus seed regions at a Cluster-level Corrected p(FWE)=.05
100-1	41150-41155	Group	_	
100-2	41156-41167	differences	_	
100-3	41168-41170	in	_	
100-4	41171-41181	functional	_	
100-5	41182-41194	connectivity	_	
100-6	41195-41197	of	_	
100-7	41198-41206	thalamus	_	
100-8	41207-41211	seed	_	
100-9	41212-41219	regions	_	
100-10	41220-41222	at	_	
100-11	41223-41224	a	_	
100-12	41225-41238	Cluster-level	_	
100-13	41239-41248	Corrected	_	
100-14	41249-41250	p	_	
100-15	41250-41251	(	_	
100-16	41251-41254	FWE	_	
100-17	41254-41255	)	_	
100-18	41255-41256	=	_	
100-19	41256-41259	.05	_	

#Text=Brain Area\tAll Psychosis Patients\tChronic Psychosis\tEarly Stage Psychosis\t \tVoxels\tMNI\tPeak t\tVoxels\tMNI\tPeak t\tVoxels\tMNI\tPeak t\t \tx\ty\tz\tx\ty\tz\tx\ty\tz\t \tThalamus PFC Seed\t \tHealthy Subjects > Psychosis\t \t R. Cerebellum, Posterior Lobe\t669\t10\t−78\t−28\t5.02\t\t\t\t\t\t\t\t\t\t\t \t\t30\t−70\t−28\t4.25\t\t\t\t\t\t\t\t\t\t\t \t\t40\t−66\t−40\t3.76\t\t\t\t\t\t\t\t\t\t\t \t L. Cerebellum, Posterior Lobe\t351\t−10\t−76\t−30\t4.77\t352\t−8\t−78\t−28\t4.66\t\t\t\t\t\t \t L./R. Superior/Medial Frontal Gyrus (BA 8/9)\t1507\t−30\t24\t54\t3.95\t1267\t−30\t22\t54\t3.90\t2780\t−22\t34\t46\t2.51\t \t\t18\t34\t50\t3.49\t\t18\t32\t50\t3.79\t\t24\t28\t40\t3.61\t \t\t−6\t46\t36\t3.55\t\t−2\t34\t40\t3.72\t\t−6\t46\t38\t3.18\t \t\t4\t52\t42\t3.53\t\t\t\t\t\t\t5\t52\t42\t3.52\t \t Thalamus\t\t\t\t\t\t471\t6\t−22\t2\t4.76\t\t\t\t\t\t \t\t\t\t\t\t\t−2\t−8\t−4\t3.64\t\t\t\t\t\t \t\t\t\t\t\t\t18\t−28\t4\t3.50\t\t\t\t\t\t \t L. Inferior Parietal Lobule (BA 39/40)\t\t\t\t\t\t508\t−46\t−50\t42\t4.25\t\t\t\t\t\t \t\t\t\t\t\t\t−62\t−60\t38\t4.05\t\t\t\t\t\t \t\t\t\t\t\t\t−32\t−62\t42\t3.26\t\t\t\t\t\t \tPsychosis > Healthy Subjects\tNo Significant Clusters\t\t\t\t\t\t\t\t\t\t\t \tThalamus Motor Seed\t \tHealthy Subjects > Psychosis\tNo Significant Clusters\t\t\t\t\t\t\t\t\t\t\t \tPsychosis > Healthy Subjects\t \t L. Precentral/Inferior Frontal Gyrus (BA 44)\t335\t−60\t10\t6\t4.9\t\t\t\t\t\t\t\t\t\t\t \t R./L. Paracentral Lobule (BA 4)\t1320\t4\t−32\t62\t4.12\t\t\t\t\t\t2068\t4\t−32\t62\t3.41\t \t\t\t\t\t\t\t\t\t\t\t\t−14\t−30\t60\t3.14\t \t R. Medial Frontal/Postcentral Gyrus (BA 6)\t\t8\t−26\t80\t3.88\t567\t8\t−26\t80\t4.47\t\t8\t−6\t50\t2.93\t \t\t\t\t\t\t\t8\t−18\t58\t3.72\t\t\t\t\t\t \t\t\t\t\t\t\t8\t−42\t72\t3.86\t\t\t\t\t\t \t L. Superior/Medial Frontal Gyrus (BA 6)\t\t−12\t6\t72\t3.93\t753\t−12\t6\t72\t4.43\t\t\t\t\t\t \t\t\t\t\t\t\t−14\t4\t64\t4.32\t\t\t\t\t\t \t\t\t\t\t\t\t−2\t−4\t68\t3.75\t\t\t\t\t\t \t R. Pre/Postcentral Gyrus (BA 3/4)\t\t\t\t\t\t431\t44\t−16\t56\t3.83\t\t\t\t\t\t \t\t\t\t\t\t\t62\t−10\t36\t5.19\t\t\t\t\t\t \t\t\t\t\t\t\t46\t−14\t42\t2.83\t\t\t\t\t\t \t L. Postcentral Gyrus (BA 5/7)\t\t\t\t\t\t424\t−14\t50\t68\t3.7\t\t\t\t\t\t \t\t\t\t\t\t\t−30\t−40\t64\t3.63\t\t\t\t\t\t \t\t\t\t\t\t\t−24\t−46\t64\t3.47
101-1	41260-41265	Brain	_	
101-2	41266-41270	Area	_	
101-3	41271-41274	All	_	
101-4	41275-41284	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[29]	
101-5	41285-41293	Patients	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[29]	
101-6	41294-41301	Chronic	_	
101-7	41302-41311	Psychosis	_	
101-8	41312-41317	Early	_	
101-9	41318-41323	Stage	_	
101-10	41324-41333	Psychosis	_	
101-11	41336-41342	Voxels	_	
101-12	41343-41346	MNI	_	
101-13	41347-41351	Peak	_	
101-14	41352-41353	t	_	
101-15	41354-41360	Voxels	_	
101-16	41361-41364	MNI	_	
101-17	41365-41369	Peak	_	
101-18	41370-41371	t	_	
101-19	41372-41378	Voxels	_	
101-20	41379-41382	MNI	_	
101-21	41383-41387	Peak	_	
101-22	41388-41389	t	_	
101-23	41392-41393	x	_	
101-24	41394-41395	y	_	
101-25	41396-41397	z	_	
101-26	41398-41399	x	_	
101-27	41400-41401	y	_	
101-28	41402-41403	z	_	
101-29	41404-41405	x	_	
101-30	41406-41407	y	_	
101-31	41408-41409	z	_	
101-32	41412-41420	Thalamus	_	
101-33	41421-41424	PFC	_	
101-34	41425-41429	Seed	_	
101-35	41432-41439	Healthy	_	
101-36	41440-41448	Subjects	_	
101-37	41449-41450	>	_	
101-38	41451-41460	Psychosis	_	
101-39	41464-41465	R	_	
101-40	41465-41466	.	_	
101-41	41467-41477	Cerebellum	_	
101-42	41477-41478	,	_	
101-43	41479-41488	Posterior	_	
101-44	41489-41493	Lobe	_	
101-45	41494-41497	669	_	
101-46	41498-41500	10	_	
101-47	41501-41502	−	_	
101-48	41502-41504	78	_	
101-49	41505-41506	−	_	
101-50	41506-41508	28	_	
101-51	41509-41513	5.02	_	
101-52	41527-41529	30	_	
101-53	41530-41531	−	_	
101-54	41531-41533	70	_	
101-55	41534-41535	−	_	
101-56	41535-41537	28	_	
101-57	41538-41542	4.25	_	
101-58	41556-41558	40	_	
101-59	41559-41560	−	_	
101-60	41560-41562	66	_	
101-61	41563-41564	−	_	
101-62	41564-41566	40	_	
101-63	41567-41571	3.76	_	
101-64	41585-41586	L	_	
101-65	41586-41587	.	_	
101-66	41588-41598	Cerebellum	_	
101-67	41598-41599	,	_	
101-68	41600-41609	Posterior	_	
101-69	41610-41614	Lobe	_	
101-70	41615-41618	351	_	
101-71	41619-41620	−	_	
101-72	41620-41622	10	_	
101-73	41623-41624	−	_	
101-74	41624-41626	76	_	
101-75	41627-41628	−	_	
101-76	41628-41630	30	_	
101-77	41631-41635	4.77	_	
101-78	41636-41639	352	_	
101-79	41640-41641	−	_	
101-80	41641-41642	8	_	
101-81	41643-41644	−	_	
101-82	41644-41646	78	_	
101-83	41647-41648	−	_	
101-84	41648-41650	28	_	
101-85	41651-41655	4.66	_	
101-86	41664-41665	L	_	
101-87	41665-41666	.	_	
101-88	41666-41667	/	_	
101-89	41667-41668	R	_	
101-90	41668-41669	.	_	
101-91	41670-41678	Superior	_	
101-92	41678-41679	/	_	
101-93	41679-41685	Medial	_	
101-94	41686-41693	Frontal	_	
101-95	41694-41699	Gyrus	_	
101-96	41700-41701	(	_	
101-97	41701-41703	BA	_	
101-98	41704-41705	8	_	
101-99	41705-41706	/	_	
101-100	41706-41707	9	_	
101-101	41707-41708	)	_	
101-102	41709-41713	1507	_	
101-103	41714-41715	−	_	
101-104	41715-41717	30	_	
101-105	41718-41720	24	_	
101-106	41721-41723	54	_	
101-107	41724-41728	3.95	_	
101-108	41729-41733	1267	_	
101-109	41734-41735	−	_	
101-110	41735-41737	30	_	
101-111	41738-41740	22	_	
101-112	41741-41743	54	_	
101-113	41744-41748	3.90	_	
101-114	41749-41753	2780	_	
101-115	41754-41755	−	_	
101-116	41755-41757	22	_	
101-117	41758-41760	34	_	
101-118	41761-41763	46	_	
101-119	41764-41768	2.51	_	
101-120	41772-41774	18	_	
101-121	41775-41777	34	_	
101-122	41778-41780	50	_	
101-123	41781-41785	3.49	_	
101-124	41787-41789	18	_	
101-125	41790-41792	32	_	
101-126	41793-41795	50	_	
101-127	41796-41800	3.79	_	
101-128	41802-41804	24	_	
101-129	41805-41807	28	_	
101-130	41808-41810	40	_	
101-131	41811-41815	3.61	_	
101-132	41819-41820	−	_	
101-133	41820-41821	6	_	
101-134	41822-41824	46	_	
101-135	41825-41827	36	_	
101-136	41828-41832	3.55	_	
101-137	41834-41835	−	_	
101-138	41835-41836	2	_	
101-139	41837-41839	34	_	
101-140	41840-41842	40	_	
101-141	41843-41847	3.72	_	
101-142	41849-41850	−	_	
101-143	41850-41851	6	_	
101-144	41852-41854	46	_	
101-145	41855-41857	38	_	
101-146	41858-41862	3.18	_	
101-147	41866-41867	4	_	
101-148	41868-41870	52	_	
101-149	41871-41873	42	_	
101-150	41874-41878	3.53	_	
101-151	41885-41886	5	_	
101-152	41887-41889	52	_	
101-153	41890-41892	42	_	
101-154	41893-41897	3.52	_	
101-155	41901-41909	Thalamus	_	
101-156	41915-41918	471	_	
101-157	41919-41920	6	_	
101-158	41921-41922	−	_	
101-159	41922-41924	22	_	
101-160	41925-41926	2	_	
101-161	41927-41931	4.76	_	
101-162	41945-41946	−	_	
101-163	41946-41947	2	_	
101-164	41948-41949	−	_	
101-165	41949-41950	8	_	
101-166	41951-41952	−	_	
101-167	41952-41953	4	_	
101-168	41954-41958	3.64	_	
101-169	41972-41974	18	_	
101-170	41975-41976	−	_	
101-171	41976-41978	28	_	
101-172	41979-41980	4	_	
101-173	41981-41985	3.50	_	
101-174	41994-41995	L	_	
101-175	41995-41996	.	_	
101-176	41997-42005	Inferior	_	
101-177	42006-42014	Parietal	_	
101-178	42015-42021	Lobule	_	
101-179	42022-42023	(	_	
101-180	42023-42025	BA	_	
101-181	42026-42028	39	_	
101-182	42028-42029	/	_	
101-183	42029-42031	40	_	
101-184	42031-42032	)	_	
101-185	42038-42041	508	_	
101-186	42042-42043	−	_	
101-187	42043-42045	46	_	
101-188	42046-42047	−	_	
101-189	42047-42049	50	_	
101-190	42050-42052	42	_	
101-191	42053-42057	4.25	_	
101-192	42071-42072	−	_	
101-193	42072-42074	62	_	
101-194	42075-42076	−	_	
101-195	42076-42078	60	_	
101-196	42079-42081	38	_	
101-197	42082-42086	4.05	_	
101-198	42100-42101	−	_	
101-199	42101-42103	32	_	
101-200	42104-42105	−	_	
101-201	42105-42107	62	_	
101-202	42108-42110	42	_	
101-203	42111-42115	3.26	_	
101-204	42123-42132	Psychosis	_	
101-205	42133-42134	>	_	
101-206	42135-42142	Healthy	_	
101-207	42143-42151	Subjects	_	
101-208	42152-42154	No	_	
101-209	42155-42166	Significant	_	
101-210	42167-42175	Clusters	_	
101-211	42188-42196	Thalamus	_	
101-212	42197-42202	Motor	_	
101-213	42203-42207	Seed	_	
101-214	42210-42217	Healthy	_	
101-215	42218-42226	Subjects	_	
101-216	42227-42228	>	_	
101-217	42229-42238	Psychosis	_	
101-218	42239-42241	No	_	
101-219	42242-42253	Significant	_	
101-220	42254-42262	Clusters	_	
101-221	42275-42284	Psychosis	_	
101-222	42285-42286	>	_	
101-223	42287-42294	Healthy	_	
101-224	42295-42303	Subjects	_	
101-225	42307-42308	L	_	
101-226	42308-42309	.	_	
101-227	42310-42320	Precentral	_	
101-228	42320-42321	/	_	
101-229	42321-42329	Inferior	_	
101-230	42330-42337	Frontal	_	
101-231	42338-42343	Gyrus	_	
101-232	42344-42345	(	_	
101-233	42345-42347	BA	_	
101-234	42348-42350	44	_	
101-235	42350-42351	)	_	
101-236	42352-42355	335	_	
101-237	42356-42357	−	_	
101-238	42357-42359	60	_	
101-239	42360-42362	10	_	
101-240	42363-42364	6	_	
101-241	42365-42368	4.9	_	
101-242	42382-42383	R	_	
101-243	42383-42384	.	_	
101-244	42384-42385	/	_	
101-245	42385-42386	L	_	
101-246	42386-42387	.	_	
101-247	42388-42399	Paracentral	_	
101-248	42400-42406	Lobule	_	
101-249	42407-42408	(	_	
101-250	42408-42410	BA	_	
101-251	42411-42412	4	_	
101-252	42412-42413	)	_	
101-253	42414-42418	1320	_	
101-254	42419-42420	4	_	
101-255	42421-42422	−	_	
101-256	42422-42424	32	_	
101-257	42425-42427	62	_	
101-258	42428-42432	4.12	_	
101-259	42438-42442	2068	_	
101-260	42443-42444	4	_	
101-261	42445-42446	−	_	
101-262	42446-42448	32	_	
101-263	42449-42451	62	_	
101-264	42452-42456	3.41	_	
101-265	42470-42471	−	_	
101-266	42471-42473	14	_	
101-267	42474-42475	−	_	
101-268	42475-42477	30	_	
101-269	42478-42480	60	_	
101-270	42481-42485	3.14	_	
101-271	42489-42490	R	_	
101-272	42490-42491	.	_	
101-273	42492-42498	Medial	_	
101-274	42499-42506	Frontal	_	
101-275	42506-42507	/	_	
101-276	42507-42518	Postcentral	_	
101-277	42519-42524	Gyrus	_	
101-278	42525-42526	(	_	
101-279	42526-42528	BA	_	
101-280	42529-42530	6	_	
101-281	42530-42531	)	_	
101-282	42533-42534	8	_	
101-283	42535-42536	−	_	
101-284	42536-42538	26	_	
101-285	42539-42541	80	_	
101-286	42542-42546	3.88	_	
101-287	42547-42550	567	_	
101-288	42551-42552	8	_	
101-289	42553-42554	−	_	
101-290	42554-42556	26	_	
101-291	42557-42559	80	_	
101-292	42560-42564	4.47	_	
101-293	42566-42567	8	_	
101-294	42568-42569	−	_	
101-295	42569-42570	6	_	
101-296	42571-42573	50	_	
101-297	42574-42578	2.93	_	
101-298	42587-42588	8	_	
101-299	42589-42590	−	_	
101-300	42590-42592	18	_	
101-301	42593-42595	58	_	
101-302	42596-42600	3.72	_	
101-303	42614-42615	8	_	
101-304	42616-42617	−	_	
101-305	42617-42619	42	_	
101-306	42620-42622	72	_	
101-307	42623-42627	3.86	_	
101-308	42636-42637	L	_	
101-309	42637-42638	.	_	
101-310	42639-42647	Superior	_	
101-311	42647-42648	/	_	
101-312	42648-42654	Medial	_	
101-313	42655-42662	Frontal	_	
101-314	42663-42668	Gyrus	_	
101-315	42669-42670	(	_	
101-316	42670-42672	BA	_	
101-317	42673-42674	6	_	
101-318	42674-42675	)	_	
101-319	42677-42678	−	_	
101-320	42678-42680	12	_	
101-321	42681-42682	6	_	
101-322	42683-42685	72	_	
101-323	42686-42690	3.93	_	
101-324	42691-42694	753	_	
101-325	42695-42696	−	_	
101-326	42696-42698	12	_	
101-327	42699-42700	6	_	
101-328	42701-42703	72	_	
101-329	42704-42708	4.43	_	
101-330	42722-42723	−	_	
101-331	42723-42725	14	_	
101-332	42726-42727	4	_	
101-333	42728-42730	64	_	
101-334	42731-42735	4.32	_	
101-335	42749-42750	−	_	
101-336	42750-42751	2	_	
101-337	42752-42753	−	_	
101-338	42753-42754	4	_	
101-339	42755-42757	68	_	
101-340	42758-42762	3.75	_	
101-341	42771-42772	R	_	
101-342	42772-42773	.	_	
101-343	42774-42777	Pre	_	
101-344	42777-42778	/	_	
101-345	42778-42789	Postcentral	_	
101-346	42790-42795	Gyrus	_	
101-347	42796-42797	(	_	
101-348	42797-42799	BA	_	
101-349	42800-42801	3	_	
101-350	42801-42802	/	_	
101-351	42802-42803	4	_	
101-352	42803-42804	)	_	
101-353	42810-42813	431	_	
101-354	42814-42816	44	_	
101-355	42817-42818	−	_	
101-356	42818-42820	16	_	
101-357	42821-42823	56	_	
101-358	42824-42828	3.83	_	
101-359	42842-42844	62	_	
101-360	42845-42846	−	_	
101-361	42846-42848	10	_	
101-362	42849-42851	36	_	
101-363	42852-42856	5.19	_	
101-364	42870-42872	46	_	
101-365	42873-42874	−	_	
101-366	42874-42876	14	_	
101-367	42877-42879	42	_	
101-368	42880-42884	2.83	_	
101-369	42893-42894	L	_	
101-370	42894-42895	.	_	
101-371	42896-42907	Postcentral	_	
101-372	42908-42913	Gyrus	_	
101-373	42914-42915	(	_	
101-374	42915-42917	BA	_	
101-375	42918-42919	5	_	
101-376	42919-42920	/	_	
101-377	42920-42921	7	_	
101-378	42921-42922	)	_	
101-379	42928-42931	424	_	
101-380	42932-42933	−	_	
101-381	42933-42935	14	_	
101-382	42936-42938	50	_	
101-383	42939-42941	68	_	
101-384	42942-42945	3.7	_	
101-385	42959-42960	−	_	
101-386	42960-42962	30	_	
101-387	42963-42964	−	_	
101-388	42964-42966	40	_	
101-389	42967-42969	64	_	
101-390	42970-42974	3.63	_	
101-391	42988-42989	−	_	
101-392	42989-42991	24	_	
101-393	42992-42993	−	_	
101-394	42993-42995	46	_	
101-395	42996-42998	64	_	
101-396	42999-43003	3.47	_	

#Text=Abbreviations: BA=Brodmann Area; FWE=Family-wise Error; L=left; MNI=Montreal Neurological Institute; PFC=Prefrontal Cortex; R=right
102-1	43012-43025	Abbreviations	_	
102-2	43025-43026	:	_	
102-3	43027-43029	BA	_	
102-4	43029-43030	=	_	
102-5	43030-43038	Brodmann	_	
102-6	43039-43043	Area	_	
102-7	43043-43044	;	_	
102-8	43045-43048	FWE	_	
102-9	43048-43049	=	_	
102-10	43049-43060	Family-wise	_	
102-11	43061-43066	Error	_	
102-12	43066-43067	;	_	
102-13	43068-43069	L	_	
102-14	43069-43070	=	_	
102-15	43070-43074	left	_	
102-16	43074-43075	;	_	
102-17	43076-43079	MNI	_	
102-18	43079-43080	=	_	
102-19	43080-43088	Montreal	_	
102-20	43089-43101	Neurological	_	
102-21	43102-43111	Institute	_	
102-22	43111-43112	;	_	
102-23	43113-43116	PFC	_	
102-24	43116-43117	=	_	
102-25	43117-43127	Prefrontal	_	
102-26	43128-43134	Cortex	_	
102-27	43134-43135	;	_	
102-28	43136-43137	R	_	
102-29	43137-43138	=	_	
102-30	43138-43143	right	_	
